"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtWith_AU_IN_FIRST","meanArtWith_AU_IN_LAST","meanArtWith_AU_IN_CORR","mean_articles_per_internal_author","mean_articles_per_internal_first_author","mean_articles_per_internal_last_author","mean_articles_per_internal_corresponding_author","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","meanCitationTrend","InternCoauthorship","AffCoauthorship","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","altmetric_score_thirdQu","cited_by_accounts_count_thirdQu","cited_by_fbwalls_count_thirdQu","cited_by_feeds_count_thirdQu","cited_by_gplus_count_thirdQu","cited_by_msm_count_thirdQu","cited_by_patents_count_thirdQu","cited_by_peer_review_sites_count_thirdQu","cited_by_policies_count_thirdQu","cited_by_posts_count_thirdQu","cited_by_rdts_count_thirdQu","cited_by_rh_count_thirdQu","cited_by_tweeters_count_thirdQu","cited_by_videos_count_thirdQu","cited_by_wikipedia_count_thirdQu","cohorts.com_thirdQu","cohorts.doc_thirdQu","cohorts.pub_thirdQu","cohorts.sci_thirdQu","readers.citeulike_thirdQu","readers.connotea_thirdQu","readers.mendeley_thirdQu","readers_count_thirdQu","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","inventor_per_AUIN_100","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","clTrial_perAUIN_100","nClTrial_w_AltmScore","cl_AltmS_rel","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internationalColl","avg_ResultingPublications_per_grant","totFundingOrgbyActivedGrant","avgPubByActivedFundingGrant_1000","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n"
"IRCCS_ISNB",2000,3,8.66666666666667,3.66666666666667,0,0.666666666666667,0,1,0,0.666666666666667,0,0,0,1,1,0,1,0.33,0.33,0,0.33,17.67,0.389726134178662,NA,0,0.666666666666667,0.11,0,0,0,"P. BOCCELLA;GIUSEPPE CANTORE;CARLO GUARNIERI;STEFANIA PETRINI;LUCIANO MERLINI;L INFUSO;CRISTINA CAPANNI;GIORGIO ZAULI;STEFANO SQUARZONI;DANIELA TONIOLO;R. BRISTOT;ALESSANDRA BARACCA;SERGIO PAOLINI;ANTONIO SANTORO;PATRIZIA SABATELLI;ANDREA OGNIBENE;D. DI STEFANO;F. COBIANCHI;ALESSANDRA BASSINI;FEDERICA D’AULOS","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","P. BOCCELLA;FEDERICA D’AULOS;PASQUALE STRIANO;V. LORETO;SALVATORE STRIANO;CRISTOFARO NOCERINO;GIUSEPPE CANTORE;L INFUSO;R. BRISTOT;SERGIO PAOLINI;ANTONIO SANTORO;D. DI STEFANO;A DORIZZI;CARLO GUARNIERI;STEFANIA PETRINI;LUCIANO MERLINI;CRISTINA CAPANNI;GIORGIO ZAULI;STEFANO SQUARZONI;DANIELA TONIOLO","0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.14;0.14;0.08;0.08;0.08;0.08;0.08;0.08;0.08","P. BOCCELLA;GIUSEPPE CANTORE;STEFANIA PETRINI;LUCIANO MERLINI;L INFUSO;R. BRISTOT;D. DI STEFANO;FEDERICA D’AULOS;SALVATORE STRIANO;CRISTOFARO NOCERINO;A DORIZZI","1;1;1;1;1;1;1;1;1;1;1","P. BOCCELLA;FEDERICA D’AULOS;SALVATORE STRIANO;CRISTOFARO NOCERINO;GIUSEPPE CANTORE;L INFUSO;R. BRISTOT;D. DI STEFANO;A DORIZZI;STEFANIA PETRINI;LUCIANO MERLINI","0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.14;0.14;0.08;0.08","CRISTOFARO NOCERINO;FEDERICA D’AULOS;P. BOCCELLA;PASQUALE STRIANO;SALVATORE STRIANO;V. LORETO;ALESSANDRA BARACCA;ALESSANDRA BASSINI;ANDREA OGNIBENE;CARLO GUARNIERI;CRISTINA CAPANNI;DANIELA TONIOLO;F. COBIANCHI;GIORGIO ZAULI;LUCIANO MERLINI;N.M. MARALDI;PATRIZIA SABATELLI;STEFANIA PETRINI;STEFANO SQUARZONI;A DORIZZI","31;31;31;31;31;31;14;14;14;14;14;14;14;14;14;14;14;14;14;8","CRISTOFARO NOCERINO;FEDERICA D’AULOS;P. BOCCELLA;SALVATORE STRIANO;LUCIANO MERLINI;STEFANIA PETRINI;A DORIZZI;D. DI STEFANO;GIUSEPPE CANTORE;L INFUSO;R. BRISTOT","31;31;31;31;14;14;8;8;8;8;8","A DORIZZI;CRISTOFARO NOCERINO;D. DI STEFANO;FEDERICA D’AULOS;GIUSEPPE CANTORE;L INFUSO;LUCIANO MERLINI;P. BOCCELLA;R. BRISTOT;SALVATORE STRIANO;STEFANIA PETRINI","1;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY","2;1;1","AUDIOLOGY;CELL BIOLOGY;GENETICS;IMMUNOLOGY;NEUROSCIENCE;RADIOLOGY;SURGERY","1;1;1;1;1;1;1","ANGIOGRAPHY;CYTOPLASM;ELECTROENCEPHALOGRAPHY;EPILEPSY;GENE;INTERNAL CAROTID ARTERY;MUSCULAR DYSTROPHY;NUCLEUS;PLATELET;RADIATION THERAPY;STENOSIS","1;1;1;1;1;1;1;1;1;1;1","HEMIPARESIS;ICTAL;LAMIN;REFLEX EPILEPSY;SEMIOLOGY;TRANSCRIPTION FACTOR","1;1;1;1;1;1","NUCLEAR PROTEIN","1","CAROTID ARTERY INJURIES;MUSCULAR DYSTROPHY, EMERY-DREIFUSS;BLOOD PLATELETS;EPILEPSY, REFLEX;HUMANS;MEGAKARYOCYTES;ADULT;ANTICONVULSANTS;BREAST NEOPLASMS;CAROTID ARTERY, INTERNAL;FEMALE;LYMPHOMA;MALE;MEMBRANE PROTEINS;RADIATION INJURIES;RADIOTHERAPY;THYMOPOIETINS;CEREBRAL ANGIOGRAPHY;ELECTROENCEPHALOGRAPHY;FEEDING BEHAVIOR","4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1","MANAGEMENT OF BRAIN METASTASES IN CANCER PATIENTS;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;STRUCTURE AND FUNCTION OF THE NUCLEAR PORE COMPLEX","1;1;1","CAROTID ARTERY STENOSIS;EMERIN;EXERCISE-INDUCED DYSFUNCTION;HEMIPARESIS;INTRACRANIAL ARTERIAL STENOSIS;REFLEX EPILEPSY;SEMIOLOGY;STENTING;TASTE RECEPTORS","1;1;1;1;1;1;1;1;1","ARTERY REPORT;CAROTID ARTERY;EATING EPILEPSY;EMERIN PRESENCE;EPILEPSY HETEROGENEITY;ICTAL SEMIOLOGY;INJURY INVOLVING;INTERNAL CAROTID;RADIATION INJURY;VIDEOEEG MONITORING","1;1;1;1;1;1;1;1;1;1","","",1,0.33,3,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,14,14,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2001,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,33,0.722220304463392,NA,0,1,0,0,0,0,"VALÉRIO CARELLI","1","VALÉRIO CARELLI","1","VALÉRIO CARELLI","1","VALÉRIO CARELLI","1","VALÉRIO CARELLI","33","VALÉRIO CARELLI","33","VALÉRIO CARELLI","1","MEDICINE;PSYCHOLOGY","1;1","NEUROSCIENCE;OPHTHALMOLOGY","1;1","ELECTROENCEPHALOGRAPHY;MYOCLONUS;OPTIC NERVE","1;1;1","OPTIC NEUROPATHY","1","LEBER'S HEREDITARY OPTIC NEUROPATHY","1","MYOCLONUS;OPTIC ATROPHY, HEREDITARY, LEBER;ANTI-INFLAMMATORY AGENTS;ANTIOXIDANTS;BENZOQUINONES;MUTATION;UBIQUINONE;ADULT;BIOPSY;DISEASE PROGRESSION;ELECTROENCEPHALOGRAPHY;ELECTROMYOGRAPHY;EVOKED POTENTIALS, VISUAL;HUMANS;MAGNETIC RESONANCE IMAGING;MALE;MIDDLE AGED;STEROIDS;TREATMENT OUTCOME;VISUAL ACUITY","5;5;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION","1","LIMBIC ENCEPHALITIS","1","HEREDITARY OPTIC;LEBERS HEREDITARY;MYOCLONUS REPORT;NEUROPATHY LHON;OPTIC NEUROPATHY","1;1;1;1;1","AVERAGING STUDY;DISCLOSE EPILEPTIC;EEG FAILED;EPILEPTIC FIGURES;PATHOGENIC MUTATION;PREVIOUSLY UNRECOGNISED;STUDY SUGGESTED;UNRECOGNISED ASSOCIATION","1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2002,5,6.4,2,0.4,0.2,0.4,1.11111111111111,0.666666666666667,0.5,0.666666666666667,0.2,0,0,5,0,0,0,1,0,0,20.4,0.369774819983968,NA,0.6,1,0.243,0,0,0,"F.N. ROSS–CISNEROS;VALÉRIO CARELLI;A.A. SADUN;GIORGIO BARLETTA;SABINA CEVOLI;SILVIA DI LEGGE;MM CRUZ;FRANCO GIUBILEI;PATRIZIÀ PANTANO;CRISTINA CAVALLARI;MARIA PIA SORMANI;GIOVANNI MANFREDI;S.O. WALKER;MICAELA SEPE‐MONTI;GIULIA PIERANGELI;P H WIN;GIOVANNI ANTONINI;FRANCESCA CARAMIA;FABIOLA MAGNIFICO;GIUSEPPE BONAVINA","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","F.N. ROSS–CISNEROS;VALÉRIO CARELLI;A.A. SADUN;CRISTINA CAVALLARI;P H WIN;M.A. HOLGADO;LORENZO RODRIGUEZ;ADAMO FINI;MM CRUZ;GIOVANNI MANFREDI;S.O. WALKER;NORBERTO AGUIRRE;GIORGIO BARLETTA;SABINA CEVOLI;GIULIA PIERANGELI;FABIOLA MAGNIFICO;GIUSEPPE BONAVINA;PIETRO CORTELLI;PASQUALE MONTAGNA;CARMEN GÓMEZ CANDELA","0.39;0.39;0.39;0.25;0.25;0.25;0.25;0.25;0.14;0.14;0.14;0.14;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12","VALÉRIO CARELLI;SABINA CEVOLI;SILVIA DI LEGGE;MARIA PIA SORMANI;MICAELA SEPE‐MONTI;GIOVANNI ANTONINI;FRANCESCA CARAMIA;R ANTONINI;ADAMO FINI","2;1;1;1;1;1;1;1;1","VALÉRIO CARELLI;ADAMO FINI;SABINA CEVOLI;SILVIA DI LEGGE;MARIA PIA SORMANI;MICAELA SEPE‐MONTI;GIOVANNI ANTONINI;FRANCESCA CARAMIA;R ANTONINI","0.39;0.25;0.12;0.11;0.11;0.11;0.11;0.11;0.11","CARLO POZZILLI;FRANCESCA CARAMIA;FRANCO GIUBILEI;GIOVANNI ANTONINI;MARIA PIA SORMANI;MICAELA SEPE‐MONTI;PATRIZIÀ PANTANO;R ANTONINI;SILVIA DI LEGGE;ADAMO FINI;CRISTINA CAVALLARI;LORENZO RODRIGUEZ;M.A. HOLGADO;CARMEN GÓMEZ CANDELA;FABIOLA MAGNIFICO;GIORGIO BARLETTA;GIULIA PIERANGELI;GIUSEPPE BONAVINA;PASQUALE MONTAGNA;PIETRO CORTELLI","76;76;76;76;76;76;76;76;76;21;21;21;21;4;4;4;4;4;4;4","FRANCESCA CARAMIA;GIOVANNI ANTONINI;MARIA PIA SORMANI;MICAELA SEPE‐MONTI;R ANTONINI;SILVIA DI LEGGE;ADAMO FINI;SABINA CEVOLI;VALÉRIO CARELLI","76;76;76;76;76;76;21;4;1","VALÉRIO CARELLI;ADAMO FINI;FRANCESCA CARAMIA;GIOVANNI ANTONINI;MARIA PIA SORMANI;MICAELA SEPE‐MONTI;R ANTONINI;SABINA CEVOLI;SILVIA DI LEGGE","2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;GEOLOGY;MATERIALS SCIENCE","3;2;1;1;1;1","ENDOCRINOLOGY;INTERNAL MEDICINE;ANATOMY;ANESTHESIA;CHEMICAL ENGINEERING;CHROMATOGRAPHY;COMPOSITE MATERIAL;CRYSTALLOGRAPHY;DERMATOLOGY;GASTROENTEROLOGY;GENETICS;IMMUNOLOGY;NEUROSCIENCE;OCEANOGRAPHY;OPHTHALMOLOGY;POLYMER CHEMISTRY;RADIOLOGY;SURGERY","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AMORPHOUS SOLID;ANHIDROSIS;ANTIBIOTICS;BLOOD PLASMA;CENTRAL NERVOUS SYSTEM;CENTRAL NERVOUS SYSTEM DISEASE;CHOLESTEROL;CIRCADIAN RHYTHM;COMPACTION;DISSOLUTION;EXCIPIENT;GENE;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;OPTIC NERVE;PARTICLE (ECOLOGY);PARTICLE SIZE;POLYVINYLPYRROLIDONE;RETINAL;SCANNING ELECTRON MICROSCOPE;SKIN TEMPERATURE;THERMOREGULATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","APOLIPOPROTEIN B;CHLORAMPHENICOL;LIPOPROTEIN;MITOCHONDRIAL DNA;MYELIN;OPTIC NEUROPATHY;RETINAL DEGENERATION;TRIGLYCERIDE","1;1;1;1;1;1;1;1","KEARNS–SAYRE SYNDROME","1","HYPOHIDROSIS;INDOMETHACIN;MULTIPLE SCLEROSIS;;APOLIPOPROTEINS E;BODY TEMPERATURE;CHOLESTEROL;CHOLESTEROL, HDL;CHOLESTEROL, LDL;CHOLESTEROL, VLDL;CIRCADIAN RHYTHM;ECCRINE GLANDS;FEMALE;HUMANS;PHARMACEUTIC AIDS;POVIDONE;SWEATING;TRIGLYCERIDES;ACUTE DISEASE;ADULT","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DRUG DELIVERY SYSTEMS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY","2;1;1;1",";ANHIDROSIS;BLOOD PLASMA;DIAGNOSTIC CRITERIA;EMULSION COMPOSITION;ENCAPSULATION TECHNIQUES;EXCIPIENT;KEARNS–SAYRE SYNDROME;MITOCHONDRIAL FUNCTION;PARTICLE (ECOLOGY);POLYVINYLPYRROLIDONE;SKIN TEMPERATURE;SWEATING RESPONSE;THERMOREGULATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1","BLOOD CHOLESTEROL;BODY CORE;CHLORAMPHENICOL-INDUCED RETINAL;CIRCADIAN RHYTHM;CLINICAL EPISODE;COMPACTION PROCESS;CONGENITAL GENERALIZED;CORE TEMPERATURE;DEGENERATION MIMICS;DISSOLUTION BEHAVIOR;EPISODE SUGGESTIVE;GENERALIZED ANHIDROSIS;HEREDITARY OPTIC;INDOMETHACINPOLYVINYLPYRROLIDONE SYSTEMS;LEBERS HEREDITARY;MIMICS KEARNS-SAYRE;MITOCHONDRIAL RETINAL;MORPHOMETRIC ANALYSIS;MRI ACTIVITY;MULTIPLE SCLEROSIS;MYELIN REMODELING;NARP SYNDROMES;NEUROPATHY REVEALS;OPTIC NERVES;OPTIC NEUROPATHY;PARTICLE MORPHOLOGY;PREFERENTIAL LOSS;RETINAL DEGENERATION;RETINAL DISEASE;REVEALS PREFERENTIAL","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CHOLESTEROL LEVEL;PLASMA CHOLESTEROL;DISEASE ACTIVITY;BIOLOGICAL MARKER;BLOOD SAMPLE;BLOOD SAMPLES;BRAIN MAGNETIC;CLINICAL EPISODE;CONSECUTIVE OUT-PATIENTS;DEMYELINATING EVENT;DENSITY LIPOPROTEIN;DETERMINEDWE FOUND;ENHANCING LESIONOUR;ENHANCING LESIONS;EPISODE SUGGESTIVE;EVALUATE TOTAL;FRACTIONS PLASMA;IMAGING MRI;LESIONOUR PRELIMINARY;LEVEL INCREASED;LIPID PROFILE;LIPOPROTEIN CHOLESTEROL;LIPOPROTEIN FRACTIONS;LOW DENSITY;MAGNETIC RESONANCE;MONTHLY BRAIN;MONTHS BLOOD;MRI BLOOD;MSEIGHTEEN CONSECUTIVE;MULTIPLE SCLEROSIS","3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2003,2,13,2,0.5,0,0.5,1,0.5,0,0.5,1,0,2,0,0,0,1,0,0,0,68.5,1.29421340696126,NA,0.5,1,0.55,0,0,0,"BARBARA SIMIONATI;GIORGIO VALLE;E. SCUDELLARO;FRANCESCA BISULLI;S. BINELLI;ROBERTO BIONDI;NICHOLAS Κ. MOSCHONAS;ROBERTO MICHELUCCI;D. PASSARELLI;C. A. TASSINARI;JUAN JOSÉ POZA;ULRICH STEPHANI;ALFONSO IUDICE;CARLO NOBILE;G. D’ORSI;PATRIZIA AVONI;ROSANNA ZIMBELLO;PAOLO TINUPER;JORDI PÉREZ‐TUR;M. R. DE FEO","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALFONSO IUDICE;ETTORE BEGHI;BARBARA SIMIONATI;GIORGIO VALLE;E. SCUDELLARO;FRANCESCA BISULLI;S. BINELLI;ROBERTO BIONDI;NICHOLAS Κ. MOSCHONAS;ROBERTO MICHELUCCI;D. PASSARELLI;C. A. TASSINARI;JUAN JOSÉ POZA;ULRICH STEPHANI;CARLO NOBILE;G. D’ORSI;PATRIZIA AVONI;ROSANNA ZIMBELLO;PAOLO TINUPER;JORDI PÉREZ‐TUR","0.5;0.5;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04;0.04","FRANCESCA BISULLI;ALFONSO IUDICE;PATRIZIA AVONI;PAOLO TINUPER","1;1;1;1","ALFONSO IUDICE;FRANCESCA BISULLI;PATRIZIA AVONI;PAOLO TINUPER","0.5;0.04;0.04;0.04","ADOLPHO LOPEZ DE MUNAIN;BARBARA SIMIONATI;C. A. TASSINARI;CARLO NOBILE;D. PASSARELLI;E. SCUDELLARO;FRANCESCA BISULLI;G. AVANZINI;G. D’ORSI;GIORGIO VALLE;JORDI PÉREZ‐TUR;JUAN JOSÉ POZA;M. R. DE FEO;NICHOLAS Κ. MOSCHONAS;PAOLO TINUPER;PATRIZIA AVONI;REINER SIEBERT;ROBERTO BIONDI;ROBERTO MICHELUCCI;ROSANNA ZIMBELLO","136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136;136","FRANCESCA BISULLI;PAOLO TINUPER;PATRIZIA AVONI;ALFONSO IUDICE","136;136;136;1","ALFONSO IUDICE;FRANCESCA BISULLI;PAOLO TINUPER;PATRIZIA AVONI","1;1;1;1","MEDICINE;BIOLOGY;PSYCHOLOGY","2;1;1","PSYCHIATRY;ANESTHESIA;GENETICS;INTENSIVE CARE MEDICINE;PEDIATRICS;RADIOLOGY;SURGERY","2;1;1;1;1;1;1","EPILEPSY;DISCONTINUATION;FAMILY HISTORY;GENE;MAGNETIC RESONANCE IMAGING;TRAUMATIC BRAIN INJURY","2;1;1;1;1;1","GENETIC LINKAGE;ICTAL;MUTATION;PEDIGREE CHART;PHENOTYPE","1;1;1;1;1","GENETIC HETEROGENEITY;MISSENSE MUTATION","1;1","ANTICONVULSANTS;BRAIN INJURIES;SEIZURES;EPILEPSY, TEMPORAL LOBE;HUMANS;PROTEINS;ADOLESCENT;ADULT;CHILD;EUROPE;FEMALE;GENES, DOMINANT;GENETIC HETEROGENEITY;GENETIC LINKAGE;INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;MALE;MIDDLE AGED;MUTATION;PEDIGREE","3;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY;MECHANISMS OF INTRACELLULAR MEMBRANE TRAFFICKING","1;1","ANTIEPILEPTIC DRUGS;DIAGNOSTIC CRITERIA;DISCONTINUATION;GENETIC LINKAGE;PEDIGREE CHART;SEIZURES","1;1;1;1;1;1","ACUTE TRAUMATIC;ANTI-EPILEPTIC DRUGS;AUTOSOMAL DOMINANT;BRAIN INJURY;CLINICAL SPECTRUM;DOMINANT LATERAL;EPILEPSY CLINICAL;EPITEMPIN MUTATIONS;EUROPEAN FAMILIES;GENETIC HETEROGENEITY;LATERAL TEMPORAL;PREVENTING SEIZURES;TEMPORAL EPILEPSY;TRAUMATIC BRAIN","1;1;1;1;1;1;1;1;1;1;1;1;1;1","APHASIC SEIZURES;MISSENSE MUTATIONS;ACUTE TRAUMATIC;ADDITIONAL PEDIGREES;ADLTE CLINICAL;ADLTE METHODS;AFFECTED INDIVIDUALS;AGENTS EFFECTIVE;ANALYSIS STRONGLY;ANTI-EPILEPTIC AGENTS;ANTIEPILEPTIC DRUG;AUDITORY AURAS;AUTOSOMAL DOMINANT;BRAIN INJURIES;CLEARCUT FOCAL;CLINICAL SPECTRUM;COMPUTED TOMOGRAPHY;CONTROLLED TRIALS;CT SCANS;DATA CONFIRM;DATA SOURCECOCHRANE;DISCONTINUATION INTERICTAL;DOMINANT LATERAL;DRUG DISCONTINUATION;DRUG TREATMENT;EEGS COMPUTED;ELEMENTARY COMPLEX;EPILEPSY ADLTE;EXAMINATION ROUTINE;EXONS FAILED","3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2004,1,10,3,1,0,1,1,0.5,0,0.5,1,0,0,0,0,0,0,0,0,0,56,1.19013177449717,NA,1,1,0,0,0,0,"MAURA FLOREANI;LUCIA VALENTE;ANNA CABRELLE;ELEONORA NAPOLI;FEDERICA DABBENI‐SALA;MARA CECCON;AARON P. RUSSELL;FEDERICA BRAGANTINI;BERTRAND LÉGER;LODOVICA VERGANI","1;1;1;1;1;1;1;1;1;1","MAURA FLOREANI;LUCIA VALENTE;ANNA CABRELLE;ELEONORA NAPOLI;FEDERICA DABBENI‐SALA;MARA CECCON;AARON P. RUSSELL;FEDERICA BRAGANTINI;BERTRAND LÉGER;LODOVICA VERGANI","0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1","MARA CECCON;FEDERICA BRAGANTINI;LODOVICA VERGANI","1;1;1","MARA CECCON;FEDERICA BRAGANTINI;LODOVICA VERGANI","0.1;0.1;0.1","AARON P. RUSSELL;ANNA CABRELLE;BERTRAND LÉGER;ELEONORA NAPOLI;FEDERICA BRAGANTINI;FEDERICA DABBENI‐SALA;LODOVICA VERGANI;LUCIA VALENTE;MARA CECCON;MAURA FLOREANI","56;56;56;56;56;56;56;56;56;56","FEDERICA BRAGANTINI;LODOVICA VERGANI;MARA CECCON","56;56;56","FEDERICA BRAGANTINI;LODOVICA VERGANI;MARA CECCON","1;1;1","BIOLOGY","1","BIOCHEMISTRY;CELL BIOLOGY","1;1","ANTIOXIDANT;ENZYME;INTRACELLULAR;MITOCHONDRION;OXIDATIVE PHOSPHORYLATION;OXIDATIVE STRESS;REACTIVE OXYGEN SPECIES","1;1;1;1;1;1;1","ACONITASE;CYTOSOL;GLUTATHIONE;MITOCHONDRIAL RESPIRATORY CHAIN;MITOCHONDRIAL ROS;SUPEROXIDE DISMUTASE","1;1;1;1;1;1","GLUTATHIONE PEROXIDASE","1","ACONITATE HYDRATASE;CATALASE;GLUTATHIONE;GLUTATHIONE PEROXIDASE;GLUTATHIONE REDUCTASE;GLUTATHIONE TRANSFERASE;SUPEROXIDE DISMUTASE;ANTIOXIDANTS;CARCINOMA;DNA, MITOCHONDRIAL;LUNG NEOPLASMS;OSTEOSARCOMA;REACTIVE OXYGEN SPECIES;RHABDOMYOSARCOMA;SUBCELLULAR FRACTIONS;BLOTTING, WESTERN;CELL LINE, TUMOR;HOMEOSTASIS;HUMANS","3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1","MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION","1","CELLULAR REDOX HOMEOSTASIS;GLUTATHIONE REDUCTASE;MITOCHONDRIAL RESPIRATORY CHAIN;MITOCHONDRIAL ROS","1;1;1;1","ANTIOXIDANT DEFENCES;CELL LINES;DNADEPLETED CELL;HUMAN MITOCHONDRIAL;MITOCHONDRIAL DNADEPLETED;OXYGEN SPECIES;REACTIVE OXYGEN","1;1;1;1;1;1;1","Ρ CELLS;CELL LINES;RESPIRATORY CHAIN;Ρ CELL;ANTIOXIDANT DEFENCES;BONE Ρ;MITOCHONDRIAL DNA;PARENTAL Ρ;ACONITASE ACTIVITY;ACTIVITY COMPARED;ACTIVITY GLUTATHIONE;BONE LUNG;BONEDERIVED Ρ;CELLS ACTIVITY;CELLS DERIVED;CELLS DISPLAYED;CELLS GSH;CELLS ORIGINATE;CHAIN PROMPTS;CONSISTENTLY ALTERED;CYTOSOLICIRON REGULATORY;DEPLETED Ρ;DEPLETION SIGNIFICANTLY;DIFFERING EXTENTS;DNA DEPLETED;DNA DEPLETION;EFFICIENT MITOCHONDRIAL;ESTABLISHED MITOCHONDRIAL;EXTENTS INDICATING;FUNCTIONAL RESPIRATORY","6;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2005,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2006,1,5,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,43,0.841846305374612,NA,0,0,0,0,0,0,"MARIA CRISTINA ACCONCIA;P FIORANI;FRANCESCO SPEZIALE;ENRICO SBARIGIA;DANILO TONI","1;1;1;1;1","MARIA CRISTINA ACCONCIA;P FIORANI;FRANCESCO SPEZIALE;ENRICO SBARIGIA;DANILO TONI","0.2;0.2;0.2;0.2;0.2","DANILO TONI","1","DANILO TONI","0.2","DANILO TONI;ENRICO SBARIGIA;FRANCESCO SPEZIALE;MARIA CRISTINA ACCONCIA;P FIORANI","43;43;43;43;43","DANILO TONI","43","DANILO TONI","1","ENGINEERING;MEDICINE","1;1","INTERNAL MEDICINE;MECHANICAL ENGINEERING;PSYCHIATRY;SURGERY","1;1;1;1","ASYMPTOMATIC;CAROTID ARTERIES;INTERNAL CAROTID ARTERY;MULTIVARIATE ANALYSIS;NEUROIMAGING;PROSPECTIVE COHORT STUDY;STROKE (ENGINE);TRANSCRANIAL DOPPLER","1;1;1;1;1;1;1;1","CAROTID ENDARTERECTOMY;UNIVARIATE ANALYSIS","1;1","","","BRAIN ISCHEMIA;CAROTID STENOSIS;STROKE;AGED;AGED, 80 AND OVER;CLINICAL PROTOCOLS;ENDARTERECTOMY, CAROTID;FEMALE;HEALTH STATUS INDICATORS;HUMANS;MALE;MIDDLE AGED;MULTIVARIATE ANALYSIS;PATIENT SELECTION;PROSPECTIVE STUDIES;TIME FACTORS;TREATMENT OUTCOME","2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE","1","CEREBROVASCULAR EVENTS;DELAYED CEREBRAL ISCHEMIA;ENDARTERECTOMY;ENDOVASCULAR TREATMENT;INFARCTION TREATMENT;STROKE (ENGINE);TRANSCRANIAL DOPPLER;UNIVARIATE ANALYSIS","1;1;1;1;1;1;1;1","CAROTID ENDARTERECTOMY;ISCHEMIC STROKE;ITALIAN STUDY;MULTICENTER ITALIAN;PROSPECTIVE MULTICENTER","1;1;1;1;1","ACUTE BRAIN;BRAIN ISCHEMIA;HOSPITAL DISCHARGE;UNIVARIATE ANALYSIS;ARTERY TERRITORY;ASSESSMENT ULTRASOUND;BRAIN INFARCT;CAROTID ARTERIES;CAROTID ENDARTERECTOMY;CEA VERSUS;CEREBRAL ARTERY;CEREBRAL INFARCTS;CONSIDERED VARIABLES;CT DEMONSTRATED;DAY MORBIDITY;DAYS DAYS;DAYS SURGERY;DEFICIT NIHSS;DEPARTMENT STROKE;DEPARTMENTS ENROLLED;DISCHARGE PATIENTS;DOPPLER PATIENTS;ELIGIBLE PATIENTS;EMERGENCY DEPARTMENT;EMERGENCY DEPARTMENTS;ENDARTERECTOMY CEA;ENROLLED PATIENTS;EVALUATE SAFETY;EXPERIENCED WORSENING;HEALTH STROKE","4;4;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2007,3,11.3333333333333,1,0,0,0,1,0,0,0,0,0,0,1,0,2,0,0.33,0,0.67,16.67,0.315800165374855,NA,0.333333333333333,1,0.107,0,0,0,"ANJALI S. MAHESHWARY;GIOVANNI PROVENZANO;CIRO' CANDIANO IC;FERDINANDA ANNESI;RUBENS BELFORT;ALDO QUATTRONE;GRAZIA ANNESI;ROCCA EF;MARIA CLARA TONINI;S. SALVI;G. BUSSONE;FRED N. ROSS‐CISNEROS;SOLANGE RIOS SALOMÃO;MARIANA MORAES;MILTON N. MORAES-FILHO;F. MOSCHIANO;ROBERTO DE SIMONE;DOMENICO D’AMICO;PAOLA TORELLI;GIAN CAMILLO MANZONI","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANJALI S. MAHESHWARY;RUBENS BELFORT;FRED N. ROSS‐CISNEROS;SOLANGE RIOS SALOMÃO;MARIANA MORAES;MILTON N. MORAES-FILHO;ALFREDO A. SADUN;VALÉRIO CARELLI;ADRIANA BEREZOVSKY;GIOVANNI PROVENZANO;CIRO' CANDIANO IC;FERDINANDA ANNESI;ALDO QUATTRONE;GRAZIA ANNESI;ROCCA EF;DONATELLA CIVITELLI;SARA CARRIDEO;DE MARCO EV;P. TARANTINO;MARIA CLARA TONINI","0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.11;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.1;0.07","FERDINANDA ANNESI;VALÉRIO CARELLI;PIETRO CORTELLI","1;1;1","VALÉRIO CARELLI;FERDINANDA ANNESI;PIETRO CORTELLI","0.11;0.1;0.07","DOMENICO D’AMICO;ETTORE BEGHI;F. D’ONOFRIO;F. MOSCHIANO;G. BUSSONE;GIAN CAMILLO MANZONI;GIANNI ALLAIS;M. QUARTAROLI;MARIA CLARA TONINI;MAURIZIO RONCOLATO;PAOLA TORELLI;PIETRO CORTELLI;ROBERTO DE SIMONE;S GENCO;S. SALVI;ALDO QUATTRONE;CIRO' CANDIANO IC;DE MARCO EV;DONATELLA CIVITELLI;FERDINANDA ANNESI","47;47;47;47;47;47;47;47;47;47;47;47;47;47;47;2;2;2;2;2","PIETRO CORTELLI;FERDINANDA ANNESI;VALÉRIO CARELLI","47;2;1","FERDINANDA ANNESI;PIETRO CORTELLI;VALÉRIO CARELLI","1;1;1","MEDICINE;BIOLOGY;ECONOMICS;PSYCHOLOGY","3;2;1;1","ANATOMY;GENETICS;MACROECONOMICS;NEUROSCIENCE;PATHOLOGY;PSYCHIATRY","1;1;1;1;1;1","AFFERENT;ANXIETY;COMORBIDITY;DEPRESSION (ECONOMICS);DISEASE;GENE;HEADACHES;MIGRAINE;NEUROLOGY;OPTIC NERVE;PATHOLOGICAL;PSYCHOPATHOLOGY","1;1;1;1;1;1;1;1;1;1;1;1","AURA;EFFERENT;HUMAN GENETICS;MUTATION;TENSION HEADACHE","1;1;1;1;1","AMINO ACID SUBSTITUTION;EFFERENT NERVE","1;1","HEADACHE DISORDERS;MIGRAINE DISORDERS;OBSESSIVE-COMPULSIVE DISORDER;PANIC DISORDER;TENSION-TYPE HEADACHE;ANXIETY DISORDERS;CODON;DEPRESSIVE DISORDER;HUMANS;PARKINSON DISEASE;UBIQUITIN-PROTEIN LIGASES;;AMINO ACID SUBSTITUTION;COMORBIDITY;CROSS-SECTIONAL STUDIES;FEMALE;MALE;MUTATION, MISSENSE;PREVALENCE","3;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;NUTRITIONAL GENOMICS: PERSONALIZED NUTRITION AND HEALTH;OPTICAL COHERENCE TOMOGRAPHY IMAGING","1;1;1","AMINO ACID SUBSTITUTION;BEHAVIOR CHANGE;CORTICAL SPREADING DEPRESSION;DEPRESSION (ECONOMICS);EFFERENT NERVE;HEADACHE DISORDERS;HUMAN GENETICS;IN VIVO IMAGING;MICROVASCULATURE DETECTION;MIGRAINE;OPTICAL COHERENCE TOMOGRAPHY;SPECTRAL-DOMAIN OCT;TENSION HEADACHE;TISSUE OPTICAL CLEARING","1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANXIETYDEPRESSIVE DISORDER;DISEASE PARKINSONS;DISORDER COMORBIDITY;EFFERENT FIBERS;GENE SYMBOL;HADAS STUDY;HUMAN OPTIC;HUMAN PATHOLOGICAL;MUTATIONS GENE;OPTIC NERVE;PARK DISEASE;PARKINSONS DISEASE;PATHOLOGICAL MUTATIONS;SYMBOL PARK","1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2008,3,5.33333333333333,2.66666666666667,0.333333333333333,0.666666666666667,0.333333333333333,1.14285714285714,0.5,0.666666666666667,0.5,0,0,1,2,0,0,0.33,0.67,0,0,37.33,0.680372891706928,NA,0.666666666666667,1,0.239,0,0,0,"ALFREDO A. SADUN;VALÉRIO CARELLI;PIERO BARBONI;JAMES EDMONDS;C. BELLUSCI;SOLANGE RIOS SALOMÃO;F.N. ROSS–CISNEROS;ANDREA SERINO;ELISABETTA LÀDAVAS;MICHELE CARBONELLI;CAROLINA DO VAL FERREIRA RAMOS;FRANCESCA PIZZOFERRATO;R. CINOTO;ADRIANA BEREZOVSKY","2;2;1;1;1;1;1;1;1;1;1;1;1;1","ALFREDO A. SADUN;VALÉRIO CARELLI;ANDREA SERINO;ELISABETTA LÀDAVAS;FRANCESCA PIZZOFERRATO;JAMES EDMONDS;F.N. ROSS–CISNEROS;PIERO BARBONI;C. BELLUSCI;SOLANGE RIOS SALOMÃO;MICHELE CARBONELLI;CAROLINA DO VAL FERREIRA RAMOS;R. CINOTO;ADRIANA BEREZOVSKY","0.36;0.36;0.33;0.33;0.33;0.25;0.25;0.11;0.11;0.11;0.11;0.11;0.11;0.11","VALÉRIO CARELLI;PIERO BARBONI;C. BELLUSCI;ANDREA SERINO;ELISABETTA LÀDAVAS;MICHELE CARBONELLI;FRANCESCA PIZZOFERRATO","2;1;1;1;1;1;1","VALÉRIO CARELLI;ANDREA SERINO;ELISABETTA LÀDAVAS;FRANCESCA PIZZOFERRATO;PIERO BARBONI;C. BELLUSCI;MICHELE CARBONELLI","0.36;0.33;0.33;0.33;0.11;0.11;0.11","ANDREA SERINO;ELISABETTA LÀDAVAS;FRANCESCA PIZZOFERRATO;ALFREDO A. SADUN;F.N. ROSS–CISNEROS;JAMES EDMONDS;VALÉRIO CARELLI;ADRIANA BEREZOVSKY;C. BELLUSCI;CAROLINA DO VAL FERREIRA RAMOS;MICHELE CARBONELLI;PIERO BARBONI;R. CINOTO;SOLANGE RIOS SALOMÃO","111;111;111;1;1;1;1;0;0;0;0;0;0;0","ANDREA SERINO;ELISABETTA LÀDAVAS;FRANCESCA PIZZOFERRATO;VALÉRIO CARELLI;C. BELLUSCI;MICHELE CARBONELLI;PIERO BARBONI","111;111;111;1;0;0;0","VALÉRIO CARELLI;ANDREA SERINO;ELISABETTA LÀDAVAS;FRANCESCA PIZZOFERRATO;C. BELLUSCI;MICHELE CARBONELLI;PIERO BARBONI","2;1;1;1;0;0;0","BIOLOGY;MEDICINE;PHYSICS;PSYCHOLOGY;SOCIOLOGY","2;2;1;1;1","OPHTHALMOLOGY;COGNITIVE PSYCHOLOGY;COMMUNICATION;GENETICS;INTERNAL MEDICINE;MICROBIOLOGY;NEUROSCIENCE;PALEONTOLOGY;PATHOLOGY;QUANTUM MECHANICS;SOCIAL SCIENCE","2;1;1;1;1;1;1;1;1;1;1","OPTIC NERVE;ANTIBIOTICS;FACE (SOCIOLOGICAL CONCEPT);GENE;NATURAL HISTORY;OBSERVER (PHYSICS);PERCEPTION;SENSATION;SENSORY SYSTEM;STAGE (STRATIGRAPHY);STIMULUS (PSYCHOLOGY);ULTRASTRUCTURE","2;1;1;1;1;1;1;1;1;1;1;1","OPTIC NEUROPATHY;CHLORAMPHENICOL;FACE PERCEPTION;TACTILE PERCEPTION;TACTILE STIMULI;TRANSITION (GENETICS)","2;1;1;1;1;1","LEBER'S HEREDITARY OPTIC NEUROPATHY","1",";ELECTRIC STIMULATION;PERCEPTUAL MASKING;STUDENTS;TOUCH;VISUAL PERCEPTION;ADULT;CHEEK;FACE;FEMALE;HUMANS;ITALY;MALE;REFERENCE VALUES","2;2;2;2;2;2;1;1;1;1;1;1;1;1","MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MULTISENSORY INTEGRATION IN HUMAN PERCEPTION AND COGNITION;OCULAR TOXICITY AND RETINAL DISORDERS FROM MEDICATIONS","1;1;1",";EMOTION RECOGNITION;FACE PERCEPTION;MACULOPATHY;OBSERVER (PHYSICS);OPTIC NEUROPATHY;PERCEPTUAL ENHANCEMENT;SENSATION;SENSORY EXPECTATIONS;STIMULUS (PSYCHOLOGY);SYNESTHETIC EXPERIENCES;TACTILE PERCEPTION;TACTILE STIMULI","1;1;1;1;1;1;1;1;1;1;1;1;1","OPTIC NEUROPATHY;ACUTE STAGE;CHLORAMPHENICOL-INDUCED OPTIC;ENHANCES TACTILE;HEREDITARY OPTIC;LEBERS HEREDITARY;MOUSE MODEL;NATURAL HISTORY;STAGE TRANSITION;TACTILE PERCEPTION;TOUCHED ENHANCES;ULTRASTRUCTURAL STUDY","2;1;1;1;1;1;1;1;1;1;1;1","","",1,0.33,17.58,4,0,2,0,0,0,1,0,4,0,0,1,0,0,0,0,1,0,0,0,169,169,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2009,5,7.2,2.2,0.6,0.4,0.6,1,0.75,0.666666666666667,0.75,0.4,0,2,3,0,0,0.4,0.6,0,0,60.2,1.30141839712717,NA,0.8,1,0.191,0,0,0,"ELISABETTA MALASPINA;M.E. MICHELINI;FEDERICO SADUN;BERIL TALIM;ALDO QUATTRONE;PAOLA VALENTINO;ALFREDO COLOSIMO;ANTONIO CERASA;PIERO BARBONI;LAURA MERLINI;LUCA PASSAMONTI;GABRIELLA PANUCCIO;SOLANGE RIOS SALOMÃO;FRANCESCA GUALANDI;ALESSANDRA FERLINI;MICHELA BASSOLINO;ANDREA SERINO;ANNARITA ARMAROLI;MARIA LIGUORI;ALFREDO A. SADUN","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MICHELA BASSOLINO;ANDREA SERINO;ELISABETTA LÀDAVAS;SILVIA UBALDI;ALFREDO COLOSIMO;GABRIELLA PANUCCIO;GIULIA CURIA;G. CRUCCU;MASSIMO AVOLI;ALDO QUATTRONE;PAOLA VALENTINO;ANTONIO CERASA;LUCA PASSAMONTI;MARIA LIGUORI;MARIA CECILIA GIOIA;RITA NISTICÒ;FRANCESCO SAVERIO FERA;ELISABETTA MALASPINA;M.E. MICHELINI;BERIL TALIM","0.25;0.25;0.25;0.25;0.2;0.2;0.2;0.2;0.2;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.12;0.11;0.11;0.11","ANTONIO CERASA;LAURA MERLINI;LUCA PASSAMONTI;MICHELA BASSOLINO;ANDREA SERINO;MARIA LIGUORI;ELISABETTA LÀDAVAS;VALÉRIO CARELLI;SILVIA UBALDI;G. CRUCCU;MARIA CECILIA GIOIA","1;1;1;1;1;1;1;1;1;1;1","MICHELA BASSOLINO;ANDREA SERINO;ELISABETTA LÀDAVAS;SILVIA UBALDI;G. CRUCCU;ANTONIO CERASA;LUCA PASSAMONTI;MARIA LIGUORI;MARIA CECILIA GIOIA;LAURA MERLINI;VALÉRIO CARELLI","0.25;0.25;0.25;0.25;0.2;0.12;0.12;0.12;0.12;0.11;0.1","ANDREA SERINO;ELISABETTA LÀDAVAS;MICHELA BASSOLINO;SILVIA UBALDI;ALDO QUATTRONE;ANTONIO CERASA;FRANCESCO SAVERIO FERA;LUCA PASSAMONTI;MARIA CECILIA GIOIA;MARIA LIGUORI;PAOLA VALENTINO;RITA NISTICÒ;ALFREDO COLOSIMO;G. CRUCCU;GABRIELLA PANUCCIO;GIULIA CURIA;MASSIMO AVOLI;A. DE NEGRI;ADRIANA BEREZOVSKY;ALESSANDRA FERLINI","159;159;159;159;110;110;110;110;110;110;110;110;32;32;32;32;32;0;0;0","ANDREA SERINO;ELISABETTA LÀDAVAS;MICHELA BASSOLINO;SILVIA UBALDI;ANTONIO CERASA;LUCA PASSAMONTI;MARIA CECILIA GIOIA;MARIA LIGUORI;G. CRUCCU;LAURA MERLINI;VALÉRIO CARELLI","159;159;159;159;110;110;110;110;32;0;0","ANDREA SERINO;ANTONIO CERASA;ELISABETTA LÀDAVAS;G. CRUCCU;LUCA PASSAMONTI;MARIA CECILIA GIOIA;MARIA LIGUORI;MICHELA BASSOLINO;SILVIA UBALDI;LAURA MERLINI;VALÉRIO CARELLI","1;1;1;1;1;1;1;1;1;0;0","MEDICINE;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;POLITICAL SCIENCE","4;3;1;1;1;1","NEUROSCIENCE;INTERNAL MEDICINE;CARDIOLOGY;COMMUNICATION;COMPUTER VISION;LAW;OPERATING SYSTEM;OPHTHALMOLOGY;PEDIATRICS;PSYCHIATRY;QUANTUM MECHANICS;RADIOLOGY;SURGERY","3;2;1;1;1;1;1;1;1;1;1;1;1","COGNITION;ACTION (PHYSICS);AMYGDALA;CARDIORESPIRATORY FITNESS;CONTRAST (VISION);DUCHENNE MUSCULAR DYSTROPHY;EPILEPSY;FUNCTIONAL MAGNETIC RESONANCE IMAGING;HEART FAILURE;INHIBITORY POSTSYNAPTIC POTENTIAL;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;OPTIC NERVE;POLITICS;PREDNISONE;RECEPTOR;RETINAL;SENSORY SYSTEM;SPACE (PUNCTUATION)","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ANTERIOR CINGULATE CORTEX;CARDIOMYOPATHY;EJECTION FRACTION;EXCITATORY POSTSYNAPTIC POTENTIAL;GABAERGIC;GLUTAMATE RECEPTOR;ICTAL;NERVE FIBER LAYER;NEURAL SUBSTRATE;OPIOID;OPTIC NEUROPATHY;PREFRONTAL CORTEX;REPRESENTATION (POLITICS);TACTILE STIMULI;WHITE MATTER","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLUTAMATERGIC;GREY MATTER;LEBER'S HEREDITARY OPTIC NEUROPATHY","1;1;1","COGNITION DISORDERS;MOOD DISORDERS;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;AMYGDALA;BRAIN;EPILEPSIES, PARTIAL;EVOKED POTENTIALS;GYRUS CINGULI;MALE;MEMBRANE POTENTIALS;NEURAL INHIBITION;NEURAL PATHWAYS;NEURONS;PREFRONTAL CORTEX;RECEPTORS, AMPA;RECEPTORS, GABA-A;RECEPTORS, GABA-B;RECEPTORS, GLUTAMATE;RECEPTORS, KAINIC ACID;RECEPTORS, N-METHYL-D-ASPARTATE","4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;MOLECULAR MECHANISMS OF SYNAPTIC PLASTICITY AND NEUROLOGICAL DISORDERS;TACTILE PERCEPTION AND CROSS-MODAL PLASTICITY","1;1;1;1;1","ANTIEPILEPTIC DRUGS;AUDITORY LOCALIZATION;GREY MATTER;NEURAL REGENERATION;NEURAL SUBSTRATE;NEUROLOGICAL IMPLICATIONS;PERIPERSONAL SPACE;PRESENCE;REPRESENTATION (POLITICS);SENSORY EXPECTATIONS;SKELETAL MUSCLE ATROPHY;TACTILE PERCEPTION;TACTILE STIMULI","1;1;1;1;1;1;1;1;1;1;1;1;1","CARDIAC FUNCTION;CINGULATE CORTEX;COMPUTER MOUSE;DUCHENNE MUSCULAR;DYSTROPHY PROLONGS;EMOTIONAL PROCESSING;EPILEPTIFORM SYNCHRONIZATION;EXTENDS PERIPERSONAL;FIBER LAYER;HEREDITARY OPTIC;LAYER THICKNESS;LEBERS HEREDITARY;LONG-TERM LOW-DOSAGE;LONGITUDINAL EVALUATION;MECHANISMS UNDERLYING;MOUSE EXTENDS;MULTIPLE SCLEROSIS;MUSCULAR DYSTROPHY;NERVE FIBER;NEUROBIOLOGICAL MECHANISMS;NEUROPATHY CARRIERS;OPTIC NEUROPATHY;PERIPERSONAL SPACE;PRESERVES RESPIRATORY;PROLONGS AMBULATION;RELAPSING-REMITTING MULTIPLE;RELEVANT VARIABILITY;RETINAL NERVE;SPACE REPRESENTATION;STEROID THERAPY","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MULTIPLE SCLEROSIS;EPILEPTIFORM SYNCHRONIZATION;SCLEROSIS PATIENTS;NEUROBIOLOGICAL MECHANISMS;EMOTIONAL SYMPTOMS;EPILEPTIFORM ACTIVITY;FUNCTIONAL CONNECTIVITY;ICTAL EVENTS;INTERICTAL EVENTS;STRUCTURAL MEASURES;TS PS;VENTROLATERAL PFC;ABNORMAL COMMUNICATION;ABOLISHED APINDUCED;ACCWHICH PLAYS;ACTIVATION ABOLISHED;ACTIVE TASK;ACTIVITY GENERATED;ADAPTIVE PROCESSES;ADDITION MUOPIOID;AFFECTIVE BEHAVIOUR;AFFECTIVE DISORDERS;AGONIST APPLICATION;AMINOPYRIDINE AP;ANTERIOR CINGULATE;AP ΜM;APINDUCED ICTAL;APPLICATION CONCLUSIONS;ASPARTATE NMDA;ASSUME DISEASE-MODIFYING","10;5;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1",2,0.4,11.25,1.75,0,0,0,2,1,0,0,1.75,0,0,0,0,0,0,0,0,0,0.75,0,189.25,190,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2010,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,"0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0","0",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2011,4,6.25,4,0.5,0.25,0.5,1.23076923076923,1,0.5,1,0,0,1,1,1,1,0.25,0.25,0.25,0.25,23.75,0.558373060587673,NA,0.25,1,0.179,0,0,0,"PIETRO GUARALDI;GIOVANNA CALANDRA‐BUONAURA;PIETRO CORTELLI;ROSSANA TERLIZZI;ELEONORA PORCU;GIORGIO BARLETTA;GIOVANNA GALEATI;ANNAGRAZIA CECERE;FRED N. ROSS‐CISNEROS;DIEGO BUCCI;CARLO TAMANINI;E LUGARESI;MARCELLA SPINACI;ALFREDO A. SADUN;PAOLO TINUPER;VALÉRIO CARELLI;CARLA GIORDANO;FEDERICA PROVINI;LAURA SOLIERI;CLAUDIA VALLORANI","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PIETRO GUARALDI;GIOVANNA CALANDRA‐BUONAURA;PIETRO CORTELLI;ROSSANA TERLIZZI;FRED N. ROSS‐CISNEROS;ALFREDO A. SADUN;VALÉRIO CARELLI;CARLA GIORDANO;ELEONORA PORCU;GIOVANNA GALEATI;DIEGO BUCCI;CARLO TAMANINI;MARCELLA SPINACI;CLAUDIA VALLORANI;GIORGIO BARLETTA;ANNAGRAZIA CECERE;LAURA SOLIERI;E LUGARESI;PAOLO TINUPER;FEDERICA PROVINI","0.27;0.27;0.27;0.27;0.25;0.25;0.25;0.25;0.17;0.17;0.17;0.17;0.17;0.17;0.14;0.14;0.14;0.12;0.12;0.12","PIETRO GUARALDI;GIOVANNA CALANDRA‐BUONAURA;PIETRO CORTELLI;ROSSANA TERLIZZI;ELEONORA PORCU;GIORGIO BARLETTA;ANNAGRAZIA CECERE;E LUGARESI;PAOLO TINUPER;VALÉRIO CARELLI;FEDERICA PROVINI;LAURA SOLIERI;PASQUALE MONTAGNA","2;2;2;2;1;1;1;1;1;1;1;1;1","PIETRO GUARALDI;GIOVANNA CALANDRA‐BUONAURA;PIETRO CORTELLI;ROSSANA TERLIZZI;VALÉRIO CARELLI;ELEONORA PORCU;GIORGIO BARLETTA;ANNAGRAZIA CECERE;LAURA SOLIERI;E LUGARESI;PAOLO TINUPER;FEDERICA PROVINI;PASQUALE MONTAGNA","0.27;0.27;0.27;0.27;0.25;0.17;0.14;0.14;0.14;0.12;0.12;0.12;0.12","GIOVANNA CALANDRA‐BUONAURA;PIETRO CORTELLI;PIETRO GUARALDI;ROSSANA TERLIZZI;E LUGARESI;FEDERICA PROVINI;PAOLO TINUPER;PASQUALE MONTAGNA;CARLO TAMANINI;CLAUDIA VALLORANI;DIEGO BUCCI;ELEONORA PORCU;GIOVANNA GALEATI;MARCELLA SPINACI;ANNAGRAZIA CECERE;GIORGIO BARLETTA;LAURA SOLIERI;ALFREDO A. SADUN;CARLA GIORDANO;FRED N. ROSS‐CISNEROS","56;56;56;56;44;44;44;44;38;38;38;38;38;38;12;12;12;1;1;1","GIOVANNA CALANDRA‐BUONAURA;PIETRO GUARALDI;ROSSANA TERLIZZI;E LUGARESI;FEDERICA PROVINI;PAOLO TINUPER;PASQUALE MONTAGNA;PIETRO CORTELLI;ELEONORA PORCU;ANNAGRAZIA CECERE;GIORGIO BARLETTA;LAURA SOLIERI;VALÉRIO CARELLI","56;56;56;44;44;44;44;44;38;12;12;12;1","GIOVANNA CALANDRA‐BUONAURA;PIETRO GUARALDI;ROSSANA TERLIZZI;ANNAGRAZIA CECERE;E LUGARESI;ELEONORA PORCU;FEDERICA PROVINI;GIORGIO BARLETTA;LAURA SOLIERI;PAOLO TINUPER;PASQUALE MONTAGNA;PIETRO CORTELLI;VALÉRIO CARELLI","2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PSYCHOLOGY","4;2;1;1;1","ANESTHESIA;INTERNAL MEDICINE;PSYCHIATRY;ANATOMY;ANDROLOGY;AUDIOLOGY;BIOCHEMISTRY;CARDIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;GENETICS;MECHANICAL ENGINEERING;NEUROSCIENCE;PATHOLOGY","2;2;2;1;1;1;1;1;1;1;1;1;1;1","ASYSTOLE;BLOOD PRESSURE;DELIRIUM TREMENS;DIABETES MELLITUS;DISEASE;EMBRYO;ENCEPHALOPATHY;EPILEPSY;GENE;HUMAN FERTILIZATION;INCUBATION;NEUROLOGY;SYNCOPE (PHONOLOGY);TILT (CAMERA);VITRIFICATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CRYOPRESERVATION;HEART RATE;IN VITRO FERTILISATION;MITOCHONDRIAL DNA;OOCYTE;PRION PROTEIN;STUPOR","1;1;1;1;1;1;1","CRYOPROTECTANT;FATAL FAMILIAL INSOMNIA;MITOCHONDRIAL DISEASE;MITOCHONDRIAL MYOPATHY;TILT TABLE TEST","1;1;1;1;1","HEART ARREST;SYNCOPE, VASOVAGAL;CRYOPRESERVATION;HEART;MALE;MOVEMENT DISORDERS;SLEEP INITIATION AND MAINTENANCE DISORDERS;SPINDLE APPARATUS;TILT-TABLE TEST;CELL SURVIVAL;CRYOPROTECTIVE AGENTS;FEMALE;FERTILIZATION IN VITRO;HUMANS;MICROSCOPY, FLUORESCENCE;MIDDLE AGED;OOCYTES;SLEEP STAGES;SLEEP, REM;SWINE","4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;FERTILITY PRESERVATION IN CANCER PATIENTS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION","1;1;1;1","ASYSTOLE;CRYOPRESERVED OOCYTES;CRYOPROTECTANT;DELIRIUM TREMENS;FATAL FAMILIAL INSOMNIA;MITOCHONDRIA;MITOCHONDRIAL DISEASE;MITOCHONDRIAL DYSFUNCTION;MITOCHONDRIAL ENCEPHALOMYOPATHIES;MITOCHONDRIAL FISSION;MITOCHONDRIAL FUNCTION;MITOCHONDRIAL FUSION;NEURALLY MEDIATED SYNCOPE;OOCYTE MATURATION;OOCYTE QUALITY;OVARIAN TISSUE CRYOPRESERVATION;PERIODIC LIMB MOVEMENTS;STUPOR;SYNCOPE;TILT TABLE TEST","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AGRYPNIA EXCITATA;CARDIOINHIBITORY SYNCOPE;CHROMOSOME CONFIGURATION;CRYOTOP METHOD;DNA ANALYSIS;ENCEPHALOMYOPATHY MNGIE;FOLLOW-UP STUDY;METHOD EFFECTS;MITOCHONDRIAL DNA;MITOCHONDRIAL NEUROGASTROINTESTINAL;MNGIE ULTRASTRUCTURAL;NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY;ONEIRIC STUPOR;OOCYTE VITRIFICATION;OPTIC NEUROPATHY;PECULIAR BEHAVIOUR;PIG OOCYTE;TILT-INDUCED CARDIOINHIBITORY;ULTRASTRUCTURAL FEATURES;VIABILITY SPINDLE;VITRO FERTILIZATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","","",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2012,39,10.3589743589744,3.30769230769231,0.512820512820513,0.358974358974359,0.769230769230769,1.75342465753425,1.17647058823529,1.4,1.2,0.358974358974359,1,22,11,2,1,0.56,0.28,0.05,0.03,49.1,1.17559304929071,3.14705882352941,0.358974358974359,0.974358974358974,0.402,0.371,0.343,0.366,"PIETRO CORTELLI;FABIO PIZZA;ROCCO LIGUORI;VALÉRIO CARELLI;GIUSEPPE PLAZZI;GIOVANNI RIZZO;MARIA PIA GIANNOCCARO;CATERINA TONON;RAFFAELE LODI;PIERO PARCHI;FRED N. ROSS‐CISNEROS;AGOSTINO BARUZZI;ALFREDO A. SADUN;FEDERICA PROVINI;FRANCESCA POLI;VINCENZO DONADIO;ISIDRÓ FERRER;ANNEMIEKE J.M. ROZEMÜLLER;PIERO BARBONI;DANIELLE SEILHEAN","7;6;6;6;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3","SILVIA CRISTOFORI;GIUSEPPE PLAZZI;PIETRO CORTELLI;ROCCO LIGUORI;GIOVANNI RIZZO;FEDERICA PROVINI;FABIO PIZZA;CATERINA TONON;RAFFAELE LODI;VALÉRIO CARELLI;FRANCESCA POLI;MARIA PIA GIANNOCCARO;AGOSTINO BARUZZI;FRANCESCA BISULLI;PAOLO TINUPER;STEFANO VANDI;VINCENZO DONADIO;DAVIDE BRAGHITTONI;ELISA CIARAMELLI;POUL JENNUM","1;0.87;0.78;0.67;0.65;0.65;0.64;0.59;0.59;0.54;0.45;0.45;0.45;0.42;0.42;0.38;0.38;0.33;0.33;0.33","PIETRO CORTELLI;FABIO PIZZA;ROCCO LIGUORI;VALÉRIO CARELLI;GIUSEPPE PLAZZI;GIOVANNI RIZZO;MARIA PIA GIANNOCCARO;PIERO PARCHI;FRED N. ROSS‐CISNEROS;AGOSTINO BARUZZI;FEDERICA PROVINI;FRANCESCA POLI;VINCENZO DONADIO;CHIARA LA MORGIA;MARIA LUCIA VALENTINO;STEFANO VANDI;GIOVANNA CALANDRA‐BUONAURA;SABINA CAPELLARI;GIANLUCA MARUCCI;GIORGIO BARLETTA","7;6;6;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;2","SILVIA CRISTOFORI;GIUSEPPE PLAZZI;PIETRO CORTELLI;ROCCO LIGUORI;GIOVANNI RIZZO;FEDERICA PROVINI;FABIO PIZZA;VALÉRIO CARELLI;FRANCESCA POLI;MARIA PIA GIANNOCCARO;AGOSTINO BARUZZI;FRANCESCA BISULLI;PAOLO TINUPER;STEFANO VANDI;VINCENZO DONADIO;DAVIDE BRAGHITTONI;ELISA CIARAMELLI;GIUSEPPE DI PELLEGRINO;GIANLUCA MARUCCI;FRED N. ROSS‐CISNEROS","1;0.87;0.78;0.67;0.65;0.65;0.64;0.54;0.45;0.45;0.45;0.42;0.42;0.38;0.38;0.33;0.33;0.33;0.33;0.33","GIUSEPPE PLAZZI;FABIO PIZZA;FRANCESCA POLI;PIERO PARCHI;VALÉRIO CARELLI;DANIELLE SEILHEAN;HANS A. KRETZSCHMAR;ISIDRÓ FERRER;EMMANUEL MIGNOT;ANNEMIEKE J.M. ROZEMÜLLER;ALFREDO A. SADUN;FRED N. ROSS‐CISNEROS;SABINA CAPELLARI;ELLEN GELPÍ;GIORGIO GIACCONE;GÁBOR G. KOVÁCS;JAMES W. IRONSIDE;ROMANA HÖFTBERGER;CASPER JANSEN;PIETRO CORTELLI","602;542;436;411;383;362;362;362;336;305;266;266;257;256;256;256;256;256;245;244","GIUSEPPE PLAZZI;FABIO PIZZA;FRANCESCA POLI;VALÉRIO CARELLI;SABINA CAPELLARI;PIETRO CORTELLI;ROCCO LIGUORI;GIOVANNI RIZZO;PIERO PARCHI;AGOSTINO BARUZZI;MARIA PIA GIANNOCCARO;GIOVANNA CALANDRA‐BUONAURA;CHIARA LA MORGIA;STEFANO VANDI;FEDERICA PROVINI;CESA SCAGLIONE;PAOLO MARTINELLI;SARA BONAZZA;KEIVAN KAVEH MOGHADAM;STEFANIA DETTO","560;500;394;383;257;244;226;215;215;194;186;161;149;144;123;102;102;102;95;95","PIETRO CORTELLI;ROCCO LIGUORI;GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;AGOSTINO BARUZZI;FEDERICA PROVINI;GIOVANNI RIZZO;MARIA PIA GIANNOCCARO;GIOVANNA CALANDRA‐BUONAURA;PIERO PARCHI;SABINA CAPELLARI;VINCENZO DONADIO;FRANCESCA POLI;ANNA FEDERICA MARLIANI;CHIARA LA MORGIA;FRANCESCA BISULLI;GIORGIO BARLETTA;GIULIA PIERANGELI;MARCO ZANELLO","7;6;5;5;5;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;PSYCHOLOGY;BIOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;CHEMISTRY;MATHEMATICS;POLITICAL SCIENCE;GEOLOGY;HISTORY;PHILOSOPHY;SOCIOLOGY","33;14;13;5;4;3;2;2;2;1;1;1;1","PATHOLOGY;INTERNAL MEDICINE;NEUROSCIENCE;PSYCHIATRY;GENETICS;ANATOMY;ANESTHESIA;ENDOCRINOLOGY;OPHTHALMOLOGY;RADIOLOGY;SURGERY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;OPERATING SYSTEM;PEDIATRICS;AUDIOLOGY;BIOCHEMISTRY;COMPUTATIONAL BIOLOGY;LAW;MECHANICAL ENGINEERING;MOLECULAR BIOLOGY;OPTICS;PHARMACOLOGY;PHYSICAL MEDICINE AND REHABILITATION;SOCIAL PSYCHOLOGY","14;12;11;11;10;8;6;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2","GENE;DISEASE;EPILEPSY;OPTIC NERVE;BLOOD PRESSURE;ELECTROENCEPHALOGRAPHY;NEUROLOGY;AROUSAL;DIABETES MELLITUS;MAGNETIC RESONANCE IMAGING;POPULATION;SLEEP (SYSTEM CALL);APNEA;ASYMPTOMATIC;BIOPSY;COGNITION;DRUG;INCIDENCE (GEOMETRY);INSOMNIA;MODAFINIL;NERVE FIBER;NUCLEUS;POLITICS;VOXEL","10;7;7;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","NARCOLEPSY;HEART RATE;OPTIC NEUROPATHY;MITOCHONDRIAL DNA;POLYSOMNOGRAPHY;SLEEP DISORDER;CORTICAL DYSPLASIA;DIFFUSION MRI;EPILEPSY SURGERY;GENE EXPRESSION;GENICULATE;GENOTYPE;MUTATION;NON-RAPID EYE MOVEMENT SLEEP;PARKINSON'S DISEASE;PERIPHERAL NEUROPATHY;PRION PROTEIN;SKIN BIOPSY;TEMPORAL LOBE;ACUPUNCTURE;ASYMPTOMATIC CARRIER;BODY SCHEMA;BRAIN AGING;CEREBELLAR ATAXIA;CHRONIC MIGRAINE;CRYOPRESERVATION;DEMENTIA;ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY;ENOLASE;EPILEPSY SYNDROMES;EPILEPTIC SPASMS;EXON;GENE DUPLICATION;GENICULATE BODY;HEREDITARY MOTOR AND SENSORY NEUROPATHY;LAMIN;LATERAL GENICULATE NUCLEUS;LEUKODYSTROPHY;METHYLPHENIDATE;MICRORNA;MUTANT;NERVE FIBER LAYER;NEUROBLASTOMA;NEUROPEPTIDE;NEURORADIOLOGY;OOCYTE;ORTHOSTATIC VITAL SIGNS;PARKINSONISM;PARVOCELLULAR CELL;PHANTOM LIMB;PHENOTYPE;POISSON REGRESSION;PREFRONTAL CORTEX;PROGERIA;RAPID EYE MOVEMENT SLEEP;REGULATION OF GENE EXPRESSION;REPRESENTATION (POLITICS);RETINAL GANGLION CELL;SEIZURE TYPES;SEPTIC SHOCK;SLOW-WAVE SLEEP;STATUS EPILEPTICUS;SYMPATHETIC NERVOUS SYSTEM;TOLERABILITY;TRANSCRIPTION FACTOR;WAKEFULNESS;WHITE (MUTATION)","5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CATAPLEXY;AUTONOMIC NERVOUS SYSTEM;LEBER'S HEREDITARY OPTIC NEUROPATHY;EXCESSIVE DAYTIME SLEEPINESS;AUTONOMIC NEUROPATHY;BAROREFLEX;COLD PRESSOR TEST;CREUTZFELDT-JAKOB SYNDROME;FATAL FAMILIAL INSOMNIA;FRACTIONAL ANISOTROPY;GENE EXPRESSION PROFILING;GENOTYPING;HEART RATE VARIABILITY;HIPPOCAMPAL SCLEROSIS;HOUSEKEEPING GENE;LMNA;MENTAL ARITHMETIC;MICROARRAY;OREXIN;PRNP;PURE AUTONOMIC FAILURE;REFERENCE GENES;REM SLEEP BEHAVIOR DISORDER;SANGER SEQUENCING;SCRAPIE;SLEEP STAGES;SYMPATHETIC ACTIVITY;VASCULAR DEMENTIA;VENTROMEDIAL PREFRONTAL CORTEX","4;3;3;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;OPTIC ATROPHY, HEREDITARY, LEBER;ADULT;MIDDLE AGED;NARCOLEPSY;AGED;SEIZURES;;MUSCLE, SKELETAL;DNA, MITOCHONDRIAL;OPTIC NERVE;PRION DISEASES;BRAIN NEOPLASMS;MUTATION;CASE-CONTROL STUDIES;CIRCADIAN RHYTHM;EPILEPSY, TEMPORAL LOBE;FIBROBLASTS","28;22;22;16;14;13;12;10;10;9;9;8;8;8;7;6;5;5;5;5","MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;EPILEPSY AND SEIZURES;ANALYSIS AND APPLICATIONS OF HEART RATE VARIABILITY;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;PRION DISEASES: CAUSES AND MOLECULAR BASIS;;ACUPUNCTURE MECHANISMS AND CLINICAL APPLICATIONS;AGE-RELATED MACULAR DEGENERATION RESEARCH;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;ERRORS AND COMMUNICATION IN RADIOLOGY IMAGING;FERTILITY PRESERVATION IN CANCER PATIENTS;GENOMIC REARRANGEMENTS AND COPY NUMBER VARIATIONS;INTEROCEPTION AND SOMATIC SYMPTOMS;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS;MOLECULAR MECHANISMS OF AMYLOIDOSIS","5;4;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NARCOLEPSY;INSOMNIA;EPILEPSY;GENICULATE;NERVE FIBER;NEURODEGENERATION;NEUROIMAGING;SEIZURES;SKIN BIOPSY;SLEEP;SLEEP DURATION;SLEEP PARALYSIS;SLEEP QUALITY;ACADEMIC YEAR;ACUPUNCTURE;AFRICAN DIASPORA;ALTERNATIVE MEDICINE;ASYMPTOMATIC CARRIER;AUTONOMIC NEUROPATHY;BODY SCHEMA","4;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","HEREDITARY OPTIC;OPTIC NEUROPATHY;LEBERS HEREDITARY;AUTOSOMAL DOMINANT;EYE MOVEMENT;HUMAN PRION;MOVEMENT SLEEP;NOCTURNAL FRONTAL;POST-GENICULATE INVOLVEMENT;RAPID EYE;SECONDARY POST-GENICULATE;ABNORMAL MEDIAL;ACUTE STROKE;ADULT-ONSET AUTOSOMAL;AGEING BRAIN;AMYLOIDOSIS TTR-RELATED;ANESTHETIZED PATIENTS;APOPTOTIC CASCADE;AROUSAL HERALDS;AROUSAL PREDICTS;ASYMPTOMATIC CARRIERS;ATAXIA DEAFNESS;AUTONOMIC AROUSAL;AUTONOMIC NEUROPATHY;BEHAVIOR DISORDER;BELIEF INFORMATION;BILIOPANCREATIC PROCEDURES;BODY REPRESENTATIONS;BRAINNET EUROPE;CARDIOVASCULAR-SLEEP INTERACTION","4;4;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MAGNETIC RESONANCE;LEGS SYNDROME;RESTLESS LEGS;NSE LEVELS;OPTIC NERVE;AUTONOMIC NEUROPATHY;HOSPITAL STAFF;MUTATION CARRIERS;PRION DISEASES;PROTON MAGNETIC;SERUM NSE;SKIN BIOPSY;CARRIERS ΜGL;DIFFUSION TENSOR;DISEASE CLASSIFICATION;HEALTHY CONTROLS;HEALTHY SUBJECTS;HEREDITARY OPTIC;MALE CARRIERS;MEDIAL THALAMUS;MUSCLE TONE;NEUROPATHY LHON;OPTIC NEUROPATHY;PRION PROTEIN;ROUTINE AUTONOMIC;SEVERE SEPSISSEPTIC;SHAPE ANALYSIS;UNAFFECTED MUTATION;VOXEL-BASED MORPHOMETRY;AFFECTED PATIENTS","7;6;6;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2",18,0.46,6.26,6,1,2,0,1,2.25,0,1,6.75,0,1,4,0,2.5,1,1,2.25,1,0,0,86.75,86.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,27.5,10397.5,3.03,2,1,184,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Germany;United States","1;1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1;1;1;1","CLINICAL RESEARCH;RARE DISEASES;BRAIN DISORDERS;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HUNTINGTON'S DISEASE;LUNG;LUNG CANCER;NEURODEGENERATIVE;NEUROSCIENCES","2;2;1;1;1;1;1;1;1;1","CANCER","1","2.4 SURVEILLANCE AND DISTRIBUTION;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","1;1;1;1","LUNG CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",2,249300,23246.67,3.5,11,1,1,17,13026.1111111111,2.99398643749733,"BAMBINO GESÙ CHILDREN'S HOSPITAL;CATHOLIC UNIVERSITY OF THE SACRED HEART;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;FONDAZIONE STELLA MARIS;ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA;ISTITUTO GIANNINA GASLINI;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF MESSINA;UNIVERSITY OF PADUA;UNIVERSITY OF TURIN;CENTRO CLINICO NEMO;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO","2;2;2;2;2;2;2;2;2;2;1;1","TELETHON FOUNDATION","2",NA,NA,"TELETHON - UILDM CLINICAL GRANT PROJECTS - 2011 (PROGRAM)","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1;1;1","BRAIN DISORDERS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;PEDIATRIC;RARE DISEASES;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;NEUROSCIENCES","2;2;2;2;2;1;1;1;1","MUSCULOSKELETAL","2","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2013,79,12.7341772151899,3.0253164556962,0.443037974683544,0.316455696202532,0.607594936708861,1.81060606060606,1.2962962962963,1.38888888888889,1.33333333333333,0.430379746835443,5,55,11,6,3,0.7,0.14,0.08,0.04,44.77,1.28314305055841,3.8,0.367088607594937,0.949367088607595,0.531,0.487,0.474,0.471,"GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;PIETRO CORTELLI;ROCCO LIGUORI;FRANCESCA BISULLI;FRANCESCA POLI;AGOSTINO BARUZZI;GIANLUCA MARUCCI;GIUSEPPE GASPARRE;VINCENZO DONADIO;DARIO DE BIASE;MARIA LUCIA VALENTINO;LUISA IOMMARINI;STEFANO VANDI;PAOLO TINUPER;ALESSANDRA MARESCA;SABINA CAPELLARI;LAURA LICCHETTA;YVES DAUVILLIERS","13;11;11;10;9;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4","TERESA CECCHI;GIUSEPPE PLAZZI;PIETRO CORTELLI;VALÉRIO CARELLI;FABIO PIZZA;ROCCO LIGUORI;VINCENZO DONADIO;ROBERTO VETRUGNO;FRANCESCA BISULLI;AGOSTINO BARUZZI;FEDERICA MARCOTULLI;FRANCESCA PASTORELLI;R. PLASMATI;DARIO DE BIASE;PAOLO TINUPER;MARGHERITA FABBRI;GIANLUCA MARUCCI;ROBERTO D’ALESSANDRO;STEFANO VANDI;ROBERTO D’ANGELO","2.5;2.02;1.96;1.63;1.26;1.09;0.63;0.62;0.53;0.52;0.5;0.5;0.5;0.47;0.47;0.47;0.46;0.45;0.39;0.34","GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;PIETRO CORTELLI;ROCCO LIGUORI;FRANCESCA BISULLI;FRANCESCA POLI;AGOSTINO BARUZZI;VINCENZO DONADIO;MARIA LUCIA VALENTINO;STEFANO VANDI;PAOLO TINUPER;ALESSANDRA MARESCA;SABINA CAPELLARI;LAURA LICCHETTA;ROBERTO D’ALESSANDRO;GUY A. ROULEAU;CHRISTIAN FRANCESCHINI;FIORENZO ALBANI;ANTONELLA PINI","13;11;11;10;9;6;6;5;4;4;4;4;4;4;4;4;3;3;3;3","TERESA CECCHI;GIUSEPPE PLAZZI;PIETRO CORTELLI;VALÉRIO CARELLI;FABIO PIZZA;ROCCO LIGUORI;VINCENZO DONADIO;FRANCESCA BISULLI;AGOSTINO BARUZZI;FRANCESCA PASTORELLI;R. PLASMATI;PAOLO TINUPER;MARGHERITA FABBRI;ROBERTO D’ALESSANDRO;STEFANO VANDI;ROBERTO D’ANGELO;MARIA PIA GIANNOCCARO;ALEX INCENSI;PATRIZIA AVONI;SABINA CAPELLARI","2.5;2.02;1.96;1.63;1.26;1.09;0.63;0.53;0.52;0.5;0.5;0.47;0.47;0.45;0.39;0.34;0.34;0.34;0.34;0.34","GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;FRANCESCA POLI;EMMANUEL MIGNOT;YVES DAUVILLIERS;ROCCO LIGUORI;GEERT MAYER;GERT JAN LAMMERS;ISABELLE ARNULF;PETER GEISLER;POUL JENNUM;ROSA PERAITA‐ADRADOS;CLAUDIO L. BASSETTI;LUISA IOMMARINI;MARIA LUCIA VALENTINO;MICHEL LECENDREUX;SEBASTIAAN OVEREEM;SIROUS JAVIDI;ÁLEX IRANZO","1182;922;852;790;656;607;551;487;487;487;487;487;487;480;473;460;429;429;429;429","GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;FRANCESCA POLI;ROCCO LIGUORI;ALESSANDRA MARESCA;MARIA LUCIA VALENTINO;FRANCESCA BISULLI;LAURA LICCHETTA;LEONARDO CAPORALI;ELENA FINOTTI;AGOSTINO BARUZZI;PIETRO CORTELLI;STEFANO VANDI;ALEX INCENSI;VINCENZO DONADIO;FEDERICA PROVINI;FIORENZO ALBANI;CHRISTIAN FRANCESCHINI;CHIARA LA MORGIA","1143;908;852;790;512;351;335;330;318;267;253;221;210;205;172;172;140;130;125;122","GIUSEPPE PLAZZI;VALÉRIO CARELLI;FABIO PIZZA;PIETRO CORTELLI;ROCCO LIGUORI;FRANCESCA BISULLI;FRANCESCA POLI;AGOSTINO BARUZZI;LAURA LICCHETTA;PAOLO TINUPER;STEFANO VANDI;MARIA LUCIA VALENTINO;ALESSANDRA MARESCA;ANTONELLA PINI;FIORENZO ALBANI;MARGHERITA FABBRI;SABINA CAPELLARI;TERESA CECCHI;VINCENZO DONADIO;ALEX INCENSI","12;11;10;10;8;6;6;5;4;4;4;3;3;3;3;3;3;3;3;2","MEDICINE;BIOLOGY;PSYCHOLOGY;ENGINEERING;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ECONOMICS;ART;MATHEMATICS;PHILOSOPHY;SOCIOLOGY","67;34;22;5;5;4;3;2;1;1;1;1","INTERNAL MEDICINE;PSYCHIATRY;GENETICS;NEUROSCIENCE;PATHOLOGY;PEDIATRICS;ANESTHESIA;IMMUNOLOGY;SURGERY;AUDIOLOGY;BIOCHEMISTRY;CANCER RESEARCH;CARDIOLOGY;ANATOMY;PHYSICAL MEDICINE AND REHABILITATION;PHYSICAL THERAPY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;MECHANICAL ENGINEERING;RADIOLOGY","41;24;22;21;16;14;9;9;9;8;7;7;7;6;6;6;5;5;5;5","GENE;DISEASE;NEUROLOGY;INSOMNIA;ELECTROENCEPHALOGRAPHY;EPILEPSY;MITOCHONDRION;APNEA;STROKE (ENGINE);BLOOD PRESSURE;COGNITION;ENZYME;MODAFINIL;ODDS RATIO;OPTIC NERVE;PROSPECTIVE COHORT STUDY;RECEPTOR;AQUEOUS SOLUTION;BIOPSY;CANCER;GLIOBLASTOMA;IMMUNE SYSTEM;ISCHEMIA;MIGRAINE;MULTIPLE SCLEROSIS;POPULATION","20;12;12;8;7;7;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3","NARCOLEPSY;MUTATION;POLYSOMNOGRAPHY;MITOCHONDRIAL DNA;SLEEP DISORDER;LEUKODYSTROPHY;PHENOTYPE;ALLELE;GENOTYPE;HEART RATE;NEUROPEPTIDE;NEUROPSYCHOLOGY;OPTIC NEUROPATHY;ORTHOSTATIC VITAL SIGNS;PARKINSON'S DISEASE;RESTLESS LEGS SYNDROME;WAKEFULNESS;CHRONIC MIGRAINE;CLINICAL ENDPOINT;DOPAMINERGIC;ELECTROLYTE;GENE DUPLICATION;ISCHEMIC STROKE;LOCUS (GENETICS);MICRORNA;MITOCHONDRIAL BIOGENESIS;NON-RAPID EYE MOVEMENT SLEEP;PRION PROTEIN;RAPID EYE MOVEMENT SLEEP;RESPIRATORY CHAIN;SKIN BIOPSY;SLEEP ONSET;T CELL;TEMOZOLOMIDE;THROMBOLYSIS;TUMOR PROGRESSION","12;8;7;6;6;4;4;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CATAPLEXY;EXCESSIVE DAYTIME SLEEPINESS;HAPLOTYPE;LEBER'S HEREDITARY OPTIC NEUROPATHY;MITOCHONDRIAL DISEASE;OREXIN;POINT MUTATION;DYSKINESIA;EXOME SEQUENCING;MODIFIED RANKIN SCALE;PENETRANCE;PURE AUTONOMIC FAILURE;ALTERNATIVE SPLICING;ANAEROBIC GLYCOLYSIS;APOMORPHINE;AUTONOMIC NERVOUS SYSTEM;BAROREFLEX;BUSULFAN;CENTRAL SLEEP APNEA;CHOLINERGIC FIBERS;DOPAMINE AGONIST;DOPAMINE TRANSPORTER;EPWORTH SLEEPINESS SCALE;FATAL FAMILIAL INSOMNIA;FRAMESHIFT MUTATION;GENETIC HETEROGENEITY;GENOTYPING;HEART RATE VARIABILITY;HETEROPLASMY;HYPOPNEA;IBRUTINIB;MEDDRA;MELANOPSIN;MISSENSE MUTATION;MITOCHONDRIAL ENCEPHALOMYOPATHY;MITOCHONDRIAL MYOPATHY;NEUROPSYCHOLOGICAL TEST;NON-MENDELIAN INHERITANCE;NUCLEAR PROTEIN;NUCLEOPLASM;OLIGODENDROCYTE;PERIPHERAL T-CELL LYMPHOMA;PERSISTENT VEGETATIVE STATE;POLYMORPHISM (COMPUTER SCIENCE);REM SLEEP BEHAVIOR DISORDER;SLEEP DEBT;SLEEP STAGES;SOD1;STIFF PERSON SYNDROME;SUBSTANTIA NIGRA;T-CELL RECEPTOR;TFAM;TRAIL MAKING TEST;VENTRAL STRIATUM;WARBURG EFFECT","9;4;3;3;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;NARCOLEPSY;MIDDLE AGED;ADULT;;CATAPLEXY;AGED;INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS;NEUROPEPTIDES;ADOLESCENT;BRAIN;CHILD;YOUNG ADULT;GLIOBLASTOMA;DNA, MITOCHONDRIAL;BRAIN NEOPLASMS;ITALY;MUTATION","53;42;40;33;29;27;25;20;16;13;13;12;11;11;11;10;9;8;8;8","SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;GLIOMAS;METABOLIC REPROGRAMMING IN CANCER BIOLOGY;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;QUANTUM COHERENCE IN PHOTOSYNTHESIS AND AQUEOUS SYSTEMS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;EPILEPSY AND SEIZURES;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;STRUCTURE AND FUNCTION OF THE NUCLEAR PORE COMPLEX;ADVERSE DRUG REACTIONS AND PHARMACOVIGILANCE;ANALYSIS OF GENE INTERACTION NETWORKS;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;BRAIN-COMPUTER INTERFACES IN NEUROSCIENCE AND MEDICINE;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS","12;3;3;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","NARCOLEPSY;STROKE (ENGINE);EPILEPSY;CANCER CELL METABOLISM;MITOCHONDRIAL DISEASE;PSYCHOMETRIC EVALUATION;RESTLESS LEGS SYNDROME;SLEEP DURATION;SURFACE INTERFACES;CHRONIC MIGRAINE;CLINICAL ENDPOINT;DEEP BRAIN STIMULATION;DIAGNOSTIC CRITERIA;HYPOCRETIN;INBORN ERRORS OF METABOLISM;MICRORNAS;MITOCHONDRIAL DYSFUNCTION;MITOCHONDRIAL METABOLISM;NERVE FIBER;PENETRANCE","12;5;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","CHILDHOOD NARCOLEPSY;HEREDITARY OPTIC;INORGANIC IONS;LEBERS HEREDITARY;MULTIPLE SCLEROSIS;OPTIC NEUROPATHY;AQUEOUS INTERFACES;AUTOSOMAL DOMINANT;CORTICAL MYOCLONIC;DOMINANT LEUKODYSTROPHY;DUPLICATION MECHANISMS;EMILIA-ROMAGNA REGION;EYE MOVEMENT;FAMILIAL CORTICAL;FAMILIAL FOCAL;FCMTE LOCUS;FOCAL EPILEPSY;ITALIAN POPULATION;LEGS SYNDROME;MITOCHONDRIAL BIOGENESIS;MITOCHONDRIAL DNA;MOVEMENT SLEEP;MYOCLONIC TREMOR;NEURO-ONCOLOGY PERNO;POPULATION STUDY;PROSPECTIVE ITALIAN;RAPID EYE;RESPIRATORY COMPLEX;RESTLESS LEGS;ABNORMAL PRION","3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","MIR MIR;BOLOGNA ITALY;ITALY SEARCH;MD PHD;ONLINE PUBLICATION;PUBLICATION DATE;BOLOGNA BOLOGNA;SLEEP LATENCY;MITOCHONDRIAL DNA;MUSCLE TONE;ONLINE NA;CROSSREFGOOGLE NA;CROSSREFGOOGLE SCHOLAR;DAYTIME SLEEPINESS;MITOCHONDRIAL BIOGENESIS;MULTIPLE SCLEROSIS;NARCOLEPSYHYPOCRETIN DEFICIENCY;SCIENZE NEUROLOGICHE;DELLE SCIENZE;DI BOLOGNA;HEALTHY CONTROLS;IRCCS ISTITUTO;ISTITUTO DELLE;NEUROMOTOR SCIENCES;OPTIC NEUROPATHY;PRION PROTEIN;PRPSC PK;SLEEP DISORDERS;SLEEP MEDICINE;VISUAL SENSITIVITY","11;10;10;10;10;10;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;6",32,0.41,9.69,7.25,2,1,1,1,2.5,0,0,7.5,1,1,7,0,1.75,2,1.25,5,1,0,0,102.75,102.75,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"PUBLIC LIBRARY OF SCIENCE","5","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3104 EVOLUTIONARY BIOLOGY;3202 CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY;51 PHYSICAL SCIENCES","5;5;2;2;1;1;1;1","NEUROSCIENCES;BIOTECHNOLOGY;BRAIN DISORDERS;CLINICAL RESEARCH;EPILEPSY;EYE DISEASE AND DISORDERS OF VISION;GENETICS;NEURODEGENERATIVE","2;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;NEUROLOGICAL","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","BIOMEDICAL","1","BASIC SCIENCE;PUBLIC HEALTH","2;1",NA,NA,NA,NA
"IRCCS_ISNB",2014,63,12.0634920634921,2.88888888888889,0.365079365079365,0.26984126984127,0.476190476190476,2.51388888888889,1.27777777777778,1.54545454545455,1.25,0.349206349206349,1,42,13,6,0,0.67,0.21,0.1,0,39.29,1.03953283842174,5.171875,0.301587301587302,0.952380952380952,0.461,0.338,0.414,0.388,"VALÉRIO CARELLI;PIETRO CORTELLI;CHIARA LA MORGIA;FABIO PIZZA;ROCCO LIGUORI;GIUSEPPE PLAZZI;CATERINA TONON;RAFFAELE LODI;FABRIZIO SALVI;ELISA SANCISI;PIETRO GUARALDI;LEONARDO CAPORALI;STEFANO VANDI;GIOVANNA CALANDRA‐BUONAURA;PIERO PARCHI;PIERO BARBONI;FRANCESCA PASTORELLI;STEFANO ZANIGNI;MARIA LUCIA VALENTINO;MARCO SERI","13;11;10;9;9;9;7;7;6;5;5;5;5;5;4;4;4;4;4;4","PIETRO CORTELLI;VALÉRIO CARELLI;TERESA CECCHI;FRANCESCA PASTORELLI;FABRIZIO SALVI;FABIO PIZZA;GIUSEPPE PLAZZI;R. PLASMATI;CHIARA LA MORGIA;ROCCO LIGUORI;STEFANO VANDI;ELISA SANCISI;CATERINA TONON;RAFFAELE LODI;PIETRO GUARALDI;GIOVANNA CALANDRA‐BUONAURA;CLAUDIO RAPEZZI;M. PEGOLI;SIMONA GUALDANI;DIEGO MAZZATENTA","1.25;1.2;1.2;1.17;1.16;1.09;0.93;0.92;0.82;0.82;0.72;0.56;0.54;0.54;0.53;0.53;0.5;0.5;0.5;0.47","VALÉRIO CARELLI;PIETRO CORTELLI;CHIARA LA MORGIA;FABIO PIZZA;ROCCO LIGUORI;GIUSEPPE PLAZZI;FABRIZIO SALVI;PIETRO GUARALDI;LEONARDO CAPORALI;STEFANO VANDI;GIOVANNA CALANDRA‐BUONAURA;PIERO PARCHI;FRANCESCA PASTORELLI;MARIA LUCIA VALENTINO;PAOLO TINUPER;EMMANUEL MIGNOT;ILARIA NALDI;VINCENZO DONADIO;MARIA PIA GIANNOCCARO;SABINA CEVOLI","13;11;10;9;9;9;6;5;5;5;5;4;4;4;4;4;3;3;3;3","PIETRO CORTELLI;VALÉRIO CARELLI;TERESA CECCHI;FRANCESCA PASTORELLI;FABRIZIO SALVI;FABIO PIZZA;GIUSEPPE PLAZZI;R. PLASMATI;CHIARA LA MORGIA;ROCCO LIGUORI;STEFANO VANDI;PIETRO GUARALDI;GIOVANNA CALANDRA‐BUONAURA;SIMONA GUALDANI;DIEGO MAZZATENTA;ERNESTO PASQUINI;PAOLO TINUPER;MATTEO ZOLI;LEONARDO CAPORALI;ROBERTO MICHELUCCI","1.25;1.2;1.2;1.17;1.16;1.09;0.93;0.92;0.82;0.82;0.72;0.53;0.53;0.5;0.47;0.47;0.45;0.44;0.43;0.41","VALÉRIO CARELLI;GIUSEPPE PLAZZI;ROCCO LIGUORI;FABIO PIZZA;DAVID C. CHAN;GIOVANNI MANFREDI;PRASHANT MISHRA;VINCENZO DONADIO;CHRISTIAN R. BAUMANN;GERT JAN LAMMERS;ISABELLE ARNULF;SABINA CAPELLARI;SEBASTIAAN OVEREEM;YVES DAUVILLIERS;MARIA PIA GIANNOCCARO;PATRIZIA AVONI;DIEGO MAZZATENTA;ERNESTO PASQUINI;GIORGIO FRANK;VALENTINA LETA","747;551;519;414;403;403;403;348;330;330;330;330;330;330;319;302;300;300;300;294","VALÉRIO CARELLI;GIUSEPPE PLAZZI;ROCCO LIGUORI;FABIO PIZZA;VINCENZO DONADIO;SABINA CAPELLARI;PATRIZIA AVONI;DIEGO MAZZATENTA;GIORGIO FRANK;MARIA PIA GIANNOCCARO;VALENTINA LETA;MATTEO ZOLI;AGOSTINO BARUZZI;ALEX INCENSI;CESA SCAGLIONE;PAOLO MARTINELLI;ERNESTO PASQUINI;CHIARA LA MORGIA;FRANCESCA POLI;STEFANO VANDI","716;551;471;414;348;324;302;300;300;294;294;280;252;252;252;252;246;216;187;161","VALÉRIO CARELLI;GIUSEPPE PLAZZI;FABIO PIZZA;CHIARA LA MORGIA;PIETRO CORTELLI;ROCCO LIGUORI;GIOVANNA CALANDRA‐BUONAURA;PIETRO GUARALDI;STEFANO VANDI;FABRIZIO SALVI;FRANCESCA PASTORELLI;LEONARDO CAPORALI;PAOLO TINUPER;R. PLASMATI;FRANCESCA BISULLI;ILARIA NALDI;LAURA LICCHETTA;VINCENZO DONADIO;CARLOTTA STIPA;DIEGO MAZZATENTA","11;9;9;8;8;8;5;5;5;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;PSYCHOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;PHILOSOPHY;ENGINEERING;ECONOMICS;POLITICAL SCIENCE;ART;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY;SOCIOLOGY","55;23;16;5;5;5;4;3;2;2;1;1;1;1;1","INTERNAL MEDICINE;PATHOLOGY;GENETICS;PSYCHIATRY;PEDIATRICS;SURGERY;NEUROSCIENCE;RADIOLOGY;ANATOMY;ANESTHESIA;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;CELL BIOLOGY;OPERATING SYSTEM;ARTIFICIAL INTELLIGENCE;AUDIOLOGY;CLINICAL PSYCHOLOGY;DERMATOLOGY;DEVELOPMENTAL PSYCHOLOGY;ENDOCRINOLOGY;EPISTEMOLOGY;LAW;LINGUISTICS;NUCLEAR MEDICINE;ONCOLOGY;OPTICS;PHYSICAL THERAPY;QUANTUM MECHANICS;SOCIAL PSYCHOLOGY;VIROLOGY","24;22;20;18;11;8;7;6;5;5;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENE;DISEASE;EPILEPSY;NEUROLOGY;ALTERNATIVE MEDICINE;INSOMNIA;OPTIC NERVE;ELECTROENCEPHALOGRAPHY;MAGNETIC RESONANCE IMAGING;MELATONIN;MITOCHONDRION;MODAFINIL;MULTIPLE SCLEROSIS;NOCTURNAL;POPULATION;RANDOMIZED CONTROLLED TRIAL;APNEA;ATAXIA;ATROPHY;BLINDED STUDY;COHORT;ETIOLOGY;EYE MOVEMENT;FAMILY HISTORY;NEUROSURGERY;SLEEP (SYSTEM CALL);VIRUS","21;10;10;9;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MUTATION;NARCOLEPSY;MITOCHONDRIAL DNA;EXON;GENOTYPE;PHENOTYPE;LEUKODYSTROPHY;OPTIC NEUROPATHY;POLYSOMNOGRAPHY;SLEEP DISORDER;ACTIGRAPHY;ALLELE;CEREBELLAR ATAXIA;IN VIVO MAGNETIC RESONANCE SPECTROSCOPY;LOCUS (GENETICS);PLACEBO;ADRENOCORTICOTROPIC HORMONE;AGE OF ONSET;AMYOTROPHIC LATERAL SCLEROSIS;ANTIEPILEPTIC DRUG;ANTIOXIDANT CAPACITY;BASILAR INVAGINATION;CANDIDATE GENE;CD30;CELL NUCLEUS;CHROMOSOME;CHRONOTYPE;CLEAVAGE (GEOLOGY);CYTOCHROME;CYTOCHROME C;DEMENTIA;ELECTROOCULOGRAPHY;ENCEPHALITIS;EPILEPSY SYNDROMES;ESOPHAGEAL CANCER;EXERCISE INTOLERANCE;EXPANDED DISABILITY STATUS SCALE;FINGOLIMOD;GENE ISOFORM;GENETIC LINKAGE;HEART RATE;HOLISTIC HEALTH;HUMAN LEUKOCYTE ANTIGEN;ICTAL;INNER MEMBRANE;INNER MITOCHONDRIAL MEMBRANE;INTERNAL ELASTIC LAMINA;IRRITABILITY;LAMIN;LAMOTRIGINE;LEUKOENCEPHALOPATHY;LEVETIRACETAM;LIPID BILAYER FUSION;METHYLATION;MITOCHONDRIAL BIOGENESIS;MITOCHONDRIAL RESPIRATORY CHAIN;MOTOR NEURON;MUTANT;MYOCLONIC EPILEPSY;MYOCLONIC JERK;MYOTONIA;NAIVE BAYES CLASSIFIER;NERVE FIBER LAYER;NEUROTOXICITY;NON-RAPID EYE MOVEMENT SLEEP;PAIN MEDICINE;PALSY;PARKINSONISM;PRION PROTEIN;PROBIOTIC;PROGRESSIVE MYOCLONUS EPILEPSY;RAPID EYE MOVEMENT SLEEP;RELAPSING REMITTING;RESPIRATORY CHAIN;RETINAL GANGLION CELL;SELF-EXPANDABLE METALLIC STENT;SPIKE-AND-WAVE;SPIRITUALITY;STAIN;STOP CODON;SUBLUXATION;SYMPATHETIC NERVOUS SYSTEM;TEMOZOLOMIDE;TEMPORAL LOBE;TETRAPARESIS;THERMOGENESIS;TRANSCRIPTION FACTOR;TRANSFECTION;VARICELLA ZOSTER VIRUS;VENOUS VALVES;WEIGHT GAIN;WHITE MATTER","9;8;6;4;4;4;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CATAPLEXY;EXCESSIVE DAYTIME SLEEPINESS;HAPLOTYPE;COMPOUND HETEROZYGOSITY;CYTOCHROME B;DOUBLE BLINDED;LEBER'S HEREDITARY OPTIC NEUROPATHY;MITOCHONDRIAL DISEASE;MITOCHONDRIAL ENCEPHALOMYOPATHY;SINGLE-NUCLEOTIDE POLYMORPHISM;ALTERNATIVE SPLICING;AMYLOID POLYNEUROPATHY;AUTONOMIC NERVOUS SYSTEM;AUTOSOME;BAROREFLEX;BRENTUXIMAB VEDOTIN;EXOME SEQUENCING;FRAMESHIFT MUTATION;FRONTOTEMPORAL DEMENTIA;GENE MUTATION;GENOTYPING;HETEROPLASMY;HLA-DQB1;LOWER MOTOR NEURON;MICROSATELLITE;MISSENSE MUTATION;MITOCHONDRIAL FUSION;MITOCHONDRIAL MYOPATHY;MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION;NUCLEAR PROTEIN;NUCLEAR TRANSPORT;PENETRANCE;POINT MUTATION;PROBAND;SLEEP STAGES;WILD TYPE","6;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;NARCOLEPSY;;ADOLESCENT;BRAIN;MUTATION;YOUNG ADULT;AGED;CHILD;RETROSPECTIVE STUDIES;ITALY;SLEEP;BIOMARKERS;GENETIC PREDISPOSITION TO DISEASE;EPILEPSY;MULTIPLE SCLEROSIS","43;34;34;27;26;23;19;17;16;16;16;12;10;10;9;9;8;8;7;7","SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;EPILEPSY AND SEIZURES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF AMYLOIDOSIS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT;BIOLOGY AND PATHOLOGY OF KERATINS AND RELATED DISORDERS;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;BROWN ADIPOSE TISSUE FUNCTION AND PHYSIOLOGY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CILIOPATHIES: GENETIC DISORDERS INVOLVING PRIMARY CILIA;DEVELOPMENTAL PHARMACOLOGY IN PEDIATRIC DRUG USE;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS","9;7;5;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","NARCOLEPSY;MITOCHONDRIA;SLEEP DISRUPTION;MITOCHONDRIAL DYSFUNCTION;MITOCHONDRIAL FISSION;DIAGNOSTIC CRITERIA;EPILEPSY;MELATONIN;MITOCHONDRIAL FUNCTION;SLEEP;ANTIEPILEPTIC DRUGS;BLINDED STUDY;CEREBELLAR ATAXIA;COMPOUND HETEROZYGOSITY;DOUBLE BLINDED;ETIOLOGY;FAMILIAL AMYLOID POLYNEUROPATHY;HEADACHE DISORDERS;INBORN ERRORS OF METABOLISM;INSOMNIA","8;6;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","AUTOSOMAL DOMINANT;MELATONIN REGULATION;MELATONIN SUPPLEMENTATION;MULTIPLE SCLEROSIS;NOCTURNAL MELATONIN;POST-TRAUMATIC VEGETATIVE;ADULT-ONSET LEUKODYSTROPHY;AUDITORY FEATURES;BRAIN LACTATE;CONTROLLED STUDY;DOMINANT ADULT-ONSET;EDUCATIONAL CAMPAIGN;ENDOSCOPIC ENDONASAL;H-MR SPECTROSCOPY;HEADACHE MOH;ITALIAN PRIMARY;LEUKODYSTROPHY ADLD;MEDICATION OVERUSE;OPTIC ATROPHY;OVERUSE HEADACHE;PARTIAL EPILEPSY;PLACEBO CONTROLLED;PRIMARY SCHOOL;RANDOMIZED SINGLE-BLINDED;SCHOOL TEACHERS;SINGLE-BLINDED PLACEBO;SPECTROSCOPY STUDY;WITHDRAWAL HEADACHE;ABSENCE SEIZURES;ACTH THERAPY","5;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","MEMBRANE FUSION;CSF HCRT-;MULTIPLE SCLEROSIS;PROXIMAL STRICTURES;NARCOLEPSY TYPE;SLEEP LATENCY;DEEP INTRONIC;ODDS RATIO;OPTIC ATROPHY;ANNUALIZED RELAPSE;AUTOSOMAL DOMINANT;DISABILITY PROGRESSION;DQB ODDS;EDSS SCORES;FAMILY HISTORY;INTERNAL JUGULAR;OPTIC NEUROPATHY;RELAPSE RATE;SELF-EXPANDING METAL;BASAL GANGLIA;CEREBROSPINAL FLUID;COVERED SELF-EXPANDING;ESOPHAGEAL SPHINCTER;ESOPHAGEAL STRICTURES;HCRT- DEFICIENCY;ICTAL EEG;INHERITED OPTIC;INTRONIC MUTATION;JUGULAR VEIN;LATENCY MINUTES","10;8;8;8;7;7;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3",30,0.48,8.53,5,2,1.5,2,4.25,2.25,0,1,5,0,1,8,2,1,2,2,10,2.5,0,0,82.5,82.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,225824,22582.4,5,10,1,1,21,17542.5911111111,3.59125967201602,"BAMBINO GESÙ CHILDREN'S HOSPITAL;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRO CLINICO NEMO;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;FONDAZIONE STELLA MARIS;ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA;ISTITUTO GIANNINA GASLINI;UNIVERSITY OF MESSINA;UNIVERSITY OF PADUA;UNIVERSITY OF TURIN","1;1;1;1;1;1;1;1;1;1","TELETHON FOUNDATION","1",NA,NA,"TELETHON SPECIAL PROJECTS - 2013 (PROGRAM)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;NEURODEGENERATIVE;NEUROSCIENCES;ORPHAN DRUG;PEDIATRIC;PEDIATRIC RESEARCH INITIATIVE;RARE DISEASES;SPINAL MUSCULAR ATROPHY","1;1;1;1;1;1;1;1;1;1;1","MUSCULOSKELETAL","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,17,"PUBLIC LIBRARY OF SCIENCE","17","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;3202 CLINICAL SCIENCES;5203 CLINICAL AND HEALTH PSYCHOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3109 ZOOLOGY;3207 MEDICAL MICROBIOLOGY;38 ECONOMICS;3801 APPLIED ECONOMICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4403 DEMOGRAPHY;49 MATHEMATICAL SCIENCES;5204 COGNITIVE AND COMPUTATIONAL PSYCHOLOGY","15;8;8;6;3;1;1;1;1;1;1;1;1;1;1;1;1","BRAIN DISORDERS;BEHAVIORAL AND SOCIAL SCIENCE;CLINICAL RESEARCH;ACQUIRED COGNITIVE IMPAIRMENT;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);NEURODEGENERATIVE;NEUROSCIENCES;DOWN SYNDROME;MENTAL HEALTH;PEDIATRIC;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);AUTOIMMUNE DISEASE;BASIC BEHAVIORAL AND SOCIAL SCIENCE;CARDIOVASCULAR;DEMENTIA;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;MIND AND BODY","6;4;4;3;3;3;3;3;2;2;2;1;1;1;1;1;1;1;1;1","CARDIOVASCULAR;MENTAL HEALTH","1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","1;1","CLINICAL","2","CLINICAL MEDICINE AND SCIENCE","8",NA,NA,NA,NA
"IRCCS_ISNB",2015,54,13.0185185185185,3.7037037037037,0.296296296296296,0.37037037037037,0.351851851851852,2.22222222222222,1.14285714285714,1.81818181818182,1.11764705882353,0.481481481481481,1,32,14,7,0,0.59,0.26,0.13,0,33.81,0.907336755447195,5.55151515151515,0.425925925925926,1,0.512,0.512,0.275,0.445,"PIETRO CORTELLI;PAOLO TINUPER;DIEGO MAZZATENTA;FABIO PIZZA;ERNESTO PASQUINI;ROCCO LIGUORI;MATTEO ZOLI;GIORGIO FRANK;FRANCESCA BISULLI;GIOVANNA CALANDRA‐BUONAURA;VALÉRIO CARELLI;GIUSEPPE PLAZZI;MARCO FAUSTINI‐FUSTINI;RAFFAELE LODI;SABINA CAPELLARI;CATERINA TONON;CHIARA LA MORGIA;MARIA LUCIA VALENTINO;STEFANO VANDI;ADELAIDE VALLUZZI","15;9;7;7;7;7;7;7;6;6;6;6;6;5;5;4;4;4;4;4","PIETRO CORTELLI;DIEGO MAZZATENTA;ERNESTO PASQUINI;MATTEO ZOLI;GIORGIO FRANK;FABIO PIZZA;MARCO FAUSTINI‐FUSTINI;GIUSEPPE PLAZZI;PAOLO TINUPER;ADELAIDE VALLUZZI;ROCCO LIGUORI;GIOVANNA CALANDRA‐BUONAURA;STEFANO VANDI;FRANCESCA BISULLI;SABINA CAPELLARI;VALÉRIO CARELLI;FEDERICA PROVINI;RAFFAELE LODI;LAURA LICCHETTA;LUISA SAMBATI","2.32;1.05;1.05;1.05;1.05;0.86;0.79;0.77;0.71;0.7;0.54;0.53;0.48;0.47;0.42;0.37;0.34;0.34;0.32;0.32","PIETRO CORTELLI;PAOLO TINUPER;DIEGO MAZZATENTA;FABIO PIZZA;ROCCO LIGUORI;MATTEO ZOLI;GIORGIO FRANK;FRANCESCA BISULLI;GIOVANNA CALANDRA‐BUONAURA;VALÉRIO CARELLI;GIUSEPPE PLAZZI;MARCO FAUSTINI‐FUSTINI;SABINA CAPELLARI;CHIARA LA MORGIA;MARIA LUCIA VALENTINO;STEFANO VANDI;ADELAIDE VALLUZZI;LAURA LICCHETTA;VINCENZO DONADIO;GUIDO RUBBOLI","15;9;7;7;7;7;7;6;6;6;6;6;5;4;4;4;4;4;3;3","PIETRO CORTELLI;DIEGO MAZZATENTA;MATTEO ZOLI;GIORGIO FRANK;FABIO PIZZA;MARCO FAUSTINI‐FUSTINI;GIUSEPPE PLAZZI;PAOLO TINUPER;ADELAIDE VALLUZZI;ROCCO LIGUORI;GIOVANNA CALANDRA‐BUONAURA;STEFANO VANDI;FRANCESCA BISULLI;SABINA CAPELLARI;VALÉRIO CARELLI;FEDERICA PROVINI;LAURA LICCHETTA;LUISA SAMBATI;CHIARA LA MORGIA;AGOSTINO BARUZZI","2.32;1.05;1.05;1.05;0.86;0.79;0.77;0.71;0.7;0.54;0.53;0.48;0.47;0.42;0.37;0.34;0.32;0.32;0.29;0.29","ROCCO LIGUORI;PAOLO TINUPER;VALÉRIO CARELLI;PIETRO CORTELLI;FRANCESCA BISULLI;FLAVIA PALOMBO;TOMMASO PIPPUCCI;RAFFAELE LODI;STEFANO MELETTI;LAURA LICCHETTA;INGRID E. SCHEFFER;FABIO PIZZA;SARA BALDASSARI;CHIARA LA MORGIA;MARGHERITA SANTUCCI;GIUSEPPE PLAZZI;GUIDO RUBBOLI;ALESSANDRA MARESCA;SAMUEL F. BERKOVIC;LEONARDO CAPORALI","567;426;387;370;363;309;309;302;298;293;292;273;258;257;255;248;246;231;213;210","ROCCO LIGUORI;PAOLO TINUPER;VALÉRIO CARELLI;FRANCESCA BISULLI;PIETRO CORTELLI;LAURA LICCHETTA;FABIO PIZZA;CHIARA LA MORGIA;MARGHERITA SANTUCCI;GIUSEPPE PLAZZI;ALESSANDRA MARESCA;LEONARDO CAPORALI;ALEX INCENSI;VINCENZO DONADIO;CLAUDIA ZANNA;MARIA LUCIA VALENTINO;AGOSTINO BARUZZI;STEFANO VANDI;GIOVANNA CALANDRA‐BUONAURA;CRISTINA PICCININI","567;426;387;363;342;293;273;257;255;248;231;210;198;198;180;170;169;166;130;122","PIETRO CORTELLI;PAOLO TINUPER;FABIO PIZZA;ROCCO LIGUORI;FRANCESCA BISULLI;MARCO FAUSTINI‐FUSTINI;GIUSEPPE PLAZZI;VALÉRIO CARELLI;SABINA CAPELLARI;ADELAIDE VALLUZZI;CHIARA LA MORGIA;DIEGO MAZZATENTA;GIORGIO FRANK;GIOVANNA CALANDRA‐BUONAURA;LAURA LICCHETTA;MARIA LUCIA VALENTINO;MATTEO ZOLI;STEFANO VANDI;AGOSTINO BARUZZI;ALEX INCENSI","13;9;7;7;6;6;6;6;5;4;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;PSYCHOLOGY;ENGINEERING;ART;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;SOCIOLOGY;ECONOMICS;PHILOSOPHY","51;22;7;3;2;2;2;2;2;1;1","INTERNAL MEDICINE;PATHOLOGY;PSYCHIATRY;GENETICS;NEUROSCIENCE;SURGERY;PEDIATRICS;AUDIOLOGY;BIOINFORMATICS;ENVIRONMENTAL HEALTH;OPHTHALMOLOGY;RADIOLOGY;ANESTHESIA;GASTROENTEROLOGY;IMMUNOLOGY;ONCOLOGY;PHYSICAL MEDICINE AND REHABILITATION;CANCER RESEARCH;CARDIOLOGY;COMPUTATIONAL BIOLOGY;DEMOGRAPHY;ENDOCRINOLOGY;FAMILY MEDICINE;NURSING;OPERATING SYSTEM;VIROLOGY","29;17;17;16;12;9;6;4;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","DISEASE;GENE;NEUROLOGY;EPILEPSY;ATROPHY;BLOOD PRESSURE;COHORT;COGNITION;HORMONE;POPULATION;BIOPSY;CANCER;OPTIC NERVE;RANDOMIZED CONTROLLED TRIAL;ADENOMA;ANESTHESIOLOGY;ANTIBODY;APNEA;CEREBROSPINAL FLUID;CHEMOTHERAPY;ELECTROENCEPHALOGRAPHY;ELECTROPHYSIOLOGY;EYE MOVEMENT;INSOMNIA;MAGNETIC RESONANCE IMAGING;NEUROSURGERY;PATHOGENESIS;PITUITARY TUMORS;QUALITY OF LIFE (HEALTHCARE);RECEPTOR;RETINA;SKULL;SLEEP (SYSTEM CALL);SPINAL CORD;VACCINATION","17;16;11;8;6;5;5;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MUTATION;NARCOLEPSY;PARKINSON'S DISEASE;PHENOTYPE;GENE EXPRESSION;HEART RATE;OPTIC NEUROPATHY;COGNITIVE IMPAIRMENT;DEMENTIA;ENDOSCOPIC ENDONASAL SURGERY;GENE DUPLICATION;GENOTYPE;GLUCOCEREBROSIDASE;LEUKODYSTROPHY;MITOCHONDRIAL DNA;NEUROPEPTIDE;NEURORADIOLOGY;ORTHOSTATIC VITAL SIGNS;PAIN MEDICINE;PARKINSONISM;PITUITARY ADENOMA;POLYSOMNOGRAPHY;RAPID EYE MOVEMENT SLEEP;SKIN BIOPSY;SLEEP DISORDER;WAKEFULNESS;WHITE MATTER","9;5;5;5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","EXOME SEQUENCING;HEART RATE VARIABILITY;LEBER'S HEREDITARY OPTIC NEUROPATHY;CATAPLEXY;DNA METHYLATION;EXCESSIVE DAYTIME SLEEPINESS;FRACTIONAL ANISOTROPY;GENE MUTATION;OREXIN;PURE AUTONOMIC FAILURE;ACROMEGALY;ALTERNATIVE SPLICING;BOSTON NAMING TEST;CADASIL;COGNITIVE DECLINE;CREUTZFELDT-JAKOB SYNDROME;EPWORTH SLEEPINESS SCALE;ERLOTINIB;EXECUTIVE DYSFUNCTION;FRONTOTEMPORAL DEMENTIA;GEFITINIB;GENOMICS;GLYCOGEN STORAGE DISEASE TYPE II;HAPLOINSUFFICIENCY;HLA-DQB1;LEVODOPA;MISSENSE MUTATION;MITOCHONDRIAL FUSION;NIVOLUMAB;NULL ALLELE;OPTIC RADIATION;PRNP;PROBAND;PROMOTER;RNA SPLICING;SLEEP STAGES;TRANSSPHENOIDAL SURGERY;V600E;VAGUS NERVE STIMULATION;VENTROMEDIAL PREFRONTAL CORTEX","4;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;;NARCOLEPSY;YOUNG ADULT;EPILEPSY;ADOLESCENT;AGED;CHILD;SKIN;AGED, 80 AND OVER;AUTONOMIC NERVOUS SYSTEM DISEASES;ITALY;MUTATION;OPTIC ATROPHY, AUTOSOMAL DOMINANT;PARKINSON DISEASE;SLEEP WAKE DISORDERS","39;33;31;26;24;15;14;14;13;11;11;8;8;7;7;7;7;7;7;7","DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EPILEPSY AND SEIZURES;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;LYSOSOMAL STORAGE DISORDERS IN HUMAN HEALTH AND DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;GLIOMAS;ADVANCEMENTS IN LUNG CANCER RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BONE TUMORS AND TUMOR-LIKE CONDITIONS IN SKELETAL SYSTEM;CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIDEMIOLOGY AND MANAGEMENT OF SEXUAL DYSFUNCTION;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GENETIC BASIS OF NEUROPATHIES AND RELATED DISORDERS;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES","5;5;5;5;5;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","EPILEPSY;NARCOLEPSY;NEURODEGENERATION;EXOME;AUTONOMIC FUNCTION;CRANIOPHARYNGIOMAS;DEEP BRAIN STIMULATION;ENDOSCOPIC ENDONASAL SURGERY;HYPOTHALAMIC REGULATION;NEUROMODULATION;NEURORADIOLOGY;PAIN MEDICINE;PATHOGENESIS;PITUITARY TUMORS;PURE AUTONOMIC FAILURE;SKIN BIOPSY;SLEEP;SLEEP DURATION;STATUS EPILEPTICUS;AFATINIB","6;6;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1","ENDOSCOPIC ENDONASAL;PARKINSONS DISEASE;AUTONOMIC DYSFUNCTION;AUTOSOMAL DOMINANT;COGNITIVE IMPAIRMENT;COHORT STUDY;COMMON GLUCOCEREBROSIDASE;DOMINANT LEUKODYSTROPHY;ENDONASAL SURGERY;FOCAL EPILEPSY;GENE MUTATIONS;GLUCOCEREBROSIDASE GENE;MAGNETIC RESONANCE;MITOCHONDRIAL OPTIC;NARCOLEPSY TYPE;OPTIC NEUROPATHIES;TYPE NARCOLEPSY;ACTH ADENOMAS;ADENOMAS INVADING;ADENOMAS TRANSFORMING;ADULT POPULATION;ADULT-ONSET AUTOSOMAL;ADVANCED PARKINSON;ADVANCED SCC;ALSFRS-R DECLINE;ALTERNATING HEMIPLEGIA;ANATOMICAL PROFILE;ATROPHY SPECTRUM;ATYPICAL CREUTZFELDT-JAKOB;AUDITORY FEATURES","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","BOLOGNA ITALY;BOLOGNA BOLOGNA;ITALY SEARCH;DI SCIENZE;DIPARTIMENTO DI;CROSSREFGOOGLE SCHOLAR;DI NEUROLOGIA;CROSSREFGOOGLE NA;DELLE SCIENZE;IRCCS ISTITUTO;ISTITUTO DELLE;SCIENZE NEUROLOGICHE;DIBINEM UNIVERSITY;NEUROLOGIA DIPARTIMENTO;NEUROMOTORIE DIBINEM;SCIENZE BIOMEDICHE;UNITA DI;GENERALIZED EPILEPSY;SKELETAL MUSCLE;CHIRURGICHE DIMEC;DI BOLOGNA;DIMEC UNIVERSITY;MEDICHE CHIRURGICHE;NEUROLOGICHE DI;OPTIC ATROPHY;SCIENZE MEDICHE;SODIUM OXYBATE;CADASIL PATIENT;NARCOLEPSY TYPE;SUPPLEMENTARY FIG","67;49;40;37;37;20;20;19;18;18;18;18;17;17;17;17;17;15;14;13;13;13;13;13;13;13;13;12;12;12",24,0.44,11.78,9,5,2.5,1,2,3,0,1,9.25,0,1,5,0,2,2.5,1.5,5.25,1,1,0,92.75,93,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3,6,5515,3.8,2,0.67,45.67,0,0,1,0,0,0,0,2,0,1,1,0,0,0,1,0,0,3,0,0,2,0,0,0,0,1,0,0,0,0,"Belgium;Germany","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","1;1;1;1;1;1","CLINICAL RESEARCH;AGING;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEURODEGENERATIVE;NEUROSCIENCES;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BEHAVIORAL AND SOCIAL SCIENCE;COMPARATIVE EFFECTIVENESS RESEARCH;COMPLEMENTARY AND INTEGRATIVE HEALTH;DEMENTIA;HEALTH SERVICES;PARKINSON'S DISEASE;PATIENT SAFETY;PREVENTION","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL","2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES;4202 EPIDEMIOLOGY","4;2;1;1;1;1","ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);BIOTECHNOLOGY;BRAIN DISORDERS;CLINICAL RESEARCH;DEMENTIA;DIABETES;GENETICS;HUMAN GENOME;NEURODEGENERATIVE;NUTRITION;PREVENTION","1;1;1;1;1;1;1;1;1;1;1;1;1;1","METABOLIC AND ENDOCRINE","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","BIOMEDICAL;CLINICAL","1;1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","1;1",NA,NA,NA,NA
"IRCCS_ISNB",2016,49,14.6530612244898,2.55102040816327,0.26530612244898,0.387755102040816,0.408163265306122,1.66666666666667,1.18181818181818,1.46153846153846,1.17647058823529,0.530612244897959,1,30,13,4,1,0.61,0.27,0.08,0.02,72.53,2.23287841752237,5.41414141414142,0.448979591836735,1,0.427,0.256,0.317,0.358,"GIUSEPPE PLAZZI;TIM SPELMAN;JEANNETTE LECHNER‐SCOTT;FABIO PIZZA;MARIA TROJANO;HELMUT BUTZKUEVEN;EUGENIO PUCCI;ALESSANDRA LUGARESI;PIERRE DUQUETTE;GERARDO IULIANO;PIERRE GRAMMOND;ALBA A. BRANDES;ROBERTO BERGAMASCHI;FRANCO GRANELLA;RAFFAELE FERRI;CATERINA TONON;STEFANIA EVANGELISTI;RAFFAELE LODI;PIERO PARCHI;DANA HORÁKOVÁ","8;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4","GIUSEPPE PLAZZI;V. DONAIO;FABIO PIZZA;ELISA CIARAMELLI;ELENA BERTOSSI;PIERO PARCHI;SABINA CAPELLARI;RAFFAELE FERRI;PIETRO CORTELLI;DIEGO MAZZATENTA;CARMELO LUCIO STURIALE;ROCCO BONFATTI;ERNESTO PASQUINI;MATTEO ZOLI;GIORGIO FRANK;VINCENZO DONADIO;STEFANO VANDI;ROCCO LIGUORI;CATERINA TONON;STEFANIA EVANGELISTI","1.06;1;0.87;0.75;0.75;0.51;0.51;0.51;0.38;0.35;0.35;0.35;0.35;0.35;0.35;0.34;0.32;0.31;0.3;0.3","GIUSEPPE PLAZZI;FABIO PIZZA;ALESSANDRA LUGARESI;ALBA A. BRANDES;PIERO PARCHI;SABINA CAPELLARI;PIETRO CORTELLI;VINCENZO DONADIO;FRANCESCA BISULLI;DIEGO MAZZATENTA;CARMELO LUCIO STURIALE;ROCCO BONFATTI;ANTONELLA PINI;PAOLO TINUPER;ROCCO LIGUORI;CORRADO ZENESINI;MATTEO ZOLI;GIORGIO FRANK;LAURA LICCHETTA;ILARIA NALDI","8;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;2","GIUSEPPE PLAZZI;V. DONAIO;FABIO PIZZA;ELISA CIARAMELLI;ELENA BERTOSSI;PIERO PARCHI;SABINA CAPELLARI;PIETRO CORTELLI;DIEGO MAZZATENTA;CARMELO LUCIO STURIALE;ROCCO BONFATTI;MATTEO ZOLI;GIORGIO FRANK;VINCENZO DONADIO;STEFANO VANDI;ROCCO LIGUORI;CORRADO ZENESINI;ALBA A. BRANDES;CHIARA TESINI;ALESSANDRO CAPPELLI","1.06;1;0.87;0.75;0.75;0.51;0.51;0.38;0.35;0.35;0.35;0.35;0.35;0.34;0.32;0.31;0.3;0.27;0.25;0.25","GIUSEPPE PLAZZI;RAFFAELE FERRI;MAX HIRSHKOWITZ;ALON Y. AVIDAN;ANDREW D. KRYSTAL;CONSTANCE H. FUNG;DAVID GOZAL;EMERSON M. WICKWIRE;FRANK A. J. L. SCHEER;FRANK J. DALY;KENNETH L. LICHSTEIN;MAURICE M. OHAYON;MICHAEL V. VITIELLO;MONICA P. MALLAMPALLI;NANCY HAZEN;ROBERT RAWDING;STEVEN M. ALBERT;VIREND K. SOMERS;YVES DAUVILLIERS;ALESSANDRA LUGARESI","1234;1149;1088;924;924;924;924;924;924;924;924;924;924;924;924;924;924;924;924;714","GIUSEPPE PLAZZI;ALESSANDRA LUGARESI;ALBA A. BRANDES;ELENA BERTOSSI;ELISA CIARAMELLI;PIERO PARCHI;NICOLETTA ZINI;PIETRO CORTELLI;SABINA CAPELLARI;FRANCESCA BISULLI;FABIO PIZZA;ALESSANDRO CAPPELLI;CHIARA TESINI;ANTONELLA PINI;ILARIA NALDI;LAURA LICCHETTA;PAOLO TINUPER;S BONFIGLIO;FEDERICO OPPI;ROBERTO PODA","1229;714;540;162;162;128;127;122;117;113;97;95;95;91;81;81;81;76;70;70","GIUSEPPE PLAZZI;ALESSANDRA LUGARESI;ALBA A. BRANDES;PIERO PARCHI;SABINA CAPELLARI;FABIO PIZZA;ROCCO LIGUORI;ANTONELLA PINI;FRANCESCA BISULLI;PIETRO CORTELLI;VINCENZO DONADIO;MATTEO ZOLI;CARMELO LUCIO STURIALE;CORRADO ZENESINI;DIEGO MAZZATENTA;ELENA BERTOSSI;ELISA CIARAMELLI;FEDERICO OPPI;GIORGIO FRANK;ILARIA NALDI","7;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;PSYCHOLOGY;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;ECONOMICS;ENGINEERING;PHYSICS;POLITICAL SCIENCE;BUSINESS;GEOLOGY;MATERIALS SCIENCE;PHILOSOPHY","45;15;11;7;6;4;2;2;2;1;1;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;GENETICS;SURGERY;NEUROSCIENCE;ONCOLOGY;BIOCHEMISTRY;ANATOMY;CANCER RESEARCH;PEDIATRICS;RADIOLOGY;OPERATING SYSTEM;PHYSICAL MEDICINE AND REHABILITATION;ENDOCRINOLOGY;IMMUNOLOGY;NUCLEAR MEDICINE;PHYSICAL THERAPY;ACCOUNTING;AUDIOLOGY;CARDIOLOGY;CELL BIOLOGY;COGNITIVE PSYCHOLOGY;DEVELOPMENTAL PSYCHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;MANAGEMENT;MEDICAL EDUCATION;MOLECULAR BIOLOGY;NURSING;VIROLOGY","29;13;12;8;8;7;7;6;5;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","DISEASE;GENE;COGNITION;COHORT;ELECTROENCEPHALOGRAPHY;MULTIPLE SCLEROSIS;CONFIDENCE INTERVAL;MAGNETIC RESONANCE IMAGING;NEUROLOGY;SLEEP (SYSTEM CALL);BIOPSY;BLOOD PRESSURE;CANCER;CHEMOTHERAPY;COHORT STUDY;GLIOMA;RECEPTOR;ATROPHY;CEREBROSPINAL FLUID;DENERVATION;DIABETES MELLITUS;DUCHENNE MUSCULAR DYSTROPHY;EPILEPSY;EXTRACELLULAR MATRIX;HIPPOCAMPUS;INSOMNIA;OPTIC NERVE;PROPORTIONAL HAZARDS MODEL;QUALITY OF LIFE (HEALTHCARE);RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;SKULL;SUDOMOTOR;TASK (PROJECT MANAGEMENT);TENDON","10;8;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","GENOTYPE;NARCOLEPSY;PRION PROTEIN;HEART RATE;PHENOTYPE;POLYSOMNOGRAPHY;ADRENERGIC;ASTROCYTOMA;COLLAGEN VI;COLLAGEN, TYPE I, ALPHA 1;ENDOSCOPIC ENDONASAL SURGERY;HAZARD RATIO;PREFRONTAL CORTEX;SKIN BIOPSY;SLEEP DISORDER;SYMPATHETIC NERVOUS SYSTEM;TEMOZOLOMIDE;ACCRUAL;ACTIGRAPHY;AGE OF ONSET;ALLELE;ANTIDEPRESSANT;ASTROCYTE;AUTOIMMUNITY;BEVACIZUMAB;BIOSTATISTICS;CANDIDATE GENE;CELL MIGRATION;CEREBELLAR ATAXIA;CEREBELLAR HEMISPHERE;CEREBRAL PERFUSION PRESSURE;CHROMOSOME;CLINICAL ENDPOINT;CYCLOPHOSPHAMIDE;DEFAULT MODE NETWORK;DEMENTIA;DENTATE NUCLEUS;DIFFUSION MRI;DRUG RESISTANT EPILEPSY;EPILEPSY SYNDROMES;EPISODIC MEMORY;EXPANDED DISABILITY STATUS SCALE;EXTERNAL VENTRICULAR DRAIN;FIBRILLOGENESIS;FIBROBLAST;FIBRONECTIN;FLUID-ATTENUATED INVERSION RECOVERY;GENE ISOFORM;GENETIC LINKAGE;GIST;HYPERINTENSITY;IMATINIB;IN VIVO MAGNETIC RESONANCE SPECTROSCOPY;INJURY PREVENTION;INTELLIGENCE QUOTIENT;INTERVERTEBRAL DISK;IRON-BINDING PROTEINS;LEUKOENCEPHALOPATHY;LOCUS (GENETICS);LOW BIRTH WEIGHT;MEMORY CONSOLIDATION;MIND-WANDERING;MISMATCH NEGATIVITY;MUTATION;MYOFIBROBLAST;NEURODEGENERATION;NEUROPSYCHOLOGY;OPHTHALMIC ARTERY;OPTIC CANAL;OPTIC NEUROPATHY;ORTHOSTATIC VITAL SIGNS;OZONE THERAPY;PARKINSON'S DISEASE;PARKINSONISM;PEDIATRIC ONCOLOGY;PERIPHERAL NEUROPATHY;PITUITARY ADENOMA;PITUITARY GLAND;PRECUNEUS;PROCEDURAL MEMORY;PROGRESSIVE SUPRANUCLEAR PALSY;PROSTATE CANCER;PROTEASES;QUARTILE;RAVEN'S PROGRESSIVE MATRICES;RECOMBINANT DNA;SEIZURE TYPES;STATUS EPILEPTICUS;SUNITINIB;SYMPATHETIC DENERVATION;THERMOSTABILITY;TRANSITION (GENETICS);TYROSINE-KINASE INHIBITOR;UNIVARIATE ANALYSIS;WAKEFULNESS;WHITE MATTER;WORKING MEMORY","6;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","AUTONOMIC NERVOUS SYSTEM;CREUTZFELDT-JAKOB SYNDROME;CATAPLEXY;OLIGODENDROGLIOMA;PHARMACOGENETICS;VENTROMEDIAL PREFRONTAL CORTEX;ALLELIC HETEROGENEITY;BAROREFLEX;CADASIL;CHRONESTHESIA;CONCUSSION;DEMENTIA WITH LEWY BODIES;EXCESSIVE DAYTIME SLEEPINESS;FRATAXIN;GENE MAPPING;GENETIC HETEROGENEITY;HAPLOTYPE;IDH1;LEBER'S HEREDITARY OPTIC NEUROPATHY;LEWY BODY;NERVE BIOPSY;PITUITARY NEOPLASM;PRNP;PURE AUTONOMIC FAILURE;REM SLEEP BEHAVIOR DISORDER;SCRAPIE;SINGLE-NUCLEOTIDE POLYMORPHISM;SLEEP MEDICINE;SLEEP STAGES;TRANSSPHENOIDAL SURGERY;VASCULAR DEMENTIA;VENLAFAXINE;VINCRISTINE","3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;BRAIN;ADULT;MIDDLE AGED;CREUTZFELDT-JAKOB SYNDROME;YOUNG ADULT;ADOLESCENT;GLIOMA;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;AGED;EPILEPSY;MENINGIOMA;MULTIPLE SCLEROSIS;NARCOLEPSY;BRAIN NEOPLASMS;CHILD;DISEASE PROGRESSION","42;32;27;24;23;22;17;11;10;10;10;10;9;9;9;9;9;8;7;7","GLIOMAS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;PRION DISEASES: CAUSES AND MOLECULAR BASIS;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES;ADAPTATION OF TENDON AND SKELETAL MUSCLE TO MECHANICAL LOADING;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND MANAGEMENT OF SYNCOPE;EPILEPSY AND SEIZURES;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DEVELOPMENTAL PERSPECTIVE ON MOTOR SKILL COMPETENCE;DIAGNOSIS AND MANAGEMENT OF CEREBRAL VEIN THROMBOSIS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS;EXOSOME BIOLOGY AND FUNCTION IN INTERCELLULAR COMMUNICATION;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;MECHANISMS OF MULTIDRUG RESISTANCE IN CANCER","6;5;4;4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","DIAGNOSTIC CRITERIA;NARCOLEPSY;SLEEP;AUTONOMIC DYSFUNCTION;CREUTZFELDT-JAKOB SYNDROME;EPILEPSY;SLEEP DURATION;SLEEP QUALITY;COLLAGEN VI;DIFFUSION MRI;ENDOSCOPIC ENDONASAL SURGERY;ENDOSCOPIC SURGERY;GLIOBLASTOMA;NEUROIMAGING;PATHOLOGICAL PROTEIN MISFOLDING;PREFRONTAL CORTEX;RADIOTHERAPY;SKIN BIOPSY;SUDOMOTOR;SYMPATHETIC NERVOUS SYSTEM","5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","MULTIPLE SCLEROSIS;ENDOSCOPIC ENDONASAL;MUSCULAR DYSTROPHY;NARCOLEPSY TYPE;CREUTZFELDT-JAKOB DISEASE;CREUTZFELDTJAKOB DISEASE;DUCHENNE MUSCULAR;ENDONASAL SURGERY;GLIOMA EORTC;HEALTH-RELATED QUALITY;HIGH-RISK LOW-GRADE;INTERGROUP STUDY;LOW-GRADE GLIOMA;OPEN-LABEL PHASE;PHASE INTERGROUP;PREFRONTAL DAMAGE;RANDOMISED OPEN-LABEL;VENTROMEDIAL PREFRONTAL;AAD RECEPTORRECEPTOR;ABNORMAL PRION;ACTIVE IMMUNOMODULATORY;ADENOMAS ROLE;ADULT MYOCLONUS;ADVANCED MULTIPLE;AGE-RELATED DIFFERENCES;AMELIORATES ACCUMULATION;ANGIOGENESIS-RELATED GENES;ASTROCYTE PROCESSES;AUTOIMMUNITY-ASSOCIATED AUTONOMIC;AUTONOMIC DENERVATION","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","COLLAGEN VI;MULTIPLE SCLEROSIS;PRION PROTEIN;PROGRESSION-FREE SURVIVAL;PRP SC;SECONDARY PROGRESSIVE;TYPE NARCOLEPSY;GRAY MATTER;PROGRESSIVE MULTIPLE;SLEEP QUALITY;PARKINSONS DISEASE;DIAGNOSTIC ACCURACY;MEDICAL CENTER;NETHERLANDS DEPARTMENT;PRION STRAINS;PROGRESSIVE SUPRANUCLEAR;UNIVERSITY MEDICAL;VENTRICLE VOLUME;WHITE MATTER;CENTER AMSTERDAM;CHOROIDAL THICKNESS;DISABILITY STATUS;EXPANDED DISABILITY;EXTRACELLULAR MATRIX;HEALTHY CONTROLS;HEIDENHAIN VARIANT;LOW-GRADE GLIOMA;MONTHS CI;PALSY-RICHARDSONS SYNDROME;PATIENTS TREATED","18;9;9;8;8;8;8;7;7;7;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4",30,0.61,18.76,16,2.75,2.75,1,4,1.25,0,2,18.5,0,0,15,1,1,2,3.5,7.5,4,0,0,93.25,93.25,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,3,345,1.41,0,0,2,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,"Belgium","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","1;1","AGING;BRAIN DISORDERS;CLINICAL RESEARCH;NEURODEGENERATIVE;NEUROSCIENCES;PARKINSON'S DISEASE","1;1;1;1;1;1","NEUROLOGICAL","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES","1;1",NA,NA,NA,NA,1,239498,9579.92,3,25,13,1,18,7709.78666666667,6.35555847632619,"BAMBINO GESÙ CHILDREN'S HOSPITAL;CENTRO HOSPITALAR DO PORTO;CHILDREN'S MEMORIAL HEALTH INSTITUTE;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;HOSPICES CIVILS DE LYON;HOSPITAL SANT JOAN DE DÉU BARCELONA;HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE;HÔPITAL NECKER-ENFANTS MALADES;ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA;ISTITUTO NEUROLOGICO CARLO BESTA;KU LEUVEN;KUOPIO UNIVERSITY HOSPITAL;OXFORD UNIVERSITY HOSPITALS NHS TRUST;PARC DE SALUT;QUEEN ELIZABETH UNIVERSITY HOSPITAL;ROYAL HOLLOWAY UNIVERSITY OF LONDON;SAHLGRENSKA UNIVERSITY HOSPITAL;SPITALUL CLINIC DE PSIHIATRIE ALEXANDRU OBREGIA;ST. ANNE´S UNIVERSITY HOSPITAL;UNIVERSITY COLLEGE LONDON","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MEDICAL RESEARCH COUNCIL","1","COALITION S;ICRP - INTERNATIONAL CANCER RESEARCH PARTNERSHIP;UKRI - UK RESEARCH AND INNOVATION","1;1;1","INTRAMURAL (PROJECT CATEGORY)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","1;1","BRAIN DISORDERS;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPLEMENTARY AND INTEGRATIVE HEALTH;EPILEPSY;HEALTH SERVICES;NEURODEGENERATIVE;NEUROSCIENCES;NUTRITION;PEDIATRIC","1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL","1","5.7 PHYSICAL;6.1 PHARMACEUTICALS;6.7 PHYSICAL;7.1 INDIVIDUAL CARE NEEDS","1;1;1;1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"IRCCS_ISNB",2017,51,14.9607843137255,2.2156862745098,0.156862745098039,0.235294117647059,0.215686274509804,2.01785714285714,1,1.71428571428571,1.22222222222222,0.588235294117647,1,32,15,0,2,0.63,0.29,0,0.04,71.71,2.43276730880534,6.09745762711864,0.509803921568627,0.980392156862745,0.419,0.245,0.316,0.357,"ALBA A. BRANDES;GIUSEPPE PLAZZI;WOLFGANG WICK;MARTIN J. VAN DEN BENT;FABIO PIZZA;THIERRY GORLIA;VASSILIS GOLFINOPOULOS;PAUL M. CLÉMENT;WALTER TAAL;ROGER STUPP;VALÉRIO CARELLI;MURAT TERZI;JEANNETTE LECHNER‐SCOTT;MICHAEL WELLER;TOMÁŠ KALINČÍK;DANA HORÁKOVÁ;HELMUT BUTZKUEVEN;ALESSANDRA LUGARESI;MARCO FILARDI;JULIEN DÔMONT","9;8;7;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4","GIUSEPPE PLAZZI;FERRUCCIO TRIFIRÒ;FABIO PIZZA;MARCO FILARDI;VALÉRIO CARELLI;ELENA ANTELMI;PIETRO CORTELLI;LORENZO TONETTI;VINCENZO NATALE;ALBA A. BRANDES;CHIARA BENEDETTO;GIANNI ALLAIS;PATRIZIA AVONI;WOLFGANG WICK;CARLO BORTOLOTTI;DIEGO MAZZATENTA;CARMELO LUCIO STURIALE;ERNESTO PASQUINI;CORRADO ZENESINI;MATTEO ZOLI","1.2;1;0.83;0.63;0.55;0.5;0.49;0.42;0.42;0.4;0.33;0.33;0.33;0.31;0.29;0.27;0.27;0.27;0.27;0.27","ALBA A. BRANDES;GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;ALESSANDRA LUGARESI;ELENA ANTELMI;DIEGO MAZZATENTA;CARMELO LUCIO STURIALE;PATRIZIA AVONI;CORRADO ZENESINI;MATTEO ZOLI;GIORGIO FRANK;LAURA MILANESE;PIETRO CORTELLI;MARCO FAUSTINI‐FUSTINI;LORENZO FERRI;FRANCESCA BISULLI;GIOVANNI RIZZO;MARIA GIULIA BACALINI;CARLO BORTOLOTTI","9;8;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","GIUSEPPE PLAZZI;FERRUCCIO TRIFIRÒ;FABIO PIZZA;VALÉRIO CARELLI;ELENA ANTELMI;PIETRO CORTELLI;ALBA A. BRANDES;PATRIZIA AVONI;CARLO BORTOLOTTI;DIEGO MAZZATENTA;CARMELO LUCIO STURIALE;CORRADO ZENESINI;MATTEO ZOLI;GIORGIO FRANK;LAURA MILANESE;VANESSA CANDELA;LEONARDO CAPORALI;GIOVANNI RIZZO;STEFANO VANDI;SABINA CAPELLARI","1.2;1;0.83;0.55;0.5;0.49;0.4;0.33;0.29;0.27;0.27;0.27;0.27;0.27;0.27;0.25;0.23;0.22;0.22;0.22","ALBA A. BRANDES;VASSILIS GOLFINOPOULOS;WOLFGANG WICK;BRIGITTA G. BAUMERT;OLIVIER CHINOT;WARREN MASON;MARTIN J. VAN DEN BENT;MICHAEL WELLER;PAUL M. CLÉMENT;THIERRY GORLIA;WALTER TAAL;ROGER STUPP;ANTJE WICK;ARJUN SAHGAL;CHAD WINCH;CHRISTOPHER J. O’CALLAGHAN;CLAIRE PHILLIPS;DAVID OSOBA;ENRICO FRANCESCHI;FLORENCE LAIGLE–DONADEY","2049;2046;2046;1268;1268;1268;1127;1127;1127;1127;1127;1126;919;919;919;919;919;919;919;919","ALBA A. BRANDES;ENRICO FRANCESCHI;VALÉRIO CARELLI;ALESSANDRA LUGARESI;MARCO FAUSTINI‐FUSTINI;GIUSEPPE PLAZZI;LUCA VIGNATELLI;CARMELO LUCIO STURIALE;CORRADO ZENESINI;DIEGO MAZZATENTA;GIORGIO FRANK;LAURA MILANESE;MATTEO ZOLI;CLAUDIO FRANCESCHI;FABIO PIZZA;MARIA GIULIA BACALINI;CHIARA PIRAZZINI;PATRIZIA AVONI;ROCCO BONFATTI;ELENA ANTELMI","2049;919;282;223;191;188;159;153;153;153;153;153;153;110;110;110;90;89;89;80","ALBA A. BRANDES;GIUSEPPE PLAZZI;FABIO PIZZA;VALÉRIO CARELLI;ALESSANDRA LUGARESI;ELENA ANTELMI;PIETRO CORTELLI;CARMELO LUCIO STURIALE;CORRADO ZENESINI;DIEGO MAZZATENTA;GIORGIO FRANK;LAURA MILANESE;MARCO FAUSTINI‐FUSTINI;MATTEO ZOLI;PATRIZIA AVONI;CHIARA LA MORGIA;CLAUDIO FRANCESCHI;FRANCESCA BISULLI;GIOVANNI RIZZO;LUCA VIGNATELLI","9;8;6;5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","MEDICINE;PSYCHOLOGY;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHILOSOPHY;PHYSICS;MATHEMATICS;ART;ECONOMICS;ENGINEERING;POLITICAL SCIENCE","47;14;12;6;5;4;4;3;2;1;1;1","INTERNAL MEDICINE;PSYCHIATRY;ONCOLOGY;SURGERY;PATHOLOGY;RADIOLOGY;NEUROSCIENCE;GENETICS;ANESTHESIA;AUDIOLOGY;BIOCHEMISTRY;CELL BIOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;IMMUNOLOGY;PEDIATRICS;PHYSICAL THERAPY;CANCER RESEARCH;ENDOCRINOLOGY;LINGUISTICS;NUCLEAR MEDICINE;OPHTHALMOLOGY","28;12;11;10;9;9;8;6;5;5;5;4;4;4;4;4;4;3;3;3;3;3","GENE;CHEMOTHERAPY;DISEASE;ELECTROENCEPHALOGRAPHY;NEUROLOGY;CANCER;COGNITION;CONFIDENCE INTERVAL;EPILEPSY;MAGNETIC RESONANCE IMAGING;MULTIPLE SCLEROSIS;NEUROIMAGING;RANDOMIZED CONTROLLED TRIAL;ATROPHY;CEREBROSPINAL FLUID;CLINICAL TRIAL;COHORT;POPULATION;PROPORTIONAL HAZARDS MODEL;ALTERNATIVE MEDICINE;CLINICAL PRACTICE;DUCHENNE MUSCULAR DYSTROPHY;GLIOMA;MITOCHONDRION;MULTIVARIATE ANALYSIS;MUSCULAR DYSTROPHY;OVERALL SURVIVAL;OXIDATIVE PHOSPHORYLATION;RADIATION THERAPY;RECEPTOR;RETINA;RETINAL;SKELETAL MUSCLE;SKULL;SLEEP (SYSTEM CALL);SPINAL CORD;TERMINOLOGY;TRANSPLANTATION","8;7;7;6;6;5;5;5;5;5;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CYCLOPHOSPHAMIDE;HAZARD RATIO;NARCOLEPSY;BEVACIZUMAB;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;COLORECTAL CANCER;FINGOLIMOD;MUTATION;RANDOMIZATION;TEMOZOLOMIDE;CLINICAL NEUROPHYSIOLOGY;DACARBAZINE;EPILEPSY SYNDROMES;MUTANT;NATALIZUMAB;PARKINSON'S DISEASE;POLYSOMNOGRAPHY;PREFRONTAL CORTEX;RAPID EYE MOVEMENT SLEEP;RESPIRATORY CHAIN;WHITE MATTER","5;5;5;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","VINCRISTINE;CATAPLEXY;REM SLEEP BEHAVIOR DISORDER;WILD TYPE;ACROMEGALY;ALPHA-SYNUCLEIN;ANAPLASTIC ASTROCYTOMA;ATRX;CHRONESTHESIA;DNA METHYLATION;DOPAMINE TRANSPORTER;GREY MATTER;IDH1;INTERFERON BETA-1A;INTERFERON BETA-1B;KRAS;LEBER'S HEREDITARY OPTIC NEUROPATHY;MDX MOUSE;MISSENSE MUTATION;OLIGODENDROGLIOMA;PARASOMNIA;PDGFRA;PITUITARY APOPLEXY;PRIMARY INSOMNIA;PTEN;REGORAFENIB;SDHA;SLEEP STAGES;SUBSTANTIA NIGRA;SUMATRIPTAN;TERIFLUNOMIDE;TRACTOGRAPHY;TRANSSPHENOIDAL SURGERY;TRINUCLEOTIDE REPEAT EXPANSION;VENTROMEDIAL PREFRONTAL CORTEX;VOXEL-BASED MORPHOMETRY","5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;;AGED;EPILEPSY;MITOCHONDRIA;SEIZURES;BRAIN;ELECTROENCEPHALOGRAPHY;GLIOBLASTOMA;MUSCULAR DYSTROPHY, DUCHENNE;POSTOPERATIVE COMPLICATIONS;AGED, 80 AND OVER;ADOLESCENT;BIOMARKERS;CENTRAL NERVOUS SYSTEM DEPRESSANTS;MAGNETIC RESONANCE IMAGING","35;28;27;21;19;16;15;13;10;9;8;8;8;8;8;7;6;6;6;6","GLIOMAS;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;EPILEPSY AND SEIZURES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;MOLECULAR MECHANISMS OF MUSCLE REGENERATION AND ATROPHY;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;AMINO ACID TRANSPORT AND METABOLISM IN HEALTH AND DISEASE;DIFFUSION MAGNETIC RESONANCE IMAGING;DISEASES RELATED TO BLOOD GROUP VARIANTS;GLOBAL PREVALENCE AND TREATMENT OF GLAUCOMA;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;INTEROCEPTION AND SOMATIC SYMPTOMS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES","8;7;4;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","LOMUSTINE;NARCOLEPSY;CLINICAL ENDPOINT;GLIOBLASTOMA;PROGRESSION-FREE SURVIVAL;SLEEP;TEMOZOLOMIDE;CLINICAL NEUROPHYSIOLOGY;CLINICAL PRACTICE;DACARBAZINE;EPILEPSY;EPILEPSY DETECTION;EPILEPSY SYNDROMES;NATALIZUMAB;SLEEP DISRUPTION;WILD TYPE;5-HYDROXYMETHYLCYTOSINE;A-SYNUCLEIN;ACROMEGALY;ANAPLASTIC ASTROCYTOMA","5;5;4;4;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1","ENDOSCOPIC ENDONASAL;GLIOBLASTOMA PATIENTS;BEHAVIOR DISORDER;BREAST CANCER;CLINICAL PRACTICE;DOMINANT OPTIC;DUCHENNE MUSCULAR;DÉJÀ VU;ENDONASAL SURGERY;EPILEPSY SYNDROMES;ILAE NEUROPHYSIOLOGY;MULTIPLE SCLEROSIS;MUSCULAR DYSTROPHY;NARCOLEPTIC PATIENTS;NEUROPHYSIOLOGY TASK;OPTIC ATROPHY;REM SLEEP;SLEEP BEHAVIOR;TASK FORCE;ACUTE MIGRAINE;ADHD SYMPTOMS;ADJUVANT TEMOZOLOMIDE;ADULT NARCOLEPTIC;ALEMTUZUMAB COMPARED;ALISPORIVIR RESCUES;ALTERED CINGULATE;ANAPLASTIC GLIOMA;ANTAGONIZES GLUTAMINE;ANTIBIOTIC PROPHYLAXIS;ANTIPORTER ANTAGONIZES","3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","BOLOGNA ITALY;BOLOGNA BOLOGNA;SLEEP-WAKE RHYTHM;CROSSREFGOOGLE SCHOLAR;NEUROMOTOR SCIENCES;SCIENCES UNIVERSITY;CROSSREFGOOGLE NA;DIBINEM DEPARTMENT;MELATONIN SECRETION;MULTIPLE SCLEROSIS;PINEAL CYST;IDH WILD;INTERFERON BETA;MD PHD;WILD TYPE;COMPLEX II;DELLE SCIENZE;DI BOLOGNA;IDH MUTATION;IRCCS ISTITUTO;ISTITUTO DELLE;MELATONIN CURVE;NEURAL TUBE;NT PATIENTS;SCIENZE NEUROLOGICHE;XCT ANTIPORTER;ADJUVANT TEMOZOLOMIDE;ALTERED MELATONIN;AUSL DI;BODY-CORE TEMPERATURE","23;17;12;10;10;10;9;9;9;9;9;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6;5;5;5;5",29,0.57,8.15,11,2,2,1,10,9.5,1,2,11,0,1,9.5,0,0,2,2,7,3,0,0,95,95,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE","6;3","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES","7;5;4;2",NA,NA,NA,NA,"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;2","NOT SITE-SPECIFIC CANCER;SKIN CANCER","3;1",NA,NA
"IRCCS_ISNB",2018,74,15.6891891891892,2.9054054054054,0.337837837837838,0.283783783783784,0.418918918918919,1.93693693693694,1.04166666666667,1.4,1.19230769230769,0.527027027027027,1,37,25,3,4,0.5,0.34,0.04,0.05,34.04,1.11578133025856,6.30743243243243,0.472972972972973,0.986486486486487,0.464,0.427,0.417,0.448,"FABIO PIZZA;GIUSEPPE PLAZZI;ELENA ANTELMI;SABINA CAPELLARI;ROCCO LIGUORI;ALESSANDRA LUGARESI;PIERO BARBANTI;PIERO PARCHI;LICIA GRAZZI;GIULIA PIERANGELI;PATRIZIA SOLA;CORRADO ZENESINI;PIETRO CORTELLI;DIANA FERRARO;VINCENZO DONADIO;SIMONE BAIARDI;FRANCO GRANELLA;SABINA CEVOLI;HELMUT BUTZKUEVEN;LUISA SAMBATI","10;10;9;9;8;7;6;6;6;6;6;5;5;4;4;4;4;4;4;4","GIUSEPPE PLAZZI;FABIO PIZZA;ELENA ANTELMI;FERRUCCIO TRIFIRÒ;SABINA CAPELLARI;CORRADO ZENESINI;ROCCO LIGUORI;PIERO PARCHI;MINO ZUCCHELLI;ERCOLE GALASSI;GIULIA PIERANGELI;PIETRO CORTELLI;PIERO BARBANTI;LICIA GRAZZI;LUISA SAMBATI;RAFFAELE FERRI;MARCO FILARDI;STEFANO VANDI;ANNA BARTOLETTI‐STELLA;DIEGO MAZZATENTA","1.18;1.1;1.06;1;0.83;0.78;0.69;0.54;0.5;0.5;0.48;0.46;0.45;0.45;0.45;0.43;0.42;0.41;0.4;0.38","FABIO PIZZA;GIUSEPPE PLAZZI;ELENA ANTELMI;SABINA CAPELLARI;ROCCO LIGUORI;ALESSANDRA LUGARESI;PIERO PARCHI;GIULIA PIERANGELI;CORRADO ZENESINI;PIETRO CORTELLI;VINCENZO DONADIO;SABINA CEVOLI;LUISA SAMBATI;ANNA BARTOLETTI‐STELLA;STEFANO VANDI;CESA SCAGLIONE;DIEGO MAZZATENTA;CHIARA PIRAZZINI;GIOVANNI RIZZO;FABRIZIO SALVI","10;10;9;9;8;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3","GIUSEPPE PLAZZI;FABIO PIZZA;ELENA ANTELMI;FERRUCCIO TRIFIRÒ;SABINA CAPELLARI;CORRADO ZENESINI;ROCCO LIGUORI;PIERO PARCHI;MINO ZUCCHELLI;GIULIA PIERANGELI;PIETRO CORTELLI;LUISA SAMBATI;STEFANO VANDI;ANNA BARTOLETTI‐STELLA;DIEGO MAZZATENTA;MATTEO ZOLI;FEDERICA GUARALDI;ALESSANDRA LUGARESI;CESA SCAGLIONE;FEDERICA PROVINI","1.18;1.1;1.06;1;0.83;0.78;0.69;0.54;0.5;0.48;0.46;0.45;0.41;0.4;0.38;0.38;0.38;0.36;0.36;0.33","GIUSEPPE PLAZZI;FABIO PIZZA;EMMANUEL MIGNOT;ALBA A. BRANDES;ELENA ANTELMI;YVES DAUVILLIERS;STEFANO VANDI;FANG HAN;PAUL E. PEPPARD;BIRGIT HÖGL;LUCIE BARATEAU;MARICA EOLI;ANDREA PACE;ARDI PAMBUKU;BRUNO DANIELE;FRANCESCO PASQUALETTI;GIAN LUCA DE SALVO;GIOVANNA MAGNI;GIUSEPPE LOMBARDI;IVAN LOLLI","619;537;452;427;423;400;367;353;353;318;318;291;288;288;288;288;288;288;288;288","GIUSEPPE PLAZZI;FABIO PIZZA;ALBA A. BRANDES;ELENA ANTELMI;STEFANO VANDI;VINCENZO DONADIO;FRANCESCA BISULLI;LAURA LICCHETTA;PAOLO TINUPER;SABINA CAPELLARI;ROCCO LIGUORI;CESA SCAGLIONE;GIOVANNI RIZZO;LAURA LOMBARDO;DIEGO MAZZATENTA;ALEX INCENSI;PIERO PARCHI;FEDERICA GUARALDI;MATTEO ZOLI;MICHELANGELO STANZANI MASERATI","573;491;427;423;367;248;204;204;204;202;176;151;143;139;133;124;124;117;117;108","GIUSEPPE PLAZZI;ELENA ANTELMI;FABIO PIZZA;SABINA CAPELLARI;ROCCO LIGUORI;CORRADO ZENESINI;GIULIA PIERANGELI;ALESSANDRA LUGARESI;PIERO PARCHI;ANNA BARTOLETTI‐STELLA;CESA SCAGLIONE;PIETRO CORTELLI;SABINA CEVOLI;STEFANO VANDI;VINCENZO DONADIO;GIOVANNI RIZZO;DIEGO MAZZATENTA;FABRIZIO SALVI;LUISA SAMBATI;MICHELANGELO STANZANI MASERATI","10;9;9;6;6;5;5;5;5;4;4;4;4;4;4;3;3;3;3;3","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;SOCIOLOGY;ECONOMICS;ENGINEERING;PHILOSOPHY;POLITICAL SCIENCE;HISTORY;ART;BUSINESS;GEOLOGY;PHYSICS","67;23;17;10;5;4;4;3;3;3;3;2;1;1;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;GENETICS;PEDIATRICS;SURGERY;NEUROSCIENCE;ANESTHESIA;PHYSICAL THERAPY;BIOCHEMISTRY;RADIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;AUDIOLOGY;BIOINFORMATICS;GASTROENTEROLOGY;PHYSICAL MEDICINE AND REHABILITATION;ANATOMY;ARTIFICIAL INTELLIGENCE;CELL BIOLOGY;NURSING","41;30;16;15;11;11;10;9;9;8;7;6;6;6;5;5;5;5;4;4;4;4","DISEASE;GENE;NEUROLOGY;MIGRAINE;MULTIPLE SCLEROSIS;POPULATION;RANDOMIZED CONTROLLED TRIAL;COGNITION;COHORT;MAGNETIC RESONANCE IMAGING;MODAFINIL;NEUROSURGERY;CANCER;ELECTROENCEPHALOGRAPHY;EPILEPSY;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;BLOOD PRESSURE;CHEMOTHERAPY;CONFIDENCE INTERVAL;CONTEXT (ARCHAEOLOGY);MULTIVARIATE ANALYSIS;OPTIC NERVE;SKULL;STIMULATION","18;12;12;7;6;6;6;5;5;5;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3","NARCOLEPSY;NEURORADIOLOGY;DEMENTIA;EXPANDED DISABILITY STATUS SCALE;CLINICAL ENDPOINT;GENE EXPRESSION;PARKINSON'S DISEASE;PHENOTYPE;CHRONIC MIGRAINE;HAZARD RATIO;MUTATION;OPTIC NEUROPATHY;POLYSOMNOGRAPHY;SLEEP DISORDER;VAGUS NERVE;ACTIGRAPHY;ALZHEIMER'S DISEASE;AMYOTROPHIC LATERAL SCLEROSIS;AURA;BEVACIZUMAB;BREAST CANCER;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;EPIGENETICS;HEART RATE;METHYLATION;MOVEMENT DISORDERS;ORTHOSTATIC VITAL SIGNS;PHASES OF CLINICAL RESEARCH;PLACEBO;TEMOZOLOMIDE;UNIVARIATE ANALYSIS","9;6;5;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CATAPLEXY;DEMENTIA WITH LEWY BODIES;LEBER'S HEREDITARY OPTIC NEUROPATHY;VAGUS NERVE STIMULATION;DNA METHYLATION;EXCESSIVE DAYTIME SLEEPINESS;FRONTOTEMPORAL DEMENTIA;HEREDITARY SPASTIC PARAPLEGIA;REGORAFENIB;SLEEP STAGES;TRANSCRIPTOME;VINCRISTINE;AGRIN;ALPHA-SYNUCLEIN;ANTHRACYCLINE;AUTONOMIC NERVOUS SYSTEM;COGNITIVE DECLINE;CORTICOSPINAL TRACT;DOPAMINE AGONIST;DOUBLE BLIND;DYSKINESIA;GENE EXPRESSION PROFILING;GENETIC HETEROGENEITY;GENETICALLY MODIFIED MOUSE;HEART RATE VARIABILITY;HORMONE THERAPY;INDUSTRIAL HERITAGE;LEVODOPA;LEWY BODY;LOSS FUNCTION;MICROARRAY;MICROARRAY ANALYSIS TECHNIQUES;OPTINEURIN;PLACENTAL GROWTH FACTOR;PRAMIPEXOLE;PRESENILIN;PROBAND;PURE AUTONOMIC FAILURE;RETROMER;RILUZOLE;ROTIGOTINE;SINGLE-NUCLEOTIDE POLYMORPHISM;SLEEP DIARY;SLEEP MEDICINE;SPASTIC CEREBRAL PALSY;TAXANE;TERIFLUNOMIDE;TRACTOGRAPHY;TRASTUZUMAB;TRINUCLEOTIDE REPEAT EXPANSION;UPPER MOTOR NEURON","3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;ADULT;MIDDLE AGED;AGED;NARCOLEPSY;MIGRAINE DISORDERS;BRAIN;ITALY;;EPILEPSY;CHILD;MULTIPLE SCLEROSIS;YOUNG ADULT;POLYSOMNOGRAPHY;ADOLESCENT;PARKINSON DISEASE;AGED, 80 AND OVER;CREUTZFELDT-JAKOB SYNDROME","60;52;50;33;31;23;23;19;17;15;14;14;13;13;13;12;11;10;9;9","SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;PRION DISEASES: CAUSES AND MOLECULAR BASIS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;EPILEPSY AND SEIZURES;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;NEURO-IMMUNE MODULATION VIA VAGUS NERVE STIMULATION;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;GLIOMAS;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;CHILD ABUSE AND TRAUMATIC BRAIN INJURY;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF FACIAL PARALYSIS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIFFUSION MAGNETIC RESONANCE IMAGING;ENDOCANNABINOID SYSTEM AND ITS EFFECTS ON HEALTH","9;7;4;4;4;3;3;3;3;3;2;2;2;1;1;1;1;1;1;1","NARCOLEPSY;NEURODEGENERATION;NEURORADIOLOGY;MIGRAINE;MIGRAINE PREVENTION;CHRONIC MIGRAINE;CLINICAL ENDPOINT;DIAGNOSTIC CRITERIA;EPILEPSY;PSYCHOMETRIC EVALUATION;TREATMENT;VAGUS NERVE STIMULATION;A-SYNUCLEIN;C9ORF72;CELLULAR PRION PROTEIN;DEPRESSION (ECONOMICS);ETIOLOGY;HEREDITARY SPASTIC PARAPLEGIA;LOMUSTINE;MOVEMENT DISORDERS","8;6;6;5;5;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2","NARCOLEPSY TYPE;MULTIPLE SCLEROSIS;ACUTE TREATMENT;HEREDITARY OPTIC;LEBERS HEREDITARY;NERVE STIMULATION;NON-INVASIVE VAGUS;OPTIC NEUROPATHY;PILOT STUDY;PRESTO TRIAL;SODIUM OXYBATE;STIMULATION NVNS;VAGUS NERVE;ALZHEIMERS DISEASE;CHRONIC MIGRAINE;CLINICAL PRACTICE;CREUTZFELDT-JAKOB DISEASE;DOUBLE-BLIND PRESTO;ENDOSCOPIC ENDONASAL;MS PATIENTS;RANDOMIZED SHAM-CONTROLLED;RELAPSED GLIOBLASTOMA;SHAM-CONTROLLED DOUBLE-BLIND;TYPE NARCOLEPSY;Α-SYNUCLEIN DEPOSITS;ACTIGRAPHIC STUDY;ACTIVITIES CAUSED;ACTR- TWO-YEAR;ACUTE ADMINISTRATION;ADCY-RELATED DISEASE","7;6;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","POSITIVE MSLT;NARCOLEPSY TYPE;BOLOGNA ITALY;BOLOGNA BOLOGNA;HR CI;MD PHD;ICSD- CRITERIA;SLEEP LATENCY;CROSSREFGOOGLE SCHOLAR;NT VERSUS;RECURRENT STUPOR;TYPE NT;DIBINEM UNIVERSITY;MSL MINUTES;NEUROMOTOR SCIENCES;NVNS SHAM;PAIN INTENSITY;SCIENCES DIBINEM;WISCONSIN SLEEP;INITIAL POSITIVE;ITALY SEARCH;SLEEP COHORT;SLEEP DISORDERS;CENTER CINCINNATI;CEREBROSPINAL FLUID;CROSSREFGOOGLE NA;DELLE SCIENZE;DI BOLOGNA;EYE MOVEMENT;INTERNATIONAL CLASSIFICATION","24;23;16;15;15;14;11;11;9;9;9;9;8;8;8;8;8;8;8;7;7;7;7;6;6;6;6;6;6;6",49,0.66,9.5,10,1,1,1,3,0,0,1,10,0,0,8,0,1,1,2.5,5,3,0,0,68,68,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,6,90,0.93,1,1,14,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,NA,NA,"32 BIOMEDICAL AND CLINICAL SCIENCES;3212 OPHTHALMOLOGY AND OPTOMETRY","1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EYE DISEASE AND DISORDERS OF VISION;GENE THERAPY;GENE THERAPY CLINICAL TRIALS;GENETICS;NEUROSCIENCES;PATIENT SAFETY","1;1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;TAYLOR & FRANCIS GROUP","3;1;1","31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","6;4;3;1;1","CLINICAL RESEARCH;GENETICS;NEURODEGENERATIVE;GENETIC TESTING;RARE DISEASES;BRAIN DISORDERS;MULTIPLE SCLEROSIS;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC;SLEEP RESEARCH","3;3;3;2;2;1;1;1;1;1;1","NEUROLOGICAL","3","4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2;2;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","3;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","3;1","NOT SITE-SPECIFIC CANCER","1",NA,NA
"IRCCS_ISNB",2019,145,16.3931034482759,3.09655172413793,0.255172413793103,0.344827586206897,0.496551724137931,2.72121212121212,1.37037037037037,1.92307692307692,1.5,0.655172413793103,0,76,33,4,7,0.52,0.23,0.03,0.05,25.43,1.04567603322645,6.56164383561643,0.496551724137931,0.979310344827586,0.499,0.327,0.395,0.4,"GIUSEPPE PLAZZI;PIERO PARCHI;ROCCO LIGUORI;FABIO PIZZA;SABINA CAPELLARI;PIETRO CORTELLI;ALESSANDRA LUGARESI;PAOLO TINUPER;LAURA LICCHETTA;ALBA A. BRANDES;FRANCO GRANELLA;FRANCESCA BISULLI;EUGENIO PUCCI;ELENA ANTELMI;DIANA FERRARO;VINCENZO DONADIO;SABINA CEVOLI;TOMÁŠ KALINČÍK;HELMUT BUTZKUEVEN;CHIARA LA MORGIA","16;15;15;13;13;13;11;10;9;9;8;8;8;8;7;7;7;7;7;7","GIUSEPPE PLAZZI;ANNIO POSAR;FABIO PIZZA;ROCCO LIGUORI;PAOLA VISCONTI;PIERO PARCHI;SABINA CAPELLARI;PIETRO CORTELLI;ALESSANDRA LUGARESI;PAOLO TINUPER;VINCENZO DONADIO;ELENA ANTELMI;LAURA LICCHETTA;FRANCESCA BISULLI;DIEGO MAZZATENTA;STEFANO VANDI;FEDERICA PROVINI;CHIARA LA MORGIA;CORRADO ZENESINI;SABINA CEVOLI","2.03;1.92;1.71;1.6;1.59;1.24;1.07;1.05;0.92;0.92;0.91;0.91;0.86;0.84;0.83;0.82;0.73;0.73;0.72;0.7","GIUSEPPE PLAZZI;PIERO PARCHI;ROCCO LIGUORI;FABIO PIZZA;SABINA CAPELLARI;PIETRO CORTELLI;ALESSANDRA LUGARESI;PAOLO TINUPER;LAURA LICCHETTA;ALBA A. BRANDES;FRANCESCA BISULLI;ELENA ANTELMI;VINCENZO DONADIO;SABINA CEVOLI;CHIARA LA MORGIA;STEFANO VANDI;CORRADO ZENESINI;VALÉRIO CARELLI;FEDERICA PROVINI;ANDREA ZINI","16;15;15;13;13;13;11;10;9;9;8;8;7;7;7;7;7;7;7;6","GIUSEPPE PLAZZI;ANNIO POSAR;FABIO PIZZA;ROCCO LIGUORI;PAOLA VISCONTI;PIERO PARCHI;SABINA CAPELLARI;PIETRO CORTELLI;ALESSANDRA LUGARESI;PAOLO TINUPER;VINCENZO DONADIO;ELENA ANTELMI;LAURA LICCHETTA;FRANCESCA BISULLI;DIEGO MAZZATENTA;STEFANO VANDI;FEDERICA PROVINI;CHIARA LA MORGIA;CORRADO ZENESINI;SABINA CEVOLI","2.03;1.92;1.71;1.6;1.59;1.24;1.07;1.05;0.92;0.92;0.91;0.91;0.86;0.84;0.83;0.82;0.73;0.73;0.72;0.7","ALESSANDRA LUGARESI;EUGENIO PUCCI;FRANCO GRANELLA;DIANA FERRARO;HELMUT BUTZKUEVEN;RAED ALROUGHANI;TOMÁŠ KALINČÍK;PIERO PARCHI;EVA HAVRDOVÁ;FRANÇOIS GRAND’MAISON;GUILLERMO IZQUIERDO;JEANNETTE LECHNER‐SCOTT;MARIA TROJANO;MURAT TERZI;PAMELA MCCOMBE;PATRIZIA SOLA;ALEXANDRE PRAT;DANA HORÁKOVÁ;MARC GIRARD;MARK SLEE","673;652;652;639;633;633;633;630;620;620;620;620;620;620;620;620;586;586;586;586","ALESSANDRA LUGARESI;PIERO PARCHI;SABINA CAPELLARI;PIETRO CORTELLI;ROCCO LIGUORI;FRANCESCA BISULLI;LAURA LICCHETTA;GIUSEPPE PLAZZI;PAOLO TINUPER;FABIO PIZZA;BARBARA POLISCHI;STEFANO VANDI;ELENA ANTELMI;CORRADO ZENESINI;FEDERICA PROVINI;ANGELA MAMMANA;CHIARA LA MORGIA;ANNA BARTOLETTI‐STELLA;VINCENZO DONADIO;VALÉRIO CARELLI","673;596;411;409;360;358;358;323;271;242;198;195;184;183;174;167;159;153;150;149","GIUSEPPE PLAZZI;ROCCO LIGUORI;PIERO PARCHI;FABIO PIZZA;SABINA CAPELLARI;PIETRO CORTELLI;ALESSANDRA LUGARESI;FEDERICA PROVINI;FRANCESCA BISULLI;LAURA LICCHETTA;PAOLO TINUPER;ALBA A. BRANDES;SABINA CEVOLI;VINCENZO DONADIO;ELENA ANTELMI;STEFANO VANDI;CORRADO ZENESINI;CHIARA LA MORGIA;GIOVANNI RIZZO;ANDREA ZINI","16;14;14;13;13;12;11;11;9;9;9;9;8;7;7;7;7;6;6;6","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;CHEMISTRY;ENGINEERING;PHYSICS;ECONOMICS;MATHEMATICS;PHILOSOPHY;SOCIOLOGY;POLITICAL SCIENCE;ART;GEOGRAPHY","128;48;30;18;11;9;9;6;6;4;3;2;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;GENETICS;PEDIATRICS;NEUROSCIENCE;AUDIOLOGY;SURGERY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;OPERATING SYSTEM;BIOCHEMISTRY;PHYSICAL MEDICINE AND REHABILITATION;RADIOLOGY;ANESTHESIA;ONCOLOGY;ANATOMY;CANCER RESEARCH;CARDIOLOGY;CELL BIOLOGY;ENDOCRINOLOGY;MECHANICAL ENGINEERING;NURSING;OPHTHALMOLOGY;PHYSICAL THERAPY","78;53;35;30;25;24;17;17;14;13;13;11;10;10;9;9;7;7;7;7;7;7;7;7;7","DISEASE;GENE;EPILEPSY;NEUROLOGY;CEREBROSPINAL FLUID;COGNITION;COHORT;MULTIPLE SCLEROSIS;INSOMNIA;POPULATION;ELECTROENCEPHALOGRAPHY;SLEEP (SYSTEM CALL);CANCER;STROKE (ENGINE);ATROPHY;CLINICAL TRIAL;COHORT STUDY;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;BIOMARKER;MIGRAINE;OPTIC NERVE;QUALITY OF LIFE (HEALTHCARE)","37;27;17;17;12;12;12;12;11;11;10;10;8;7;6;6;6;6;6;5;5;5;5","DEMENTIA;POLYSOMNOGRAPHY;MUTATION;NARCOLEPSY;PHENOTYPE;SLEEP DISORDER;ALZHEIMER'S DISEASE;NON-RAPID EYE MOVEMENT SLEEP;SLEEP ONSET;ALLELE;AUTISM SPECTRUM DISORDER;GENOTYPE;HAZARD RATIO;NEURODEGENERATION;NEUROPATHOLOGY;PRION PROTEIN;BREAST CANCER;CHRONIC MIGRAINE;DRUG RESISTANT EPILEPSY;GENE EXPRESSION;ISCHEMIC STROKE;MITOCHONDRIAL DNA;NEUROPSYCHOLOGY;NEURORADIOLOGY;OPTIC NEUROPATHY;PARKINSON'S DISEASE;THROMBOLYSIS","12;10;9;8;7;7;6;6;6;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","EXOME SEQUENCING;EXCESSIVE DAYTIME SLEEPINESS;FATAL FAMILIAL INSOMNIA;FRONTOTEMPORAL DEMENTIA;MODIFIED RANKIN SCALE;PRNP;SLEEPWALKING;ALPHA-SYNUCLEIN;DEMENTIA WITH LEWY BODIES;DNA METHYLATION;GENOME INSTABILITY;HAPLOTYPE;MISSENSE MUTATION;NORMAL PRESSURE HYDROCEPHALUS;PARASOMNIA;PROBAND;REGORAFENIB;TAU PROTEIN;TAUOPATHY;TRASTUZUMAB;VINCRISTINE","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;ADULT;AGED;BRAIN ISCHEMIA;ADOLESCENT;MULTIPLE SCLEROSIS, RELAPSING-REMITTING;ITALY;PRION DISEASES;STROKE;CHILD;BRAIN;ALZHEIMER DISEASE;NARCOLEPSY;RETROSPECTIVE STUDIES;YOUNG ADULT;AGED, 80 AND OVER","90;69;67;51;47;42;34;20;19;19;18;17;17;16;15;14;14;14;14;13","DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;PRION DISEASES: CAUSES AND MOLECULAR BASIS;EPILEPSY AND SEIZURES;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GLIOMAS;AUTISM SPECTRUM DISORDERS;EPIDEMIOLOGY AND TREATMENT OF HEAD AND NECK CANCER;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;GUILLAIN-BARRÉ SYNDROME AND RELATED NEUROPATHIES;HEALTH ECONOMICS AND QUALITY OF LIFE ASSESSMENT;HISTORY OF MEDICINE AND MEDICAL PRACTICES;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS","12;12;10;6;6;5;5;4;4;4;4;3;3;3;2;2;2;2;2;2","EPILEPSY;SLEEP;NARCOLEPSY;DIAGNOSTIC CRITERIA;STROKE (ENGINE);SLEEP DURATION;CELLULAR PRION PROTEIN;INSOMNIA;TREATMENT;INFARCTION TREATMENT;NEUROPATHOLOGY;SLEEP (SYSTEM CALL);STATUS EPILEPTICUS;CHRONIC MIGRAINE;DEPRESSION (ECONOMICS);DNA METHYLATION;DRUG RESISTANT EPILEPSY;FATAL FAMILIAL INSOMNIA;INTERQUARTILE RANGE;MIGRAINE","10;9;8;7;7;6;5;5;5;4;4;4;4;3;3;3;3;3;3;3","MULTIPLE SCLEROSIS;CEREBROSPINAL FLUID;SPECTRUM DISORDER;DNA METHYLATION;AUTISM SPECTRUM;HEALTH-RELATED QUALITY;METHYLATION ANALYSIS;ORAL BRUSHING;ALZHEIMERS DISEASE;BREAST CANCER;COHORT STUDY;CSF BIOMARKERS;FOCAL EPILEPSY;GENE DNA;NARCOLEPSY TYPE;OPTIC ATROPHY;PROGRESSIVE MULTIPLE;RANDOMIZED PHASE;SECONDARY PROGRESSIVE;ADULT MYOCLONIC;ANALYZING REGORAFENIB;BEHAVIOR DISORDER;BOLOGNA PRO-HYDRO;CELL CARCINOMA;CLINICAL TRIAL;CLUSTER HEADACHE;CROSS-SECTIONAL STUDY;DISEASE-MODIFYING THERAPY;EORTC RANDOMIZED;FAMILIAL ADULT","10;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2","MD PHD;MD DEPARTMENT;MULTIPLE SCLEROSIS;HR CI;PRION DISEASE;MEDICAL UNIVERSITY;UNIVERSITY INNSBRUCK;CEREBROSPINAL FLUID;FAMILIAL INSOMNIA;FATAL FAMILIAL;NREM SLEEP;BOLOGNA ITALY;DNA METHYLATION;INNSBRUCK MEDICAL;LACRIMAL GLAND;MEDIAN FOLLOW-UP;MEDICAL CENTER;NEUROLOGY INNSBRUCK;NEUROLOGY UNIVERSITY;PRION PROTEIN;SECONDARY PROGRESSIVE;BOLOGNA BOLOGNA;NEURODEGENERATIVE DISEASES;ORAL BRUSHING;GENE DNA;INNSBRUCK AUSTRIASEARCH;METHYLATION ANALYSIS;PATIENTS TREATED;PHD ORCIDORG---;SLEEP STAGE","54;18;16;15;15;14;14;13;13;13;13;12;12;12;12;12;12;12;12;12;12;11;11;11;10;10;10;10;10;10",95,0.66,10.62,7.5,1,1.5,2,1,1,0,1,9,0,0,7.75,1,1,2,3,6,4,0,0,60,60,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,3,514,1.37,0,0,52.5,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,2,0,0,2,0,0,0,0,0,0,0,0,0,"Switzerland;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","2;2;1;1","CLINICAL RESEARCH;NEUROSCIENCES;CHRONIC PAIN;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEADACHES;MIGRAINES;PAIN RESEARCH","2;2;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE","5;3","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;52 PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;44 HUMAN SOCIETY;4403 DEMOGRAPHY;4901 APPLIED MATHEMATICS;5202 BIOLOGICAL PSYCHOLOGY","6;3;2;2;2;1;1;1;1;1;1","CLINICAL RESEARCH;NEURODEGENERATIVE;NEUROSCIENCES;AGING;BIOENGINEERING;BIOMEDICAL IMAGING;BRAIN DISORDERS;GENETICS;PARKINSON'S DISEASE;PERIPHERAL NEUROPATHY;RARE DISEASES","5;2;2;1;1;1;1;1;1;1;1","NEUROLOGICAL","3","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;7.1 INDIVIDUAL CARE NEEDS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","3;3;1","BIOMEDICAL;CLINICAL","1;1","HEALTH SERVICES RESEARCH;CLINICAL MEDICINE AND SCIENCE","3;2",NA,NA,NA,NA
"IRCCS_ISNB",2020,227,17.8766519823789,3.43171806167401,0.26431718061674,0.383259911894273,0.374449339207048,3.40174672489083,1.17647058823529,1.97727272727273,1.49122807017544,0.722466960352423,0,113,75,10,6,0.5,0.33,0.04,0.03,23.28,0.92393899817225,7.02325581395349,0.449339207048458,0.982378854625551,0.536,0.368,0.349,0.343,"PIETRO CORTELLI;ROCCO LIGUORI;FABIO PIZZA;GIUSEPPE PLAZZI;VALÉRIO CARELLI;FRANCESCA BISULLI;GIOVANNA CALANDRA‐BUONAURA;CORRADO ZENESINI;SABINA CEVOLI;PAOLO TINUPER;SABINA CAPELLARI;UMBERTO PENSATO;ANDREA ZINI;ALESSANDRA LUGARESI;FEDERICA PROVINI;SOFIA ASIOLI;DIEGO MAZZATENTA;CHIARA LA MORGIA;GIULIA GIANNINI;MATTEO ZOLI","33;19;18;18;17;16;16;16;13;13;13;12;12;12;12;11;11;11;11;11","PIETRO CORTELLI;GIUSEPPE PLAZZI;FABIO PIZZA;ANNIO POSAR;PAOLA VISCONTI;ROCCO LIGUORI;UMBERTO PENSATO;CORRADO ZENESINI;SABINA CEVOLI;FEDERICA PROVINI;FRANCESCA BISULLI;GIOVANNA CALANDRA‐BUONAURA;ELENA ANTELMI;VALÉRIO CARELLI;LUIGI CIRILLO;SABINA CAPELLARI;PAOLO TINUPER;VINCENZO DONADIO;FRANCESCO TONI;ANGELO RUSSO","3.16;2.18;2.11;1.89;1.79;1.66;1.6;1.59;1.57;1.43;1.42;1.41;1.32;1.21;1.13;1.08;1.06;1.03;1.03;1.02","PIETRO CORTELLI;ROCCO LIGUORI;FABIO PIZZA;GIUSEPPE PLAZZI;VALÉRIO CARELLI;FRANCESCA BISULLI;GIOVANNA CALANDRA‐BUONAURA;CORRADO ZENESINI;SABINA CEVOLI;PAOLO TINUPER;SABINA CAPELLARI;UMBERTO PENSATO;ANDREA ZINI;ALESSANDRA LUGARESI;FEDERICA PROVINI;SOFIA ASIOLI;DIEGO MAZZATENTA;CHIARA LA MORGIA;GIULIA GIANNINI;MATTEO ZOLI","33;19;18;18;17;16;16;16;13;13;13;12;12;12;12;11;11;11;11;11","PIETRO CORTELLI;GIUSEPPE PLAZZI;FABIO PIZZA;ANNIO POSAR;PAOLA VISCONTI;ROCCO LIGUORI;UMBERTO PENSATO;CORRADO ZENESINI;SABINA CEVOLI;FEDERICA PROVINI;FRANCESCA BISULLI;GIOVANNA CALANDRA‐BUONAURA;ELENA ANTELMI;VALÉRIO CARELLI;LUIGI CIRILLO;SABINA CAPELLARI;PAOLO TINUPER;VINCENZO DONADIO;FRANCESCO TONI;ANGELO RUSSO","3.16;2.18;2.11;1.89;1.79;1.66;1.6;1.59;1.57;1.43;1.42;1.41;1.32;1.21;1.13;1.08;1.06;1.03;1.03;1.02","PIETRO CORTELLI;GIUSEPPE PLAZZI;CHIARA LA MORGIA;CORRADO ZENESINI;GIOVANNA CALANDRA‐BUONAURA;SABINA CAPELLARI;VALÉRIO CARELLI;GIULIA GIANNINI;CLAUDIO FRANCESCHI;ELENA ANTELMI;PIERO PARCHI;ALESSANDRA LUGARESI;ROCCO LIGUORI;MARIA TROJANO;DIANA FERRARO;NANCY J. NEWMAN;PATRICK YU‐WAI‐MAN;VALÉRIE BIOUSSE;ROBERTO BERGAMASCHI;PATRIZIA SOLA","854;841;648;571;522;510;497;489;477;476;467;459;446;441;425;423;423;423;400;398","CHIARA LA MORGIA;CORRADO ZENESINI;GIOVANNA CALANDRA‐BUONAURA;GIUSEPPE PLAZZI;SABINA CAPELLARI;ALESSANDRA LUGARESI;PIETRO CORTELLI;VALÉRIO CARELLI;FABIO PIZZA;ANGELA MAMMANA;LUCA VIGNATELLI;CLAUDIO FRANCESCHI;FRANCESCA BISULLI;MARIA GIULIA BACALINI;MARCELLO ROSSI;SIMONE BAIARDI;SABINA CEVOLI;PAOLO TINUPER;ROCCO LIGUORI;GIULIA GIANNINI","648;571;496;482;481;459;435;394;359;357;349;341;328;319;316;284;273;263;246;207","PIETRO CORTELLI;FABIO PIZZA;GIUSEPPE PLAZZI;CORRADO ZENESINI;FRANCESCA BISULLI;ROCCO LIGUORI;GIOVANNA CALANDRA‐BUONAURA;SABINA CEVOLI;VALÉRIO CARELLI;PAOLO TINUPER;ALESSANDRA LUGARESI;ANDREA ZINI;FEDERICA PROVINI;CHIARA LA MORGIA;LAURA LICCHETTA;SABINA CAPELLARI;ALBA A. BRANDES;GIULIA GIANNINI;LUCA VIGNATELLI;MARIA GIULIA BACALINI","27;18;18;16;15;15;14;14;14;13;12;12;11;11;11;11;10;9;9;9","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;PHYSICS;ECONOMICS;PHILOSOPHY;POLITICAL SCIENCE;MATHEMATICS;SOCIOLOGY;CHEMISTRY;BUSINESS;HISTORY;MATERIALS SCIENCE","211;65;54;24;19;10;7;7;7;6;6;5;1;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;GENETICS;SURGERY;PEDIATRICS;RADIOLOGY;NEUROSCIENCE;PHYSICAL THERAPY;ANESTHESIA;AUDIOLOGY;ENVIRONMENTAL HEALTH;ONCOLOGY;MECHANICAL ENGINEERING;CLINICAL PSYCHOLOGY;OPERATING SYSTEM;IMMUNOLOGY;PHYSICAL MEDICINE AND REHABILITATION;CARDIOLOGY;OPHTHALMOLOGY","136;89;55;52;40;31;29;28;24;20;17;17;17;16;14;14;12;12;11;11","DISEASE;GENE;NEUROLOGY;COHORT;EPILEPSY;MAGNETIC RESONANCE IMAGING;POPULATION;CONFIDENCE INTERVAL;STROKE (ENGINE);COGNITION;MULTIPLE SCLEROSIS;ELECTROENCEPHALOGRAPHY;SLEEP (SYSTEM CALL);CANCER;NEUROSURGERY;ATROPHY;RETROSPECTIVE COHORT STUDY;INSOMNIA;ENCEPHALOPATHY;ISCHEMIA","61;53;39;28;27;18;17;16;16;14;14;13;12;11;11;10;10;9;8;8","MUTATION;NARCOLEPSY;NEURORADIOLOGY;PARKINSON'S DISEASE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;PHENOTYPE;POLYSOMNOGRAPHY;GENE EXPRESSION;SLEEP DISORDER;EPIGENETICS;METHYLATION;MITOCHONDRIAL DNA;2019-20 CORONAVIRUS OUTBREAK;AUTISM SPECTRUM DISORDER;GENOTYPE;HAZARD RATIO;ISCHEMIC STROKE;PARKINSONISM;EXPANDED DISABILITY STATUS SCALE;NON-RAPID EYE MOVEMENT SLEEP;ORTHOSTATIC VITAL SIGNS;RAPID EYE MOVEMENT SLEEP","22;16;15;15;13;12;12;12;9;8;7;7;7;6;6;6;6;6;6;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;MISSENSE MUTATION;REM SLEEP BEHAVIOR DISORDER;CATAPLEXY;EXCESSIVE DAYTIME SLEEPINESS;EXOME SEQUENCING;FRONTOTEMPORAL DEMENTIA;MITOCHONDRIAL MYOPATHY;MODIFIED RANKIN SCALE;PROBAND;ALPHA-SYNUCLEIN;COGNITIVE DECLINE;IDH1;LEVODOPA;MITOCHONDRIAL DISEASE;OPHTHALMIC PATHOLOGY;DEMENTIA WITH LEWY BODIES;DYSKINESIA;GENETIC HETEROGENEITY;HAPLOTYPE;LEBER'S HEREDITARY OPTIC NEUROPATHY;LEWY BODY;LOSS FUNCTION;LYMPHOVASCULAR INVASION;MYOTONIA CONGENITA;PENETRANCE;PRNP;PURE AUTONOMIC FAILURE;SINGLE-NUCLEOTIDE POLYMORPHISM;SLEEP MEDICINE;SLEEP STAGES","13;9;8;8;7;6;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;NARCOLEPSY;ITALY;CREUTZFELDT-JAKOB SYNDROME;PARKINSON DISEASE;COHORT STUDIES;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ADOLESCENT;CHILD;COVID-19;MULTIPLE SCLEROSIS;STROKE;MITOCHONDRIA","128;97;77;64;50;42;39;29;26;23;21;19;19;19;17;17;17;17;17;16","SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;EPILEPSY AND SEIZURES;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;PRION DISEASES: CAUSES AND MOLECULAR BASIS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;GLIOMAS;PATHOPHYSIOLOGY AND MANAGEMENT OF CEREBRAL ANEURYSMS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME (PRES);ATRIAL FIBRILLATION;CEREBROSPINAL FLUID DISORDERS AND HEMATOMAS;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;EPIDEMIOLOGY AND IMPACT OF TRAUMATIC BRAIN INJURY;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS","16;15;12;9;9;9;7;7;6;5;5;5;5;4;4;3;3;3;3;3","STROKE (ENGINE);NEURORADIOLOGY;NARCOLEPSY;SLEEP;INFARCTION TREATMENT;DIAGNOSTIC CRITERIA;EPILEPSY;SLEEP DURATION;2019-20 CORONAVIRUS OUTBREAK;PANDEMIC;AUTISM;DNA METHYLATION;NEURODEGENERATION;SLEEP (SYSTEM CALL);CELLULAR PRION PROTEIN;EPILEPSY DETECTION;MIGRAINE;MIGRAINE PREVENTION;TREATMENT;ACUTE STROKE","16;15;14;13;10;8;8;8;7;7;6;6;6;6;5;5;5;5;5;4","MULTIPLE SCLEROSIS;NARCOLEPSY TYPE;PARKINSONS DISEASE;AUTISM SPECTRUM;BEHAVIOR DISORDER;ITALIAN PATIENTS;SPECTRUM DISORDER;BREAST CANCER;COHORT STUDY;COVID- PANDEMIC;DNA METHYLATION;EYE MOVEMENT;MAGNETIC RESONANCE;RAPID EYE;REM SLEEP;RESPONSE ASSESSMENT;SLEEP BEHAVIOR;ALZHEIMERS DISEASE;AMYOTROPHIC LATERAL;ARTERY DISSECTION;BRAIN INJURY;CHRONIC MIGRAINE;COGNITIVE IMPAIRMENT;ENDOSCOPIC ENDONASAL;INJURY REHABILITATION;INTERNAL CAROTID;ISCHAEMIC STROKE;ISCHEMIC STROKE;LATERAL SCLEROSIS;MECHANICAL THROMBECTOMY","14;7;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","MULTIPLE SCLEROSIS;REM SLEEP;CEREBELLAR ATAXIA;DNA METHYLATION;MAGNETIC RESONANCE;SLEEP DISORDERS;AUTOSOMAL DOMINANT;RESONANCE IMAGING;SLEEP LATENCY;CEREBROSPINAL FLUID;PARKINSONS DISEASE;STROKE PATIENTS;NERVOUS SYSTEM;DISEASE ONSET;EYE MOVEMENT;PRION DISEASE;RESPONSE ASSESSMENT;CAROTID ARTERY;CLINICAL TRIALS;CONFIDENCE INTERVAL;DEPRESSION ANXIETY;DOMINANT CEREBELLAR;HR CI;MD PHD;NARCOLEPSY TYPE;RAPID EYE;RISK FACTORS;ATAXIA DEAFNESS;AUTISM SPECTRUM;BREAST CANCER","28;18;17;17;15;15;14;14;14;13;13;13;12;11;11;11;11;10;10;10;10;10;10;10;10;10;10;9;9;9",148,0.65,11.32,11,2,1,0,2,1,1,1,12.25,1,1,10,1.75,1.25,2,3.25,7.75,4,0,0,57.5,57.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,3.29,219.14,3.55,2,0.29,49.14,0,0,0,0,3,0,0,4,0,7,0,0,0,0,0,0,0,7,0,0,6,0,0,1,0,0,0,0,0,0,"Italy;Denmark","5;2","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE","4;3;2;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;BRAIN DISORDERS;NEURODEGENERATIVE;PAIN RESEARCH;BEHAVIORAL AND SOCIAL SCIENCE;CHRONIC PAIN;PATIENT SAFETY;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;PREVENTION;REHABILITATION;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);ALZHEIMER'S DISEASE RELATED DEMENTIAS (ADRD);ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;BIOMEDICAL IMAGING","7;6;5;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1","NEUROLOGICAL","4","6.1 PHARMACEUTICALS;6.7 PHYSICAL;7.2 END OF LIFE CARE;7.3 MANAGEMENT AND DECISION MAKING","3;1;1;1","NOT SITE-SPECIFIC CANCER","1","6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;6.6 END-OF-LIFE CARE","1;1",0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,15,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH","9;4;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;46 INFORMATION AND COMPUTING SCIENCES;3107 MICROBIOLOGY;4208 TRADITIONAL, COMPLEMENTARY AND INTEGRATIVE MEDICINE;4611 MACHINE LEARNING","16;10;4;4;3;2;2;1;1;1","CLINICAL RESEARCH;BRAIN DISORDERS;GENETICS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;NEUROSCIENCES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;GENETIC TESTING;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;NEURODEGENERATIVE;PEDIATRIC;PREVENTION;RARE DISEASES;AGING;CHRONIC PAIN;HEADACHES;PAIN RESEARCH;ACQUIRED COGNITIVE IMPAIRMENT;APHASIA;BREAST CANCER","9;7;6;5;5;3;3;3;3;3;3;3;3;2;2;2;2;1;1;1","NEUROLOGICAL;CANCER;CARDIOVASCULAR;STROKE","4;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS","4;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","4;1;1","CLINICAL MEDICINE AND SCIENCE","8","BREAST CANCER","2","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_ISNB",2021,338,17.5118343195266,3.12721893491124,0.245562130177515,0.316568047337278,0.316568047337278,3.42071197411003,1.38333333333333,2.27659574468085,1.35443037974684,0.642011834319527,2,167,94,22,7,0.49,0.28,0.07,0.02,15.02,0.974252626127927,7.20268456375839,0.423076923076923,0.979289940828402,0.552,0.418,0.416,0.454,"PIETRO CORTELLI;VALÉRIO CARELLI;ROCCO LIGUORI;GIUSEPPE PLAZZI;ANDREA ZINI;ALESSANDRA LUGARESI;SABINA CEVOLI;SABINA CAPELLARI;CHIARA LA MORGIA;PIERO PARCHI;CORRADO ZENESINI;RAFFAELE LODI;FABIO PIZZA;ALBA A. BRANDES;MASSIMO FILIPPI;FRANCO GRANELLA;DUCCIO MARIA CORDELLI;FRANCESCO PATTI;CATERINA TONON;DIEGO MAZZATENTA","32;29;28;26;25;21;20;20;19;17;16;15;14;14;13;13;13;13;12;12","PIETRO CORTELLI;ROCCO LIGUORI;GIUSEPPE PLAZZI;ANDREA ZINI;SABINA CEVOLI;FABIO PIZZA;VALÉRIO CARELLI;SABINA CAPELLARI;PIERO PARCHI;UMBERTO PENSATO;ANTONIA PARMEGGIANI;PIETRO GUARALDI;JACOPO PRUCCOLI;RAFFAELE LODI;CHIARA LA MORGIA;DIEGO MAZZATENTA;VINCENZO DONADIO;CORRADO ZENESINI;ALBA A. BRANDES;PAOLO TINUPER","4.03;2.64;2.34;1.97;1.81;1.79;1.76;1.64;1.64;1.53;1.47;1.46;1.4;1.36;1.33;1.29;1.29;1.28;1.25;1.22","PIETRO CORTELLI;VALÉRIO CARELLI;ROCCO LIGUORI;GIUSEPPE PLAZZI;ANDREA ZINI;ALESSANDRA LUGARESI;SABINA CEVOLI;SABINA CAPELLARI;CHIARA LA MORGIA;PIERO PARCHI;CORRADO ZENESINI;RAFFAELE LODI;FABIO PIZZA;ALBA A. BRANDES;DUCCIO MARIA CORDELLI;CATERINA TONON;DIEGO MAZZATENTA;MARIA GIULIA BACALINI;VERIA VACCHIANO;PAOLO TINUPER","32;29;28;26;25;21;20;20;19;17;16;15;14;14;13;12;12;12;12;12","PIETRO CORTELLI;ROCCO LIGUORI;GIUSEPPE PLAZZI;ANDREA ZINI;SABINA CEVOLI;FABIO PIZZA;VALÉRIO CARELLI;SABINA CAPELLARI;PIERO PARCHI;UMBERTO PENSATO;ANTONIA PARMEGGIANI;PIETRO GUARALDI;JACOPO PRUCCOLI;RAFFAELE LODI;CHIARA LA MORGIA;DIEGO MAZZATENTA;VINCENZO DONADIO;CORRADO ZENESINI;ALBA A. BRANDES;PAOLO TINUPER","4.03;2.64;2.34;1.97;1.81;1.79;1.76;1.64;1.64;1.53;1.47;1.46;1.4;1.36;1.33;1.29;1.29;1.28;1.25;1.22","GIUSEPPE PLAZZI;VALÉRIO CARELLI;ANDREA ZINI;LUIGI DE GENNARO;CHRISTIAN H. NOLTE;SABINA CAPELLARI;CHIARA LA MORGIA;PATRIK MICHEL;PAUL J. NEDERKOORN;STEFANO VALLONE;ROCCO LIGUORI;PIERO PARCHI;BJØRN BJORVATN;CHARLES B.L.M. MAJOIE;YVES DAUVILLIERS;AAD VAN DER LUGT;ADRIAAN C.G.M. VAN ES;ALBERT J. YOO;ALE ALGRA;BART J. EMMER","734;609;580;499;432;431;424;419;412;403;396;395;394;385;379;378;378;378;378;378","GIUSEPPE PLAZZI;VALÉRIO CARELLI;ANDREA ZINI;ROCCO LIGUORI;SABINA CEVOLI;CHIARA LA MORGIA;SABINA CAPELLARI;ALBA A. BRANDES;PIERO PARCHI;CORINNE QUADALTI;SIMONE BAIARDI;MARCELLO ROSSI;CORRADO ZENESINI;PIETRO CORTELLI;VALENTINA FAVONI;ANGELA MAMMANA;VINCENZO DONADIO;VERIA VACCHIANO;FEDERICA GUARALDI;ALESSANDRA MARESCA","695;591;569;382;355;321;312;307;303;302;299;295;258;249;246;236;228;220;213;210","VALÉRIO CARELLI;PIETRO CORTELLI;GIUSEPPE PLAZZI;ROCCO LIGUORI;ANDREA ZINI;ALESSANDRA LUGARESI;SABINA CEVOLI;CHIARA LA MORGIA;CORRADO ZENESINI;SABINA CAPELLARI;RAFFAELE LODI;FABIO PIZZA;VALENTINA FAVONI;PIERO PARCHI;MARIA GIULIA BACALINI;CATERINA TONON;VERIA VACCHIANO;DUCCIO MARIA CORDELLI;FEDERICA PROVINI;LEONARDO CAPORALI","27;26;26;24;23;19;19;18;16;15;15;14;13;13;12;12;12;11;11;11","MEDICINE;BIOLOGY;PSYCHOLOGY;ENGINEERING;COMPUTER SCIENCE;PHYSICS;ECONOMICS;CHEMISTRY;SOCIOLOGY;POLITICAL SCIENCE;MATHEMATICS;PHILOSOPHY;ART;GEOGRAPHY;MATERIALS SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY;HISTORY","314;101;83;32;28;26;16;13;12;11;10;9;8;3;3;2;1;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;GENETICS;NEUROSCIENCE;PEDIATRICS;SURGERY;RADIOLOGY;ENVIRONMENTAL HEALTH;PHYSICAL THERAPY;IMMUNOLOGY;MECHANICAL ENGINEERING;ONCOLOGY;CARDIOLOGY;ANESTHESIA;CANCER RESEARCH;PHYSICAL MEDICINE AND REHABILITATION;CLINICAL PSYCHOLOGY;AUDIOLOGY;ENDOCRINOLOGY;FAMILY MEDICINE","193;112;94;75;59;57;55;42;34;32;25;25;25;22;21;21;21;20;19;14;14","DISEASE;GENE;NEUROLOGY;POPULATION;EPILEPSY;COHORT;STROKE (ENGINE);ELECTROENCEPHALOGRAPHY;MIGRAINE;MULTIPLE SCLEROSIS;MAGNETIC RESONANCE IMAGING;COGNITION;RETROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;INSOMNIA;ISCHEMIA;CANCER;CONFIDENCE INTERVAL;MYOCARDIAL INFARCTION;ADVERSE EFFECT;OBSERVATIONAL STUDY;RECEPTOR","89;63;34;33;28;27;26;20;19;19;18;16;16;14;14;14;13;13;13;12;12;12","INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;GENE EXPRESSION;PARKINSON'S DISEASE;PHENOTYPE;MUTATION;POLYSOMNOGRAPHY;MITOCHONDRIAL DNA;ISCHEMIC STROKE;NEURORADIOLOGY;THROMBOLYSIS;OPTIC NEUROPATHY;SLEEP DISORDER;2019-20 CORONAVIRUS OUTBREAK;METHYLATION;NARCOLEPSY;MIDDLE CEREBRAL ARTERY;PARKINSONISM;CHRONIC MIGRAINE;EPIGENETICS;HAZARD RATIO;PRION PROTEIN","26;17;16;16;16;15;13;12;11;11;11;10;10;9;9;9;8;8;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;LEBER'S HEREDITARY OPTIC NEUROPATHY;MITOCHONDRIAL DISEASE;MODIFIED RANKIN SCALE;ALPHA-SYNUCLEIN;DEMENTIA WITH LEWY BODIES;IDH1;LEWY BODY;CALCITONIN GENE-RELATED PEPTIDE;EXCESSIVE DAYTIME SLEEPINESS;HEART RATE VARIABILITY;HETEROPLASMY;PARASOMNIA;PRNP;AUTONOMIC NERVOUS SYSTEM;CATAPLEXY;CHIMERIC ANTIGEN RECEPTOR;EPWORTH SLEEPINESS SCALE;FATAL FAMILIAL INSOMNIA;FRONTOTEMPORAL DEMENTIA;MELANOPSIN;NORMAL PRESSURE HYDROCEPHALUS;PENETRANCE;SINGLE-NUCLEOTIDE POLYMORPHISM;TRACTOGRAPHY;VENTRICULOMEGALY","26;14;9;8;7;6;6;5;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;ADULT;STROKE;AGED;ITALY;MUTATION;ADOLESCENT;BRAIN NEOPLASMS;CHILD;COVID-19;PARKINSON DISEASE;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;EPILEPSY;BRAIN ISCHEMIA;MULTIPLE SCLEROSIS","176;160;69;65;53;52;48;40;40;28;26;26;25;24;23;23;23;22;21;20","SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;GLIOMAS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;EPILEPSY AND SEIZURES;IMPACT OF COVID-19 ON MENTAL HEALTH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES;PRION DISEASES: CAUSES AND MOLECULAR BASIS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;SLEEP AND INSOMNIA;DEVELOPMENT AND DISORDERS OF FETAL BRAIN;FACTORS AFFECTING VACCINE HESITANCY AND ACCEPTANCE;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;MAMMALIAN CIRCADIAN RHYTHMS AND PHYSIOLOGY;MOLECULAR BASIS OF RETT SYNDROME AND RELATED DISORDERS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH","18;17;17;16;16;15;14;11;7;6;6;6;5;5;4;4;4;4;4;3","STROKE (ENGINE);INFARCTION TREATMENT;PANDEMIC;DIAGNOSTIC CRITERIA;MIGRAINE PREVENTION;NEURORADIOLOGY;TREATMENT;2019-20 CORONAVIRUS OUTBREAK;NARCOLEPSY;DNA METHYLATION;EPILEPSY;MIGRAINE;CHRONIC MIGRAINE;GLIOBLASTOMA;MITOCHONDRIAL DISEASE;ETIOLOGY;SLEEP;ANOREXIA NERVOSA;DEPRESSION (ECONOMICS);ENDOVASCULAR THERAPY","26;18;16;12;12;11;11;10;10;9;9;9;8;8;8;7;7;6;6;6","MULTIPLE SCLEROSIS;COHORT STUDY;DNA METHYLATION;CHRONIC MIGRAINE;HEREDITARY OPTIC;ISCHEMIC STROKE;OPTIC NEUROPATHY;COVID- PANDEMIC;ALZHEIMERS DISEASE;ANOREXIA NERVOSA;NARCOLEPSY TYPE;PARKINSONS DISEASE;CAROTID ARTERY;CLINICAL FEATURES;CLINICAL PRACTICE;INTERNAL CAROTID;MULTICENTER STUDY;OBSERVATIONAL STUDY;ACUTE ISCHEMIC;BEHAVIOR DISORDER;BRAIN INJURY;GENE THERAPY;ITALIAN MULTICENTER;LEBER HEREDITARY;LEBERS HEREDITARY;LEWY BODIES;LONGITUDINAL STUDY;NEUROLOGICAL DISORDERS;PILOT STUDY;PROSTATE CANCER","22;10;10;9;8;8;8;7;6;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4","REM SLEEP;MD PHD;BOLOGNA ITALY;BOLOGNA BOLOGNA;DI BOLOGNA;PERSONAL FEES;DNA METHYLATION;DELLE SCIENZE;IRCCS ISTITUTO;ISTITUTO DELLE;NEUROLOGICHE DI;SCIENZE NEUROLOGICHE;CLINICAL PRACTICE;EYE MOVEMENT;SLEEP BEHAVIOR;CROSSREFGOOGLE SCHOLAR;MIDDLE-AGED PATIENTS;SLEEP QUALITY;BEHAVIOR DISORDER;SCIENCES UNIVERSITY;FAMILY HISTORY;MAGNETIC RESONANCE;NREM SLEEP;COVID- PANDEMIC;MULTIPLE SCLEROSIS;RAPID EYE;SLEEP LATENCY;SLEEP TIME;TOTAL SLEEP;NEUROMOTOR SCIENCES","78;60;42;37;31;30;29;27;27;27;27;27;25;25;23;22;22;21;20;19;18;18;18;17;17;17;17;17;17;16",201,0.59,10.75,10,1,2.5,0,6.25,1.75,1,1,12,1,0,9,1,4,2,2,7,3,0,0,33,33,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,1.8,426,1.97,2,0.4,46.6,0,0,1,0,1,0,1,2,0,3,2,0,0,0,0,0,0,5,0,0,5,0,0,0,0,0,0,0,0,0,"Denmark;Italy","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","5;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;PREVENTION;STROKE;AGING;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC PAIN;COMPLEMENTARY AND INTEGRATIVE HEALTH;HEADACHES;HEART DISEASE;LUNG;PAIN RESEARCH;SLEEP RESEARCH","5;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","STROKE;CARDIOVASCULAR;NEUROLOGICAL","2;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1","NOT SITE-SPECIFIC CANCER","1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1",3,319303.33,98267.44,4,8.66666666666667,1,0.666666666666667,3.33333333333333,73700.5769230769,4.58612420840041,"ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA;BAMBINO GESÙ CHILDREN'S HOSPITAL;CENTRO CLINICO NEMO;FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO;ISTITUTO GIANNINA GASLINI;UNIVERSITY OF CAMPANIA ""LUIGI VANVITELLI"";UNIVERSITY OF MESSINA;UNIVERSITY OF TURIN;AGOSTINO GEMELLI UNIVERSITY POLYCLINIC;CATHOLIC UNIVERSITY OF THE SACRED HEART;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;FONDAZIONE STELLA MARIS;IRCCS OSPEDALE SAN RAFFAELE;NATIONAL RESEARCH COUNCIL;UNIVERSITY OF FERRARA;UNIVERSITY OF PADUA;UNIVERSITY OF PISA","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","TELETHON FOUNDATION","3",NA,NA,"TELETHON-UILDM CLINICAL PROJECTS 2021 (PROGRAM);TELETHON GRANT PROJECTS - 2020 (PROGRAM)","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES","2;1;1;1","BRAIN DISORDERS;CLINICAL RESEARCH;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DUCHENNE/ BECKER MUSCULAR DYSTROPHY;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;NEURODEGENERATIVE;NEUROSCIENCES;PEDIATRIC;STEM CELL RESEARCH","2;2;2;1;1;1;1;1;1;1;1;1","GENERIC HEALTH RELEVANCE;MUSCULOSKELETAL","1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.2 CELLULAR AND GENE THERAPIES;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT)","1;1;1;1;1","NOT SITE-SPECIFIC CANCER","1","5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","1","A01 CLINICAL MEDICINE","2","3 GOOD HEALTH AND WELL BEING","1",35,"FRONTIERS;ZENODO;KARGER PUBLISHERS","23;10;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;3105 GENETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;5202 BIOLOGICAL PSYCHOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;36 CREATIVE ARTS AND WRITING;3602 CREATIVE AND PROFESSIONAL WRITING;5201 APPLIED AND DEVELOPMENTAL PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY;5204 COGNITIVE AND COMPUTATIONAL PSYCHOLOGY","37;28;19;12;9;8;7;4;2;2;2;2;1;1;1;1;1;1","NEUROSCIENCES;NEURODEGENERATIVE;CLINICAL RESEARCH;BRAIN DISORDERS;GENETICS;EYE DISEASE AND DISORDERS OF VISION;ACQUIRED COGNITIVE IMPAIRMENT;AGING;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);DEMENTIA;HUMAN GENOME;RARE DISEASES;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;EPILEPSY;PATIENT SAFETY;PEDIATRIC;ALS;BEHAVIORAL AND SOCIAL SCIENCE;GENETIC TESTING","24;17;15;14;14;10;8;8;8;8;8;7;7;5;3;3;3;2;2;2","NEUROLOGICAL;EYE;CANCER;MENTAL HEALTH","16;5;2;2","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.3 PSYCHOLOGICAL, SOCIAL AND ECONOMIC FACTORS","14;7;5;2;1","CLINICAL;BIOMEDICAL;POPULATION & SOCIETY","12;11;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","15;9;1","NOT SITE-SPECIFIC CANCER;PROSTATE CANCER","2;2",NA,NA
"IRCCS_ISNB",2022,299,18.0769230769231,3.19397993311037,0.224080267558528,0.297658862876254,0.331103678929766,3.27054794520548,1.39583333333333,1.93478260869565,1.62295081967213,0.755852842809365,1,146,77,14,9,0.49,0.26,0.05,0.03,11.38,1.27532873914656,6.84342379958248,0.474916387959866,0.986622073578595,0.544,0.486,0.446,0.473,"VALÉRIO CARELLI;GIUSEPPE PLAZZI;ANDREA ZINI;PIETRO CORTELLI;CATERINA TONON;RAFFAELE LODI;CHIARA LA MORGIA;ROCCO LIGUORI;CORRADO ZENESINI;PIERO PARCHI;DIEGO MAZZATENTA;LEONARDO CAPORALI;GIOVANNA CALANDRA‐BUONAURA;SABINA CEVOLI;SIMONE BAIARDI;PATRICK YU‐WAI‐MAN;ALFREDO CONTI;SABINA CAPELLARI;YVES DAUVILLIERS;PIETRO GUARALDI","32;28;23;22;18;18;18;17;16;15;14;14;14;13;12;12;12;12;12;11","VALÉRIO CARELLI;GIUSEPPE PLAZZI;CHIARA LA MORGIA;ANTONIA PARMEGGIANI;JACOPO PRUCCOLI;PIETRO CORTELLI;ANDREA ZINI;CATERINA TONON;DIEGO MAZZATENTA;CORRADO ZENESINI;RAFFAELE LODI;PATRICK YU‐WAI‐MAN;ALFREDO CONTI;ROCCO LIGUORI;THOMAS KLOPSTOCK;PIERO PARCHI;LORENZO MUCCIOLI;MATTEO ZOLI;LIVIA TOMASSO;FEDERICA PROVINI","2.96;2.65;2.16;2.07;2.05;1.67;1.42;1.41;1.37;1.28;1.27;1.27;1.21;1.12;1.11;1.08;1.04;1.01;1;0.98","VALÉRIO CARELLI;GIUSEPPE PLAZZI;ANDREA ZINI;PIETRO CORTELLI;CATERINA TONON;RAFFAELE LODI;CHIARA LA MORGIA;ROCCO LIGUORI;CORRADO ZENESINI;PIERO PARCHI;DIEGO MAZZATENTA;LEONARDO CAPORALI;GIOVANNA CALANDRA‐BUONAURA;SABINA CEVOLI;SIMONE BAIARDI;ALFREDO CONTI;SABINA CAPELLARI;PIETRO GUARALDI;LUCA VIGNATELLI;PAOLO TINUPER","32;28;23;22;18;18;18;17;16;15;14;14;14;13;12;12;12;11;11;11","VALÉRIO CARELLI;GIUSEPPE PLAZZI;CHIARA LA MORGIA;ANTONIA PARMEGGIANI;JACOPO PRUCCOLI;PIETRO CORTELLI;ANDREA ZINI;CATERINA TONON;DIEGO MAZZATENTA;CORRADO ZENESINI;RAFFAELE LODI;ALFREDO CONTI;ROCCO LIGUORI;PIERO PARCHI;LORENZO MUCCIOLI;MATTEO ZOLI;FEDERICA PROVINI;GIOVANNA CALANDRA‐BUONAURA;FABIO PIZZA;LEONARDO CAPORALI","2.96;2.65;2.16;2.07;2.05;1.67;1.42;1.41;1.37;1.28;1.27;1.21;1.12;1.08;1.04;1.01;0.98;0.97;0.95;0.95","PAOLO TINUPER;INGRID E. SCHEFFER;ELAINE WIRRELL;EMILIO PERUCCA;KATE RINEY;NICOLA SPECCHIO;RIMA NABBOUT;SAMEER M. ZUBERI;SAMUEL WIEBE;SOLOMON L. MOSHÉ;STÉPHANE AUVIN;ÉDOUARD HIRSCH;GIUSEPPE PLAZZI;CHAHNEZ TRIKI;ELISSA YOZAWITZ;J. HELEN CROSS;JO M. WILMSHURST;O. CARTER SNEAD;PAULINE SAMIA;RONIT PRESSLER","568;534;523;523;523;523;523;523;523;523;523;523;403;398;398;398;398;398;398;398","PAOLO TINUPER;GIUSEPPE PLAZZI;ANDREA ZINI;VALÉRIO CARELLI;SABINA CEVOLI;PIERO PARCHI;CHIARA LA MORGIA;CORRADO ZENESINI;SABINA CAPELLARI;MARIA GIULIA BACALINI;PIETRO CORTELLI;LUISA SAMBATI;VALENTINA FAVONI;ROCCO LIGUORI;LEONARDO CAPORALI;ALESSANDRA LUGARESI;GIOVANNA CALANDRA‐BUONAURA;R. PANTIERI;CATERINA TONON;ALBA A. BRANDES","566;395;250;249;221;185;165;151;147;143;138;134;134;132;129;119;111;103;100;99","VALÉRIO CARELLI;GIUSEPPE PLAZZI;ANDREA ZINI;CHIARA LA MORGIA;CORRADO ZENESINI;PIETRO CORTELLI;CATERINA TONON;RAFFAELE LODI;ROCCO LIGUORI;LEONARDO CAPORALI;PIERO PARCHI;GIOVANNA CALANDRA‐BUONAURA;SABINA CEVOLI;LUCA VIGNATELLI;PIETRO GUARALDI;ALFREDO CONTI;MARIA GIULIA BACALINI;SABINA CAPELLARI;DIEGO MAZZATENTA;PAOLO TINUPER","31;27;19;18;18;17;16;16;16;14;13;12;12;11;11;11;11;11;11;10","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;PHYSICS;SOCIOLOGY;CHEMISTRY;ECONOMICS;PHILOSOPHY;MATHEMATICS;POLITICAL SCIENCE;ART;HISTORY;BUSINESS;GEOGRAPHY","281;77;64;28;26;20;14;13;13;11;10;9;3;2;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;PEDIATRICS;SURGERY;GENETICS;NEUROSCIENCE;RADIOLOGY;ENVIRONMENTAL HEALTH;PHYSICAL THERAPY;ANESTHESIA;CARDIOLOGY;MECHANICAL ENGINEERING;BIOCHEMISTRY;OPHTHALMOLOGY;CLINICAL PSYCHOLOGY;ONCOLOGY;PHYSICAL MEDICINE AND REHABILITATION;IMMUNOLOGY;NUCLEAR MEDICINE","192;111;67;63;60;51;34;34;23;22;21;21;20;18;17;15;15;14;13;13","DISEASE;GENE;COHORT;NEUROLOGY;RETROSPECTIVE COHORT STUDY;POPULATION;OPTIC NERVE;EPILEPSY;STROKE (ENGINE);ADVERSE EFFECT;MAGNETIC RESONANCE IMAGING;COHORT STUDY;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;CANCER;INSOMNIA;RANDOMIZED CONTROLLED TRIAL;SUBARACHNOID HEMORRHAGE;MIGRAINE;CLINICAL TRIAL;ISCHEMIA;MULTIPLE SCLEROSIS;MYOCARDIAL INFARCTION","81;51;42;33;24;23;21;20;19;17;16;15;14;13;13;13;13;13;12;11;11;11;11","INFECTIOUS DISEASE (MEDICAL SPECIALTY);PARKINSON'S DISEASE;OPTIC NEUROPATHY;PHENOTYPE;MITOCHONDRIAL DNA;NARCOLEPSY;DEMENTIA;NEURORADIOLOGY;INTRACEREBRAL HEMORRHAGE;THROMBOLYSIS;GENE EXPRESSION;ISCHEMIC STROKE;MUTATION;TOLERABILITY;CHRONIC MIGRAINE;CLINICAL ENDPOINT;EPIGENETICS;GENOTYPE;POLYSOMNOGRAPHY;SLEEP DISORDER","24;20;17;14;13;13;12;12;11;11;9;8;8;8;7;7;7;7;7;7","CORONAVIRUS DISEASE 2019 (COVID-19);LEBER'S HEREDITARY OPTIC NEUROPATHY;DNA METHYLATION;MITOCHONDRIAL DISEASE;MITOCHONDRIAL MYOPATHY;MODIFIED RANKIN SCALE;CATAPLEXY;EXCESSIVE DAYTIME SLEEPINESS;DEMENTIA WITH LEWY BODIES;EPWORTH SLEEPINESS SCALE;FRONTOTEMPORAL DEMENTIA;MITOCHONDRIAL ENCEPHALOMYOPATHY;PRNP;ALPHA-SYNUCLEIN;AUTOIMMUNE ENCEPHALITIS;COGNITIVE DECLINE;DEEP BRAIN STIMULATION;HAPLOINSUFFICIENCY;HAPLOTYPE;INTRACRANIAL ARTERIOVENOUS MALFORMATIONS;KRAS;LEVODOPA;REM SLEEP BEHAVIOR DISORDER","24;12;6;6;6;6;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","HUMANS;;MALE;FEMALE;RETROSPECTIVE STUDIES;OPTIC ATROPHY, HEREDITARY, LEBER;PARKINSON DISEASE;STROKE;COVID-19;ADULT;EPILEPSY;MIGRAINE DISORDERS;TREATMENT OUTCOME;AGED;BRAIN NEOPLASMS;MUTATION;BRAIN ISCHEMIA;CHILD;PROSPECTIVE STUDIES;DNA, MITOCHONDRIAL","183;112;41;39;38;31;31;31;28;27;25;25;24;22;21;21;20;20;20;19","PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;EPILEPSY AND SEIZURES;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;PRION DISEASES: CAUSES AND MOLECULAR BASIS;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;AUTISM SPECTRUM DISORDERS;GLIOMAS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIDEMIOLOGY AND TREATMENT OF MENINGIOMAS;MANAGEMENT AND PATHOPHYSIOLOGY OF INTRACEREBRAL HEMORRHAGE;MOLECULAR MECHANISMS OF RETINAL DEGENERATION AND REGENERATION;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;AUTOIMMUNE ENCEPHALITIS: CLINICAL CHARACTERISTICS AND MANAGEMENT","18;17;16;14;13;11;10;9;6;5;5;5;4;4;4;4;4;4;3;3","STROKE (ENGINE);PANDEMIC;DIAGNOSTIC CRITERIA;EPILEPSY;NARCOLEPSY;NEURORADIOLOGY;ETIOLOGY;TREATMENT;DISCONTINUATION;INFARCTION TREATMENT;MIGRAINE;NEUROIMAGING;TOLERABILITY;CHRONIC MIGRAINE;CLINICAL ENDPOINT;DEPRESSION (ECONOMICS);MIGRAINE PREVENTION;2019-20 CORONAVIRUS OUTBREAK;FUNCTIONAL MRI;MITOCHONDRIAL DISEASE","18;17;11;11;11;11;9;9;8;8;8;8;8;7;7;7;7;6;6;6","HEREDITARY OPTIC;OPTIC NEUROPATHY;PARKINSONS DISEASE;MULTIPLE SCLEROSIS;LEBERS HEREDITARY;ISCHEMIC STROKE;COVID- PANDEMIC;LEBER HEREDITARY;PILOT STUDY;ACUTE ISCHEMIC;CLINICAL PRACTICE;CREUTZFELDT-JAKOB DISEASE;MULTIPLE SYSTEM;NEUROPATHY SCPLHONSCP;SYSTEM ATROPHY;ANOREXIA NERVOSA;AUTISM SPECTRUM;COHORT STUDY;GENE THERAPY;HISTORYCONTROLLED SCPLEROSSCP;INTRACEREBRAL HEMORRHAGE;ITALIAN COHORT;NATURAL HISTORYCONTROLLED;PROSPECTIVE NATURAL;RISK FACTORS;SCPLEROSSCP STUDY;SPECTRUM DISORDER;ALZHEIMERS DISEASE;AMYOTROPHIC LATERAL;ARTERIOVENOUS MALFORMATIONS","14;14;14;12;8;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3","MD PHD;PARKINSONS DISEASE;MAGNETIC RESONANCE;CLINICAL TRIALS;HEALTHY CONTROLS;COVID- PANDEMIC;LENADOGENE NOLPARVOVEC;NATURAL HISTORY;PD PATIENTS;SLEEP QUALITY;DISEASE DURATION;LOGISTIC REGRESSION;MULTIPLE SCLEROSIS;PATIENTS TREATED;PHD ORCIDORG---;CLINICAL OUTCOME;HEREDITARY OPTIC;MITOCHONDRIAL DNA;OPTIC NERVE;RISK FACTORS;FUNCTIONAL OUTCOME;ISCHEMIC STROKE;NEURODEGENERATIVE DISEASES;OPTIC NEUROPATHY;RATING SCALE;DE NOVO;DISEASE PD;HR CI;ICP TCD;MULTIPLE SYSTEM","56;33;24;20;18;17;17;17;16;16;14;14;14;14;14;13;13;13;13;13;12;12;12;12;12;11;11;11;11;11",201,0.67,13.35,11,1,1,0,4,0,1,1.75,13,1,0,9.75,1,1,2,4,8,4,0,0,24,24,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8,2.12,421.25,2.95,4,0.5,41.88,0,0,3,1,1,0,2,1,0,7,1,0,0,0,0,0,0,8,0,0,8,0,0,0,0,0,0,0,0,0,"United States;Denmark;Germany;Italy","2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","8;3;3;3;2;1;1;1;1","CLINICAL RESEARCH;NEUROSCIENCES;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PREVENTION;CHRONIC PAIN;HEADACHES;HEMATOLOGY;HUNTINGTON'S DISEASE;MIGRAINES;NEURODEGENERATIVE;PAIN RESEARCH;PATIENT SAFETY;RARE DISEASES;STROKE;BIOMEDICAL IMAGING;DENTAL/ORAL AND CRANIOFACIAL DISEASE;GENETICS;ORPHAN DRUG","7;6;4;4;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","STROKE;CARDIOVASCULAR;NEUROLOGICAL","2;1;1","6.1 PHARMACEUTICALS;7.1 INDIVIDUAL CARE NEEDS","6;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,39,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;SPRINGER NATURE;ZENODO;KARGER PUBLISHERS;TAYLOR & FRANCIS GROUP","19;8;4;4;2;2","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3105 GENETICS;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3208 MEDICAL PHYSIOLOGY;36 CREATIVE ARTS AND WRITING;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;3004 CROP AND PASTURE PRODUCTION;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;37 EARTH SCIENCES;38 ECONOMICS;41 ENVIRONMENTAL SCIENCES;4409 SOCIAL WORK;3209 NEUROSCIENCES","39;18;12;9;8;8;7;4;4;4;4;4;4;2;2;2;2;2;2;1","BRAIN DISORDERS;CLINICAL RESEARCH;NEUROSCIENCES;PEDIATRIC;GENETICS;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);AUTISM;MENTAL HEALTH;AGING;PATIENT SAFETY;PREVENTION;BIOMEDICAL IMAGING;RARE DISEASES;ACQUIRED COGNITIVE IMPAIRMENT;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;COMPARATIVE EFFECTIVENESS RESEARCH;DEMENTIA;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;REHABILITATION;STROKE","14;13;10;8;7;7;6;6;4;4;4;3;3;2;2;2;2;2;2;2","MENTAL HEALTH;NEUROLOGICAL;INJURIES AND ACCIDENTS;STROKE;CONGENITAL;METABOLIC AND ENDOCRINE","5;5;2;2;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.6 RESOURCES AND INFRASTRUCTURE (AETIOLOGY);3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;6.1 PHARMACEUTICALS;6.7 PHYSICAL;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;2.4 SURVEILLANCE AND DISTRIBUTION;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES","6;4;2;2;2;2;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","7;5;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","19;3;2","BRAIN TUMOR;NERVOUS SYSTEM","2;1","3 GOOD HEALTH AND WELL BEING;4 QUALITY EDUCATION","1;1"
"IRCCS_ISNB",2023,299,19.3846153846154,2.81270903010033,0.193979933110368,0.290969899665552,0.28428093645485,2.628125,1.31818181818182,1.97727272727273,1.46551724137931,0.709030100334448,2,153,57,10,11,0.51,0.19,0.03,0.04,5.64,1.28572587757284,6.74315068493152,0.474916387959866,0.993311036789298,0.567,0.385,0.424,0.439,"ANDREA ZINI;GIUSEPPE PLAZZI;PIETRO CORTELLI;PIERO PARCHI;ALESSANDRA LUGARESI;ROCCO LIGUORI;SABINA CAPELLARI;SOFIA ASIOLI;SIMONE BAIARDI;CATERINA TONON;FRANCESCA BISULLI;DIEGO MAZZATENTA;RAFFAELE LODI;FRANCESCO PATTI;FABIO PIZZA;JACOPO PRUCCOLI;GIOVANNA CALANDRA‐BUONAURA;CORRADO ZENESINI;YVES DAUVILLIERS;L. SIMONETTI","25;25;22;17;16;16;13;12;12;12;12;12;11;11;10;10;10;10;10;9","JACOPO PRUCCOLI;GIUSEPPE PLAZZI;FEDERICA PROVINI;PIERO PARCHI;ANTONIA PARMEGGIANI;PAOLA VISCONTI;ANNIO POSAR;PIETRO CORTELLI;SABINA CAPELLARI;SIMONE BAIARDI;ROCCO LIGUORI;ANDREA ZINI;DIEGO MAZZATENTA;GIORGIO PALANDRI;SOFIA ASIOLI;FABIO PIZZA;ELENA PASINI;LEONARDO PELLICCIARI;CATERINA TONON;FABIO LA PORTA","2.31;2.13;2.01;2;1.83;1.61;1.61;1.51;1.34;1.22;1.17;1.16;1.16;1.08;1.07;1.07;1.06;1.03;1.02;1.01","ANDREA ZINI;GIUSEPPE PLAZZI;PIETRO CORTELLI;PIERO PARCHI;ALESSANDRA LUGARESI;ROCCO LIGUORI;SABINA CAPELLARI;SOFIA ASIOLI;SIMONE BAIARDI;CATERINA TONON;FRANCESCA BISULLI;DIEGO MAZZATENTA;RAFFAELE LODI;FABIO PIZZA;JACOPO PRUCCOLI;GIOVANNA CALANDRA‐BUONAURA;CORRADO ZENESINI;L. SIMONETTI;DUCCIO MARIA CORDELLI;MARIA GIULIA BACALINI","25;25;22;17;16;16;13;12;12;12;12;12;11;10;10;10;10;9;9;9","JACOPO PRUCCOLI;GIUSEPPE PLAZZI;FEDERICA PROVINI;PIERO PARCHI;ANTONIA PARMEGGIANI;PAOLA VISCONTI;ANNIO POSAR;PIETRO CORTELLI;SABINA CAPELLARI;SIMONE BAIARDI;ROCCO LIGUORI;ANDREA ZINI;DIEGO MAZZATENTA;GIORGIO PALANDRI;SOFIA ASIOLI;FABIO PIZZA;ELENA PASINI;LEONARDO PELLICCIARI;CATERINA TONON;FABIO LA PORTA","2.31;2.13;2.01;2;1.83;1.61;1.61;1.51;1.34;1.22;1.17;1.16;1.16;1.08;1.07;1.07;1.06;1.03;1.02;1.01","GIUSEPPE PLAZZI;PIERO PARCHI;YVES DAUVILLIERS;PIETRO CORTELLI;SIMONE BAIARDI;STEFANO FANTI;BERND J. KRAUSE;CHARLES MARCUS;DANIELA E. OPREA‐LAGER;FELIX M. MOTTAGHY;FRANCESCO CECI;FREDERIK L. GIESEL;HANS‐JÜRGEN WESTER;HEATHER A. JACENE;HEIKO SCHÖDER;JAMSHED BOMANJI;JOSEPH R. OSBORNE;JÉRÉMIE CALAIS;KAROLIEN GOFFIN;KEN HERRMANN","290;219;201;191;159;153;144;144;144;144;144;144;144;144;144;144;144;144;144;144","GIUSEPPE PLAZZI;PIERO PARCHI;PIETRO CORTELLI;SIMONE BAIARDI;STEFANO FANTI;ANGELA MAMMANA;ANDREA ZINI;MARCELLO ROSSI;ROCCO LIGUORI;SOFIA DELLAVALLE;CORINNE QUADALTI;ALESSANDRA LUGARESI;CORRADO ZENESINI;FEDERICA PROVINI;FRANCESCA BISULLI;CATERINA TONON;STEFANO FORLIVESI;SABINA CAPELLARI;LORIS PIRONI;RAFFAELE LODI","242;168;157;147;144;135;125;122;112;109;101;69;62;61;61;60;60;59;58;56","GIUSEPPE PLAZZI;ANDREA ZINI;PIERO PARCHI;PIETRO CORTELLI;ALESSANDRA LUGARESI;ROCCO LIGUORI;SABINA CAPELLARI;DIEGO MAZZATENTA;CORRADO ZENESINI;FRANCESCA BISULLI;CATERINA TONON;JACOPO PRUCCOLI;VALÉRIO CARELLI;FEDERICA PROVINI;FABIO PIZZA;MARIA GIULIA BACALINI;MATTEO ZOLI;RAFFAELE LODI;SIMONE BAIARDI;ANGELA MAMMANA","25;24;16;16;15;15;12;12;11;11;11;10;9;9;9;9;9;9;9;8","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;PHYSICS;MATHEMATICS;SOCIOLOGY;CHEMISTRY;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;BUSINESS;GEOGRAPHY;ART;HISTORY;MATERIALS SCIENCE","273;75;72;39;32;19;13;13;12;12;11;8;7;4;3;2;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;SURGERY;PEDIATRICS;GENETICS;PHYSICAL THERAPY;NEUROSCIENCE;IMMUNOLOGY;MECHANICAL ENGINEERING;BIOCHEMISTRY;RADIOLOGY;PHYSICAL MEDICINE AND REHABILITATION;CARDIOLOGY;ENVIRONMENTAL HEALTH;CLINICAL PSYCHOLOGY;ONCOLOGY;ANESTHESIA;CANCER RESEARCH;INTENSIVE CARE MEDICINE","179;112;67;63;51;43;39;30;27;26;25;24;23;21;21;20;19;18;17;16","DISEASE;GENE;NEUROLOGY;COHORT;CONFIDENCE INTERVAL;STROKE (ENGINE);EPILEPSY;POPULATION;MULTIPLE SCLEROSIS;COGNITION;RETROSPECTIVE COHORT STUDY;MYOCARDIAL INFARCTION;ODDS RATIO;ISCHEMIA;MAGNETIC RESONANCE IMAGING;COHORT STUDY;LOGISTIC REGRESSION;PROSPECTIVE COHORT STUDY;REHABILITATION;ALTERNATIVE MEDICINE;CANCER;CEREBROSPINAL FLUID;CONTEXT (ARCHAEOLOGY);INSOMNIA;OBSERVATIONAL STUDY","77;40;34;33;26;23;20;20;18;17;17;14;14;13;13;12;12;12;12;11;11;11;11;11;11","PARKINSON'S DISEASE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);DEMENTIA;NARCOLEPSY;GENE EXPRESSION;HAZARD RATIO;PHENOTYPE;POLYSOMNOGRAPHY;THROMBOLYSIS;ISCHEMIC STROKE;NEURORADIOLOGY;CLINICAL ENDPOINT;ANOREXIA NERVOSA;EPIGENETICS;INTRACEREBRAL HEMORRHAGE;SLEEP DISORDER;ALZHEIMER'S DISEASE;AMYOTROPHIC LATERAL SCLEROSIS;AUTISM SPECTRUM DISORDER;COLORECTAL CANCER;CONSTRUCT VALIDITY;FINGOLIMOD;NATALIZUMAB;NEUROPSYCHOLOGY;PROGRESSIVE MYOCLONUS EPILEPSY;STATUS EPILEPTICUS","21;16;14;14;13;13;13;12;12;11;10;8;7;7;7;6;5;5;5;5;5;5;5;5;5;5","CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;MODIFIED RANKIN SCALE;LEWY BODY;DEMENTIA WITH LEWY BODIES;EXCESSIVE DAYTIME SLEEPINESS;ALPHA-SYNUCLEIN;COGNITIVE DECLINE;DEEP BRAIN STIMULATION;REM SLEEP BEHAVIOR DISORDER;CATAPLEXY;VINCRISTINE;EPWORTH SLEEPINESS SCALE;FRONTOTEMPORAL DEMENTIA;MISSENSE MUTATION;REGORAFENIB;CALCITONIN GENE-RELATED PEPTIDE;CAROTID STENTING;CHROMATIN REMODELING;CLINICAL DEMENTIA RATING;EXOME SEQUENCING;FLUORESCENCE IN SITU HYBRIDIZATION;GENE EXPRESSION PROFILING;LEVODOPA;MITOCHONDRIAL MYOPATHY;PITTSBURGH SLEEP QUALITY INDEX;PURE AUTONOMIC FAILURE;TERIFLUNOMIDE;TILT TABLE TEST;TRANSCRIPTOME","16;9;8;7;6;6;5;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;STROKE;ADULT;PARKINSON DISEASE;MALE;RETROSPECTIVE STUDIES;BRAIN ISCHEMIA;MULTIPLE SCLEROSIS;COVID-19;TREATMENT OUTCOME;CHILD;NARCOLEPSY;EPILEPSY;MIDDLE AGED;ISCHEMIC STROKE;ANOREXIA NERVOSA;ADOLESCENT;ITALY","198;98;48;40;38;33;30;29;27;26;25;24;23;22;21;20;19;18;17;17","PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;GLIOMAS;EPILEPSY AND SEIZURES;SLEEP AND INSOMNIA;BRAIN FLUID DYNAMICS AND WASTE CLEARANCE MECHANISMS;EATING DISORDERS AND BODY IMAGE CONCERNS;EPIGENETIC MODIFICATIONS AND THEIR FUNCTIONAL IMPLICATIONS;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;PRION DISEASES: CAUSES AND MOLECULAR BASIS;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;GLYCOGEN METABOLISM AND MYOCLONIC DISORDERS;NEUROLOGICAL MANIFESTATIONS OF COVID-19 INFECTION;CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;MANAGEMENT AND PATHOPHYSIOLOGY OF TRAUMATIC BRAIN INJURY","17;15;14;14;10;9;9;7;7;6;6;6;5;5;5;4;4;4;4;4","STROKE (ENGINE);INFARCTION TREATMENT;NARCOLEPSY;SLEEP DURATION;PANDEMIC;DIAGNOSTIC CRITERIA;NEURORADIOLOGY;CLINICAL ENDPOINT;GLIOBLASTOMA;ANOREXIA NERVOSA;EPILEPSY;LEWY BODY;LEWY BODY PATHOLOGY;SLEEP QUALITY;COGNITIVE DECLINE;DEEP VEIN THROMBOSIS;DEPRESSION (ECONOMICS);REHABILITATION;SINGLE CENTER;SLEEP","23;16;13;13;12;11;10;8;8;7;7;7;7;7;6;6;6;6;6;6","MULTIPLE SCLEROSIS;PARKINSONS DISEASE;COHORT STUDY;NARCOLEPSY TYPE;ANOREXIA NERVOSA;ISCHEMIC STROKE;VESSEL OCCLUSION;BRAIN STIMULATION;DEEP BRAIN;LEWY BODY;MULTICENTER STUDY;OBSERVATIONAL STUDY;ACUTE STROKE;DIFFERENTIAL DIAGNOSIS;ITALIAN REGISTRY;ITALIAN STUDY;IV THROMBOLYSIS;MAGNETIC RESONANCE;MECHANICAL THROMBECTOMY;MULTICENTRIC STUDY;NERVOUS SYSTEM;PROSPECTIVE OBSERVATIONAL;RAPIDLY PROGRESSIVE;RELAPSING-REMITTING MULTIPLE;RESONANCE IMAGING;RETROSPECTIVE MULTICENTER;ALZHEIMERS DISEASE;AMYOTROPHIC LATERAL;ANALYSIS STUDY;ANATOMICAL STUDY","20;10;8;8;6;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3","SLEEP DURATION;PRE-EXISTING MEDICAL;MEDICAL CONDITIONS;HABITUAL SLEEP;MULTIPLE SCLEROSIS;MD PHD;CEREBROSPINAL FLUID;NARCOLEPSY TYPE;ISCHEMIC STROKE;BOLOGNA ITALY;PARKINSONS DISEASE;CLINICAL FEATURES;SARS-COV- INFECTION;ADVERSE EVENTS;HR CI;LB PATHOLOGY;NATIONAL UNIVERSITY;SEOUL NATIONAL;DNA METHYLATION;SHORT SLEEPERS;AD PATHOLOGY;LOGISTIC REGRESSION;PHD DEPARTMENT;SLEEP QUALITY;CLINICAL CHARACTERISTICS;CLINICAL TRIALS;COGNITIVE IMPAIRMENT;DAYTIME SLEEPINESS;DEPRESSIVE SYMPTOMS;MAGNETIC RESONANCE","57;48;45;33;27;24;22;20;19;18;18;17;17;16;16;16;16;16;15;15;14;14;14;14;13;13;13;13;13;13",194,0.65,11.5,12,1.25,1,0,4,0,1,0,14,1,1,12.5,1,0,2,4,9,4,0,0,11,11,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7,1.29,230.57,2.36,0,0,25.14,0,0,2,0,0,0,1,4,0,5,2,0,0,0,0,0,0,7,0,0,7,0,0,0,0,0,0,0,0,0,"Japan;Italy","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4206 PUBLIC HEALTH;44 HUMAN SOCIETY;4406 HUMAN GEOGRAPHY","6;5;3;1;1;1;1;1","CLINICAL RESEARCH;BRAIN DISORDERS;NEUROSCIENCES;SLEEP RESEARCH;BEHAVIORAL AND SOCIAL SCIENCE;BIOENGINEERING;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;MENTAL HEALTH;NEURODEGENERATIVE;ACQUIRED COGNITIVE IMPAIRMENT;AGING;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;CHRONIC PAIN;HYPERTENSION;MULTIPLE SCLEROSIS;PAIN RESEARCH;PARKINSON'S DISEASE;PERIPHERAL NEUROPATHY;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS","7;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","NEUROLOGICAL;CARDIOVASCULAR","2;1","6.1 PHARMACEUTICALS;3.2 INTERVENTIONS TO ALTER PHYSICAL AND BIOLOGICAL ENVIRONMENTAL RISKS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS","2;1;1;1;1",NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28,"FRONTIERS;ZENODO;KARGER PUBLISHERS;PUBLIC LIBRARY OF SCIENCE","10;10;6;2","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;4203 HEALTH SERVICES AND SYSTEMS;5202 BIOLOGICAL PSYCHOLOGY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;3101 BIOCHEMISTRY AND CELL BIOLOGY;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3105 GENETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;34 CHEMICAL SCIENCES;44 HUMAN SOCIETY;3210 NUTRITION AND DIETETICS;3211 ONCOLOGY AND CARCINOGENESIS;4205 NURSING","32;14;9;8;5;4;4;3;2;2;2;2;2;2;1;1;1","NEUROSCIENCES;NEURODEGENERATIVE;BRAIN DISORDERS;CLINICAL RESEARCH;BEHAVIORAL AND SOCIAL SCIENCE;AGING;MENTAL HEALTH;RARE DISEASES;AUTOIMMUNE DISEASE;PARKINSON'S DISEASE;HEALTH SERVICES;INFECTIOUS DISEASES;MULTIPLE SCLEROSIS;TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHY (TSE);EPILEPSY;EYE DISEASE AND DISORDERS OF VISION;GENETICS;NUTRITION;PERIPHERAL NEUROPATHY;PREVENTION","16;15;14;14;6;5;5;5;4;4;3;3;3;3;2;2;2;2;2;2","NEUROLOGICAL;GENERIC HEALTH RELEVANCE;MENTAL HEALTH","13;2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;6.6 PSYCHOLOGICAL AND BEHAVIOURAL;7.1 INDIVIDUAL CARE NEEDS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;8.1 ORGANISATION AND DELIVERY OF SERVICES","4;4;2;2;2;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","12;2;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","25;1;1","NOT SITE-SPECIFIC CANCER","1","3 GOOD HEALTH AND WELL BEING","1"
"IRCCS_ISNB",2024,323,18.4767801857585,3.11145510835913,0.244582043343653,0.318885448916409,0.328173374613003,2.98219584569733,1.29508196721311,2.10204081632653,1.325,0.662538699690402,1,147,75,20,4,0.46,0.23,0.06,0.01,0.81,0.851980356570945,5.38714613618974,0.46749226006192,0.996904024767802,0.535,0.387,0.405,0.447,"VALÉRIO CARELLI;GIUSEPPE PLAZZI;ANDREA ZINI;PIETRO CORTELLI;RAFFAELE LODI;ROCCO LIGUORI;CORRADO ZENESINI;ENRICO FRANCESCHI;LEONARDO PELLICCIARI;FRANCESCA BISULLI;MARIA GUARINO;ALFREDO CONTI;CATERINA TONON;FABIO PIZZA;PIERO PARCHI;DUCCIO MARIA CORDELLI;CHIARA LA MORGIA;SABINA CAPELLARI;LUIGI CIRILLO;FEDERICA PROVINI","26;22;21;20;15;15;15;14;14;13;13;13;12;12;12;12;12;12;11;11","GIUSEPPE PLAZZI;PIETRO CORTELLI;VALÉRIO CARELLI;ALFREDO CONTI;LEONARDO PELLICCIARI;FEDERICA PROVINI;ROCCO LIGUORI;PAOLO ABONDIO;PAOLA VISCONTI;ANNIO POSAR;CORRADO ZENESINI;FABIO PIZZA;THOMAS KLOPSTOCK;VINCENZO DONADIO;GRETA MAINIERI;PATRICK YU‐WAI‐MAN;ENRICO FRANCESCHI;FRANCESCA BISULLI;CHIARA LA MORGIA;YVES DAUVILLIERS","2.2;2.09;1.99;1.91;1.81;1.77;1.77;1.75;1.57;1.57;1.35;1.33;1.13;1.12;1.07;1.06;1.05;1.01;0.97;0.96","VALÉRIO CARELLI;GIUSEPPE PLAZZI;ANDREA ZINI;PIETRO CORTELLI;RAFFAELE LODI;ROCCO LIGUORI;CORRADO ZENESINI;ENRICO FRANCESCHI;LEONARDO PELLICCIARI;FRANCESCA BISULLI;MARIA GUARINO;ALFREDO CONTI;CATERINA TONON;FABIO PIZZA;PIERO PARCHI;DUCCIO MARIA CORDELLI;CHIARA LA MORGIA;SABINA CAPELLARI;LUIGI CIRILLO;FEDERICA PROVINI","26;22;21;20;15;15;15;14;14;13;13;13;12;12;12;12;12;12;11;11","GIUSEPPE PLAZZI;PIETRO CORTELLI;VALÉRIO CARELLI;ALFREDO CONTI;LEONARDO PELLICCIARI;FEDERICA PROVINI;ROCCO LIGUORI;PAOLO ABONDIO;PAOLA VISCONTI;ANNIO POSAR;CORRADO ZENESINI;FABIO PIZZA;VINCENZO DONADIO;GRETA MAINIERI;ENRICO FRANCESCHI;FRANCESCA BISULLI;CHIARA LA MORGIA;RAFFAELE LODI;LUCA BALDELLI;ANDREA ZINI","2.2;2.09;1.99;1.91;1.81;1.77;1.77;1.75;1.57;1.57;1.35;1.33;1.12;1.07;1.05;1.01;0.97;0.96;0.93;0.92","VALÉRIO CARELLI;ANGELA MAMMANA;MARCELLO ROSSI;PIERO PARCHI;SIMONE BAIARDI;ROCCO LIGUORI;CHIARA LA MORGIA;GIUSEPPE PLAZZI;SABINA CAPELLARI;ALICE TICCA;FRANCO MAGLIOCCHETTI;THOMAS KLOPSTOCK;CORINNE QUADALTI;MARIA PIA GIANNOCCARO;ANDREA MASTRANGELO;ANNA LADOGANA;ANNA POLEGGI;GIUSEPPE MARIO BENTIVENGA;LEONARDO CAPORALI;CLAUDIA PRIGLINGER","44;38;38;38;38;28;27;26;26;24;23;23;19;19;18;18;18;18;18;17","ANGELA MAMMANA;MARCELLO ROSSI;PIERO PARCHI;VALÉRIO CARELLI;ROCCO LIGUORI;CHIARA LA MORGIA;GIUSEPPE PLAZZI;SABINA CAPELLARI;FRANCO MAGLIOCCHETTI;CORINNE QUADALTI;MARIA PIA GIANNOCCARO;CLAUDIO FIORINI;FABIO PIZZA;ALESSANDRA MARESCA;LEONARDO CAPORALI;MARTINA ROMAGNOLI;CORRADO ZENESINI;CONCETTA VALENTINA TROPEANO;LAURA LUDOVICA GRAMEGNA;ANNA GHELLI","38;38;37;33;28;27;26;26;23;19;19;16;16;15;15;15;14;12;11;10","VALÉRIO CARELLI;ANDREA ZINI;GIUSEPPE PLAZZI;PIETRO CORTELLI;CORRADO ZENESINI;ROCCO LIGUORI;LEONARDO PELLICCIARI;RAFFAELE LODI;ENRICO FRANCESCHI;ALFREDO CONTI;FRANCESCA BISULLI;CHIARA LA MORGIA;DUCCIO MARIA CORDELLI;FABIO PIZZA;MARIA GUARINO;SABINA CAPELLARI;CATERINA TONON;PIERO PARCHI;SOFIA ASIOLI;FEDERICA PROVINI","22;21;21;19;15;14;14;14;14;13;13;12;12;12;12;12;11;11;10;10","MEDICINE;BIOLOGY;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;PHYSICS;MATHEMATICS;CHEMISTRY;POLITICAL SCIENCE;ECONOMICS;PHILOSOPHY;SOCIOLOGY;BUSINESS;HISTORY;GEOGRAPHY;GEOLOGY;ART;MATERIALS SCIENCE","294;97;89;55;30;25;22;16;14;12;11;11;3;3;2;2;1;1","INTERNAL MEDICINE;PSYCHIATRY;PATHOLOGY;NEUROSCIENCE;GENETICS;PEDIATRICS;SURGERY;CARDIOLOGY;PHYSICAL THERAPY;PHYSICAL MEDICINE AND REHABILITATION;RADIOLOGY;OPERATING SYSTEM;MECHANICAL ENGINEERING;ARTIFICIAL INTELLIGENCE;ANESTHESIA;BIOCHEMISTRY;ONCOLOGY;IMMUNOLOGY;AUDIOLOGY;CLINICAL PSYCHOLOGY;ENVIRONMENTAL HEALTH","158;105;61;59;53;49;49;28;28;27;27;24;23;21;20;20;20;19;16;16;16","DISEASE;GENE;NEUROLOGY;EPILEPSY;COHORT;STROKE (ENGINE);COGNITION;ELECTROENCEPHALOGRAPHY;SLEEP (SYSTEM CALL);RETROSPECTIVE COHORT STUDY;POPULATION;ISCHEMIA;NEUROSURGERY;OPTIC NERVE;ADVERSE EFFECT;ALTERNATIVE MEDICINE;RANDOMIZED CONTROLLED TRIAL;INSOMNIA;MULTIPLE SCLEROSIS;QUALITY OF LIFE (HEALTHCARE)","59;49;35;32;27;23;20;19;18;16;15;14;14;13;12;12;12;11;11;10","POLYSOMNOGRAPHY;PHENOTYPE;PARKINSON'S DISEASE;ISCHEMIC STROKE;DEMENTIA;NARCOLEPSY;NEURORADIOLOGY;OPTIC NEUROPATHY;SLEEP DISORDER;MUTATION;INFECTIOUS DISEASE (MEDICAL SPECIALTY);GENE EXPRESSION;AUTISM SPECTRUM DISORDER;COGNITIVE IMPAIRMENT;GENOTYPE;NEUROPSYCHOLOGY;MULTICENTER STUDY;MUTANT;ALLELE;ALZHEIMER'S DISEASE;ANOREXIA NERVOSA;CHRONIC MIGRAINE;CLINICAL ENDPOINT;EPIGENETICS;EPILEPSY SURGERY;EXPANDED DISABILITY STATUS SCALE;METHYLATION;MITOCHONDRIAL DNA;NEURODEGENERATION;NEUROPEPTIDE;THROMBOLYSIS;UNIVARIATE ANALYSIS","16;15;14;13;12;12;12;12;12;10;9;8;6;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4","LEBER'S HEREDITARY OPTIC NEUROPATHY;CORONAVIRUS DISEASE 2019 (COVID-19);DNA METHYLATION;EXCESSIVE DAYTIME SLEEPINESS;MISSENSE MUTATION;REM SLEEP BEHAVIOR DISORDER;DEEP BRAIN STIMULATION;ALPHA-SYNUCLEIN;CATAPLEXY;COGNITIVE DECLINE;MITOCHONDRIAL DISEASE;MODIFIED RANKIN SCALE;PENETRANCE;CALCITONIN GENE-RELATED PEPTIDE;EPWORTH SLEEPINESS SCALE;EXOME SEQUENCING;IDH1;LEWY BODY;SLEEP MEDICINE;CLINICAL PHENOTYPE;COMPOUND HETEROZYGOSITY;DEMENTIA WITH LEWY BODIES;FRONTOTEMPORAL DEMENTIA;GENE MUTATION;GLOBAL DEVELOPMENTAL DELAY;GLOBOTRIAOSYLCERAMIDE;HAPLOINSUFFICIENCY;NEUROPSYCHOLOGICAL ASSESSMENT;PARASOMNIA;PROLACTINOMA;PURE AUTONOMIC FAILURE;SLEEPWALKING;WILD TYPE","12;9;7;6;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2",";HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;ADOLESCENT;ITALY;CHILD;RETROSPECTIVE STUDIES;YOUNG ADULT;AGED, 80 AND OVER;TREATMENT OUTCOME;CHILD, PRESCHOOL;SURVEYS AND QUESTIONNAIRES;EPILEPSY;BRAIN;MUTATION;PHENOTYPE","183;138;85;84;62;58;43;25;25;23;21;21;16;15;14;14;13;12;12;10","SLEEP'S ROLE IN MEMORY CONSOLIDATION AND REGULATION;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;GLIOMAS;MITOCHONDRIAL DYNAMICS AND REACTIVE OXYGEN SPECIES REGULATION;EPILEPSY AND SEIZURES;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE;MIGRAINE PATHOPHYSIOLOGY AND TREATMENT;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;ANALYSIS OF BRAIN FUNCTIONAL CONNECTIVITY NETWORKS;SHOULDER PATHOLOGY AND TREATMENT OUTCOMES;DEEP BRAIN STIMULATION FOR NEUROLOGICAL DISORDERS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;EPIDEMIOLOGY AND MANAGEMENT OF RESTLESS LEGS SYNDROME;GENE THERAPY FOR SPINAL MUSCULAR ATROPHY;MANAGEMENT OF VASCULAR MALFORMATIONS IN THE BRAIN;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES;AUTISM SPECTRUM DISORDERS;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE","23;16;15;15;12;11;7;7;6;5;5;4;4;4;4;4;4;4;3;3","STROKE (ENGINE);DIAGNOSTIC CRITERIA;SLEEP;EPILEPSY;INFARCTION TREATMENT;SLEEP DURATION;INSOMNIA;NARCOLEPSY;NEURORADIOLOGY;ANTIEPILEPTIC DRUGS;IDEBENONE;SLEEP (SYSTEM CALL);COGNITIVE DECLINE;DEEP BRAIN STIMULATION;MIGRAINE;MIGRAINE PREVENTION;SLEEP QUALITY;TREATMENT;CHRONIC MIGRAINE;DELPHI METHOD","23;14;13;12;12;11;10;10;10;7;7;7;6;6;6;6;6;6;5;5","HEREDITARY OPTIC;OPTIC NEUROPATHY;ISCHEMIC STROKE;LEBER HEREDITARY;NARCOLEPSY TYPE;COHORT STUDY;MULTIPLE SCLEROSIS;PARKINSONS DISEASE;BEHAVIOR DISORDER;COGNITIVE IMPAIRMENT;MILD COGNITIVE;NERVOUS SYSTEM;RETROSPECTIVE STUDY;SEED AMPLIFICATION;ALZHEIMERS DISEASE;ANOREXIA NERVOSA;BRAIN STIMULATION;DEEP BRAIN;PSYCHOMETRIC PROPERTIES;RESTLESS LEGS;SLEEP BEHAVIOR;SYMPTOM ONSET;AMPLIFICATION ASSAY;ANTI-CGRP MONOCLONAL;ANTIPLATELET TREATMENT;AUTISM SPECTRUM;CENTRAL NERVOUS;CLINICAL PRACTICE;CLINICAL TRIAL;COGNITIVE DECLINE","11;11;10;9;7;6;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3","NARCOLEPSY TYPE;BRAIN HEALTH;RISK FACTORS;COGNITIVE IMPAIRMENT;PATHOGENIC VARIANTS;DNA METHYLATION;HEALTHY CONTROLS;ISCHEMIC STROKE;OPTIC NEUROPATHY;REM SLEEP;DELTA VA;EYE MOVEMENT;HEREDITARY OPTIC;INCLUDED PATIENTS;RAPID EYE;REFEEDING SYNDROME;SLEEPINESS SCALE;ADVERSE EVENTS;EPWORTH SLEEPINESS;NERVOUS SYSTEM;NEUROPATHY LHON;NH COHORT;SYMPTOM ONSET;ABSTRACT OBJECTIVE;ALZHEIMERS DISEASE;ANTI-CGRP MABS;COPING STRATEGIES;GENETIC TESTING;MITOCHONDRIAL DNA;BLOOD PRESSURE","24;21;15;14;14;13;13;13;13;13;12;12;12;12;12;12;12;11;11;11;11;11;11;10;10;10;10;10;10;9",1,0,0.5,2,0,0,0,0,0,0,0,2,0,0,2,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"ZENODO","2","31 BIOLOGICAL SCIENCES;3105 GENETICS","4;2",NA,NA,"NEUROLOGICAL","2",NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","2",NA,NA,NA,NA
